Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
abc-type xenobiotic transporter deficiency
ABCC4, a plasma membrane transporter modulating platelet aggregation.
Abortion, Habitual
Phosphodiesterase 8B gene polymorphism in women with recurrent miscarriage: a retrospective case control study.
Abscess
The Role of Phosphodiesterase Inhibitors in the Management of Cavernositis With Multifocal Abscesses: A Report of Case Series.
Acidosis
Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass.
Acidosis
Influence of Acidosis on Cardiotonic Effects of Colforsin and Epinephrine: A Dose-Response Study.
Acquired Immunodeficiency Syndrome
A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review.
Acquired Immunodeficiency Syndrome
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
Acquired Immunodeficiency Syndrome
The fine-structural distribution of G-protein receptor kinase 3, beta-arrestin-2, Ca2+/calmodulin-dependent protein kinase II and phosphodiesterase PDE1C2, and a Cl(-)-cotransporter in rodent olfactory epithelia.
Acute Coronary Syndrome
A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.
Acute Coronary Syndrome
Cilostazol and Primary-PCI: Mirage or Good Alternative?
Acute Coronary Syndrome
Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study.
Acute Kidney Injury
Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure.
Acute Kidney Injury
Further characterization of the protective effect of 8-cyclopentyl-1,3-dipropylxanthine on glycerol-induced acute renal failure in the rat.
Acute Kidney Injury
Inhibition of cytokine release by and cardiac effects of type IV phosphodiesterase inhibition in early, profound endotoxaemia in vivo.
Acute Kidney Injury
Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure.
Acute Kidney Injury
Lipopolysaccharide-induced acute renal failure in conscious rats: effects of specific phosphodiesterase type 3 and 4 inhibition.
Acute Kidney Injury
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Acute Kidney Injury
Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
Acute Kidney Injury
Zaprinast accelerates recovery from established acute renal failure in the rat.
Acute Lung Injury
Development and assessment of countermeasure formulations for treatment of lung injury induced by chlorine inhalation.
Acute Lung Injury
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung.
Acute Lung Injury
Induced nitric oxide impairs relaxation but not contraction in endotoxin-exposed rat pulmonary arteries.
Acute Lung Injury
LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression.
Acute Lung Injury
Mitigation of chlorine lung injury by increasing cyclic AMP levels.
Acute Lung Injury
Nitration of protein kinase G-I? modulates cyclic nucleotide crosstalk via phosphodiesterase 3A: Implications for acute lung injury.
Acute Lung Injury
Phosphodiesterase inhibition overcomes pulmonary vasomotor dysfunction in acute lung injury.
Acute Lung Injury
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
Acute Lung Injury
Short-term cardiovascular effects of selective phosphodiesterase 3 inhibitor olprinone versus non-selective phosphodiesterase inhibitor aminophylline in a meconium-induced acute lung injury.
Acute Lung Injury
Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury.
Adenocarcinoma
Adenosine 3' , 5'-cyclic monophsphate phosphodiesterase activities in the x-irradiation induced rat small bowel adenocarcinoma.
Adenocarcinoma
Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics.
Adenocarcinoma
Inhibition of experimental metastasis of human adenocarcinoma by cilostazol, a platelet phosphodiesterase inhibitor.
Adenocarcinoma
Parallel activation of cyclic AMP phosphodiesterase and cyclic AMP-dependent protein kinase in two human gut adenocarcinoma cells (HT 29 and HRT 18) in culture, by vasoactive intestinal peptide (VIP) and other effectors activating the cyclic AMP system.
Adenocarcinoma of Lung
Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma.
Adenoma
Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.
Adenoma
Comparative study of cyclic AMP-generation system, steroid biosynthesis and lipid metabolism in vitro in ACTH responsive and unresponsive adrenal tumors.
Adenoma
Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas.
Adenoma
How does cAMP/protein kinase A signaling lead to tumors in the adrenal cortex and other tissues?
Adenoma
Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas.
Adenoma
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Adenoma, Islet Cell
Isolation and characterization of calmodulin from an insulin-secreting tumour.
Adenomatous Polyposis Coli
Advances in the study of Lynch syndrome in China.
Adrenocortical Carcinoma
Stimulation of guanosine 3',5'-monophosphate-phosphodiesterase activity by adrenocorticotropic hormone-activated increase of guanosine 3',5'-monophosphate in isolated adrenocortical carcinoma cells.
Airway Obstruction
Evaluation of the effect of phosphodiesterase on equine platelet activation and the effect of antigen challenge on platelet phosphodiesterase activity in horses with recurrent airway obstruction.
Albuminuria
Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor.
Alopecia
Comment on 'Androgenetic alopecia is associated with increased scalp hardness': role of phosphodiesterase inhibitors?
Alopecia
The use of phosphodiesterase inhibitors for the treatment of alopecia.
Alopecia Areata
Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases.
Alstrom Syndrome
Birt-Hogg-Dubé syndrome associated with chorioretinopathy and nyctalopia: a case report and review of the literature.
Alzheimer Disease
A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers.
Alzheimer Disease
Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls.
Alzheimer Disease
Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.
Alzheimer Disease
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Alzheimer Disease
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Alzheimer Disease
Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Alzheimer Disease
Cilostazol, a Phosphodiesterase 3 Inhibitor, Moderately Attenuates Behaviors Depending on Sex in the Ts65Dn Mouse Model of Down Syndrome.
Alzheimer Disease
Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
Alzheimer Disease
Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimer's Disease.
Alzheimer Disease
Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.
Alzheimer Disease
Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.
Alzheimer Disease
Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
Alzheimer Disease
Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Alzheimer Disease
Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
Alzheimer Disease
Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
Alzheimer Disease
Ferulic acid alleviates A?25-35- and lipopolysaccharide-induced PC12 cellular damage: a potential role in Alzheimer's disease by PDE inhibition.
Alzheimer Disease
Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.
Alzheimer Disease
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
Alzheimer Disease
Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease.
Alzheimer Disease
Neurovascular Protective Function of Endothelial Nitric Oxide?- Recent Advances.
Alzheimer Disease
New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.
Alzheimer Disease
Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
Alzheimer Disease
Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
Alzheimer Disease
Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
Alzheimer Disease
Phosphodiesterase inhibitors say NO to Alzheimer's disease.
Alzheimer Disease
Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42-mediated cytotoxicity.
Alzheimer Disease
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Alzheimer Disease
Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease.
Alzheimer Disease
Targeting New Pharmacological Approaches for Alzheimer's Disease: Potential for Statins and Phosphodiesterase Inhibitors.
Alzheimer Disease
Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.
Amebiasis
Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
Amnesia
Brain cyclic AMP and memory in mice.
Amnesia
Testing cyclic AMP mediation of memory: reversal of alpha-methyl-p-tyrosine-induced amnesia.
Amyloidosis
Combined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice.
Amyotrophic Lateral Sclerosis
Calcium, calmodulin and 3',5'-cyclic nucleotide phosphodiesterase activity in human muscular disorders.
Anaphylaxis
Effect of the lipoxygenase inhibitor N-hydroxy-N-(6-methoxy-3,4-dihydro-2-naphthylmethyl)urea on bronchoconstriction and lung vascular permeability in anaphylactic guinea pigs.
Anaphylaxis
In vivo anaphylaxis in the rat: effects of phosphodiesterase inhibitors.
Anaphylaxis
Studies with two new phosphodiesterase inhibitors (ICI 58, 301 and ICI 63, 197) on anaphylaxis in guinea pigs, mice and rats.
Anaphylaxis
[Changes in the cyclic nucleotide system in experimental anaphylaxis and approaches to their correction]
Anaphylaxis
[Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock]
Anemia
Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.
Anemia, Hemolytic
Pulmonary hypertension in patients with hematological disorders following splenectomy.
Anemia, Sickle Cell
Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy.
Anemia, Sickle Cell
Increased adhesive properties of platelets in sickle cell disease: roles for alphaIIb beta3-mediated ligand binding, diminished cAMP signalling and increased phosphodiesterase 3A activity.
Anemia, Sickle Cell
Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.
Anemia, Sickle Cell
PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study.
Anemia, Sickle Cell
Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis.
Anemia, Sickle Cell
Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.
Angina Pectoris
Co-crystal structures of PKG I? (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding.
Anosmia
Aetiological relationships of nasal mucus cyclic nucleotides in patients with taste and smell dysfunction.
Anosmia
Relative resistance to oral theophylline treatment in patients with hyposmia manifested by decreased secretion of nasal mucus cyclic nucleotides.
Anthrax
Synergic TiO2 photocatalysis and guanine photoreduction for silver deposition amplification: an ultrasensitive and high-throughput visualized colorimetric analysis strategy for anthrax DNAs in blood using a wettable microwells array.
Apnea
Adenosine analogues depress ventilation in rabbit neonates. Theophylline stimulation of respiration via adenosine receptors?
Arrhythmias, Cardiac
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Arrhythmias, Cardiac
Multiorgan Drug Action of Levosimendan in Critical Illnesses.
Arrhythmias, Cardiac
Nitroxyl (HNO) for treatment of acute heart failure.
Arrhythmias, Cardiac
PDE1 Inhibition Modulates Cav1.2 Channel to Stimulate Cardiomyocyte Contraction.
Arrhythmias, Cardiac
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
Arrhythmias, Cardiac
[Progress in treatment of chronic heart failure in Western medicine and treatment strategies in traditional Chinese medicine]
Arterial Occlusive Diseases
Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.
Arterial Occlusive Diseases
Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
Arterial Occlusive Diseases
Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.
Arteritis
Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate.
Arthralgia
A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period.
Arthritis
Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram.
Arthritis
Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity.
Arthritis
Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice.
Arthritis
Effect of phosphodiesterase-5 inhibition on joint and muscle damage in rats with
adjuvant arthritis
Arthritis
Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats.
Arthritis
Tadalafil analgesia in experimental arthritis involves suppression of intra-articular TNF release.
Arthritis, Experimental
Combination therapy with DMARDs and biological agents in collagen-induced arthritis.
Arthritis, Experimental
Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis.
Arthritis, Infectious
Inhibiting the inflammatory response in joint sepsis.
Arthritis, Psoriatic
Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections.
Arthritis, Psoriatic
Apremilast in psoriatic arthritis.
Arthritis, Psoriatic
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Arthritis, Psoriatic
Proximal Renal Tubular Acidosis (Fanconi syndrome) Induced by Apremilast: A Case Report.
Arthritis, Psoriatic
Worsening of Lymphopenia during Apremilast Treatment.
Arthritis, Rheumatoid
Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis.
Arthritis, Rheumatoid
Drugs, inflammation and cell adhesion receptors.
Arthritis, Rheumatoid
Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis.
Arthritis, Rheumatoid
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Arthritis, Rheumatoid
Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity.
Arthritis, Rheumatoid
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Asthma
Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.
Asthma
A comparison of the relaxant effects of olprinone and aminophylline on methacholine-induced bronchoconstriction in dogs.
Asthma
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.
Asthma
A review on herbal antiasthmatics.
Asthma
Airway smooth muscle as a target of asthma therapy: history and new directions.
Asthma
Ariflo (SmithKline Beecham plc).
Asthma
Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
Asthma
Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients.
Asthma
Bronchodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma.
Asthma
Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma.
Asthma
Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo.
Asthma
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Asthma
Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Asthma
Chemotherapeutic potential of phosphodiesterase inhibitors.
Asthma
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Asthma
Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity.
Asthma
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Asthma
Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Asthma
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Asthma
Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs.
Asthma
Effect of T-440, a novel type IV phosphodiesterase inhibitor, on allergen-induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs.
Asthma
Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma.
Asthma
Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro.
Asthma
Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma.
Asthma
Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence.
Asthma
Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression.
Asthma
Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung.
Asthma
Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.
Asthma
Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines.
Asthma
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.
Asthma
Elevated leukocyte phosphodiesterase as a basis for depressed cyclic adenosine monophosphate responses in the Basenji greyhound dog model of asthma.
Asthma
Enantiomer Discrimination Illustrated by the High Resolution Crystal Structures of Type 4 Phosphodiesterase.
Asthma
Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline.
Asthma
Experimental and investigational phosphodiesterase inhibitors in development for asthma.
Asthma
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Asthma
Future developments in the pharmacotherapy of lung disease.
Asthma
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Asthma
Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia.
Asthma
Hesperidin-3'-o-methylether is more potent than hesperidin in phosphodiesterase inhibition and suppression of ovalbumin-induced airway hyperresponsiveness.
Asthma
Human alveolar macrophage activation: inhibition by forskolin but not beta-adrenoceptor stimulation or phosphodiesterase inhibition.
Asthma
Hypertrophic osteopathy in rats following chronic administration of SDZ MNS 949, an isoquinoline.
Asthma
Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis.
Asthma
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Asthma
Ibudilast: a non?selective phosphodiesterase inhibitor in brain disorders.
Asthma
Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease.
Asthma
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor.
Asthma
Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.
Asthma
Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
Asthma
Inhibition of phosphodiesterase suppresses allergic lung inflammation by regulating MCP-1 in an OVA-induced asthma murine model with co-exposure to lipopolysaccharide.
Asthma
Investigating the effect of sildenafil on improving lung function and quality of life in the patients with severe asthma.
Asthma
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
Asthma
Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.
Asthma
Low-dose theophylline: a new anti-inflammatory role in asthma management?
Asthma
Modulation of Cytokine Production by Cyclic Adenosine Monophosphate Analogs in Human Leukocytes.
Asthma
New Avenues for Phosphodiesterase Inhibitors in Asthma.
Asthma
New cassane-type diterpenoids from kernels of Caesalpinia bonduc (Linn.) Roxb. and their inhibitory activities on phosphodiesterase (PDE) and nuclear factor-kappa B (NF-?B) expression.
Asthma
Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models.
Asthma
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits.
Asthma
Pharmacologic modification of induced asthma.
Asthma
Pharmacologic modulation of experimentally induced allergic asthma.
Asthma
Pharmacological Basis for Medicinal Use of Lens culinaris in Gastrointestinal and Respiratory Disorders.
Asthma
Pharmacological explanation for the medicinal use of Juniperus excelsa in hyperactive gastrointestinal and respiratory disorders.
Asthma
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Asthma
Phosphodiesterase 3 inhibition and cough in elderly asthmatics.
Asthma
Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis.
Asthma
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Asthma
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Asthma
Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.
Asthma
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Asthma
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Asthma
Phosphodiesterase Type 4D Gene Polymorphism: Association with the Response to Short-Acting Bronchodilators in Paediatric Asthma Patients.
Asthma
Potent suppressive effects of 3-O-methylquercetin 5,7,3',4'-O-tetraacetate on ovalbumin-induced airway hyperresponsiveness.
Asthma
Potential and novel therapies for asthma.
Asthma
Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
Asthma
Pretreatment with antiasthmatic drug ibudilast ameliorates A?1-42-induced memory impairment and neurotoxicity in mice.
Asthma
Relationships between adenosine, cyclic nucleotides, and xanthines in asthma.
Asthma
S-Petasin, the Main Sesquiterpene of Petasites formosanus, Inhibits Phosphodiesterase Activity and Suppresses Ovalbumin-induced Airway Hyperresponsiveness.
Asthma
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Asthma
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Asthma
Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease.
Asthma
Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor.
Asthma
Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells.
Asthma
Studies on Bronchodilator Activity of Salvia officinalis (Sage): Possible Involvement of K(+) Channel Activation and Phosphodiesterase Inhibition.
Asthma
Studies on the chemical composition and possible mechanisms underlying the antispasmodic and bronchodilatory activities of the essential oil of Artemisia maritima L.
Asthma
Synthesis and biological activity of Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
Asthma
Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
Asthma
Targeting the mast cell in asthma.
Asthma
The Calcium Channel Blocking and Phosphodiesterase Inhibitory Activities of the Extract of Andropogon muricatus Explains its Medicinal Use in Airways Disorders.
Asthma
The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma.
Asthma
The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats.
Asthma
The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma.
Asthma
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Asthma
The potential role of phosphodiesterase inhibitors in the management of asthma.
Asthma
The rabbit as a model to study asthma and other lung diseases.
Asthma
The role of phosphodiesterase enzymes in allergy and asthma.
Asthma
The study of pathogenetic basis of asthma using biostatistic models.
Asthma
Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants.
Asthma
Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma.
Asthma
Theophylline attenuates Ca2+ sensitivity and modulates BK channels in porcine tracheal smooth muscle.
Asthma
Theophylline exerts complex anti-ageing and anti-cytotoxicity effects in human skin ex vivo.
Asthma
Therapeutic potential of isozyme-selective phosphodiesterase inhibitors in the treatment of asthma.
Asthma
Therapeutic responses in asthma and COPD. Bronchodilators.
Asthma
Treatment of asthma with theophylline and beta adrenergic agents.
Asthma
Two new isoxazolines from the husks of Xanthoceras sorbifolia Bunge.
Asthma
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Asthma
Update on the pharmacodynamics and pharmacokinetics of theophylline.
Asthma
Vinpocetine alleviates lung inflammation via macrophage inflammatory protein-1? inhibition in an ovalbumin-induced allergic asthma model.
Asthma
[Cyclic nucleotides phosphodiesterase activity in a rat lung model of asthma]
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
Astrocytoma
Cyclic AMP phosphodiesterase in cloned astrocytoma cells: norepinephrine induces a specific enzyme form.
Astrocytoma
Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.
Astrocytoma
Multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat cerebrum and cloned astrocytoma and neuroblastoma cells.
Astrocytoma
Pertussis toxin differentiates between two mechanisms of attenuation of cyclic AMP accumulation by muscarinic cholinergic receptors.
Astrocytoma
Receptor reserve in the calcium-dependent cyclic AMP response of astrocytoma cells to muscarinic receptor stimulation: demonstration by agonist-induced desensitization, receptor inactivation, and phorbol ester treatment.
Ataxia
Central adenosinergic system involvement in ethanol-induced motor incoordination in mice.
Atherosclerosis
Changes of cyclic-AMP and cycic-AMP phosphodiesterase in the progression and regression of experimental atherosclerosis.
Atherosclerosis
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke.
Atherosclerosis
Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis.
Atherosclerosis
Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats.
Atherosclerosis
Drugs and foods on contraction of endothelial cells as a key mechanism in atherogenesis and treatment of atherosclerosis with endothelial-cell relaxants (cyclic AMP phosphodiesterase inhibitors).
Atherosclerosis
Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial.
Atherosclerosis
Effects of phthalazinol (EG 626) on arterial lipolytic enzyme activities in the rat.
Atherosclerosis
Hyperreactive arterial endothelial cells in atherogenesis and cyclic AMP phosphodiesterase inhibitor in prevention and treatment of atherosclerotic disorders.
Atherosclerosis
Hyperreactive arterial endothelial cells: a clue for the treatment of atherosclerosis.
Atherosclerosis
PDE5 inhibitors for LUTS.
Atherosclerosis
Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea.
Atherosclerosis
Role of sGC-dependent NO signalling and myocardial infarction risk.
Atherosclerosis
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Atherosclerosis
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors.
Atherosclerosis
[Effect of cortisol on adenylate cyclase and 3',5'-AMP phosphodiesterase activity and 3',5'-AMP concentration in tissues and biological fluids in experimental atherosclerosis]
Atrial Fibrillation
A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer.
Atrial Fibrillation
Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities.
Autoimmune Diseases
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease.
Autoimmune Diseases
Phosphodiesterase 4-targeted treatments for autoimmune diseases.
Autoimmune Diseases
Phosphodiesterase inhibitors in the management of autoimmune disease.
Autoimmune Diseases
SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations.
Autoimmune Diseases
Systemic lupus erythematosus overlapping dermatomyositis owing to a heterozygous TREX1 Asp130Asn missense mutation.
Autoimmune Diseases
T Cells Produce IFN-? in the TREX1 D18N Model of Lupus-like Autoimmunity.
Autoimmune Diseases
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
Autoimmune Diseases
TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner.
Axial Spondyloarthritis
Beyond the TNF-? Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.
Bacterial Infections
Rolipram inhibits staphylococcal enterotoxin B-mediated induction of the human skin-homing receptor on T lymphocytes.
Blindness
AIPL1, a protein associated with childhood blindness, interacts with {alpha}-subunit of rod phosphodiesterase (PDE6) and is essential for its proper assembly.
Blindness
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Blindness
Phosphodiesterase dysfunction, cyclic GMP accumulation, and visual cell degeneration in early-onset inherited blindness.
Bloom Syndrome
A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1.
Bloom Syndrome
DNA End Resection: Facts and Mechanisms.
Bloom Syndrome
Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells.
Bloom Syndrome
RPA Phosphorylation Inhibits DNA Resection.
Bone Diseases, Metabolic
KMUP-1 promotes osteoblast differentiation through cAMP and cGMP pathways and signaling of BMP-2/Smad1/5/8 and Wnt/?-catenin.
Bone Resorption
Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture.
Bone Resorption
Comparative study of the effects of cyclic nucleotide phosphodiesterase inhibitors on bone resorption and cyclic AMP formation in vitro.
Bone Resorption
Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
Bone Resorption
Delayed stimulatory effect of cyclic AMP on bone resorption in vitro.
Bone Resorption
Inhibition of bone resorption and lysosomal enzyme release from calvarial bones cultured for 24 hours: synergism between cyclic AMP analogues and phosphodiesterase inhibitors.
Bone Resorption
Platelet-derived growth factor stimulates bone resorption via a prostaglandin-mediated mechanism.
Brachydactyly
Clinical and Molecular Perspectives of Monogenic Hypertension.
Brachydactyly
Clinical Effects of Phosphodiesterase 3A Mutations in Inherited Hypertension With Brachydactyly.
Brachydactyly
Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3.
Brachydactyly
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Bradycardia
Chronotropic effects of cilostazol, a new antithrombotic agent, in patients with bradyarrhythmias.
Brain Diseases
Ibudilast: a non?selective phosphodiesterase inhibitor in brain disorders.
Brain Infarction
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes.
Brain Injuries
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Brain Injuries
Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.
Brain Injuries
Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats.
Brain Injuries
Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Brain Injuries
Pentoxifylline Alleviates Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats: Possibly via Inhibiting TLR 4/NF-?B Signaling Pathway.
Brain Injuries
Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats.
Brain Injuries
Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.
Brain Injuries, Traumatic
Detection of single- and double-strand DNA breaks after traumatic brain injury in rats: comparison of in situ labeling techniques using DNA polymerase I, the Klenow fragment of DNA polymerase I, and terminal deoxynucleotidyl transferase.
Brain Injuries, Traumatic
Phosphodiesterase inhibition rescues chronic cognitive deficits induced by traumatic brain injury.
Brain Injuries, Traumatic
Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.
Brain Injuries, Traumatic
Phosphodiesterase isoform-specific expression induced by traumatic brain injury.
Brain Injuries, Traumatic
Traumatic Brain Injury Upregulates Phosphodiesterase Expression in the Hippocampus.
Brain Ischemia
A Novel Phosphodiesterase Type 4 Inhibitor, HT-0712, Enhances Rehabilitation-Dependent Motor Recovery and Cortical Reorganization After Focal Cortical Ischemia.
Brain Ischemia
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Brain Ischemia
Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone.
Brain Ischemia
Effect of propentofylline on cerebral blood flow in a gerbil focal cerebral ischemia.
Brain Ischemia
Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.
Brain Ischemia
In situ detection of neuronal DNA strand breaks using the Klenow fragment of DNA polymerase I reveals different mechanisms of neuron death after global cerebral ischemia.
Brain Ischemia
Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia.
Brain Ischemia
Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia.
Brain Ischemia
Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.
Brain Ischemia
Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil.
Brain Ischemia
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.
Brain Ischemia
The phosphodiesterase type 2 inhibitor BAY 60-7550 reverses functional impairments induced by brain ischemia by decreasing hippocampal neurodegeneration and enhancing hippocampal neuronal plasticity.
Brain Ischemia
Therapeutic Benefit of Cilostazol in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized and Nonrandomized Studies.
Brain Neoplasms
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.
Brain Neoplasms
Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability into brain tumors.
Brain Neoplasms
Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways.
Brain Neoplasms
Potential role of calmodulin-dependent phosphodiesterase in human brain tumor (review).
Breast Neoplasms
A new electrochemical method for the detection of cancer cells based on small molecule-linked DNA.
Breast Neoplasms
Atacamycins A-C, 22-membered antitumor macrolactones produced by Streptomyces sp. C38.
Breast Neoplasms
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
Breast Neoplasms
Evaluation of PDE5 and PDE9 Expression in Benign and Malignant Breast Tumors.
Breast Neoplasms
Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.
Breast Neoplasms
Implementation of micromethods to resolve problems of human breast tumor heterogeneity in analysis of cyclic 3':5'-nucleotide phosphodiesterase.
Breast Neoplasms
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Breast Neoplasms
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Breast Neoplasms
[Effect of soy isoflavones on cAMP/PKA pathway in breast cancer cells of the rat.]
Bronchial Hyperreactivity
Comparison of Effect of Leukotriene Biosynthesis Blockers and Inhibitors of Phosphodiesterase Enzyme in Patients with Bronchial Hyperreactivity.
Bronchial Hyperreactivity
Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration.
Bronchial Hyperreactivity
Effects of isoenzyme selective phosphodiesterase inhibitors on bacterial lipopolysaccharide-induced bronchial hyperreactivity in guinea pigs.
Bronchial Hyperreactivity
Phosphodiesterase inhibitors reduce bronchial hyperreactivity and airway inflammation in unrestrained guinea pigs.
Bronchial Spasm
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.
Bronchial Spasm
Effect of theophylline administered intratracheally as a dry powder formulation on bronchospasm and airway microvascular leakage in the anesthetized guinea-pig.
Bronchitis, Chronic
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Bronchitis, Chronic
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Bronchitis, Chronic
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.
Bronchopulmonary Dysplasia
Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia.
Bronchopulmonary Dysplasia
Phosphodiesterase 4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats.
Brugada Syndrome
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.
Carcinogenesis
EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.
Carcinogenesis
Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas.
Carcinogenesis
Phosphodiesterase type 5 inhibitors use and risk of colorectal cancer: a systematic review and meta-analysis.
Carcinogenesis
Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and epsilon-aminocaproic acid.
Carcinogenesis
Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.
Carcinoma
A phosphodiesterase from ascites carcinoma Krebs II cells specifically cleaves the bond between VPg and RNA of encephalomyocarditis virus.
Carcinoma
Adenosine-3',5'-cyclic monophosphate levels and adenosine-3',5'-cyclic monophosphate phosphodiesterase activity in metastasizing and nonmetastasizing rat mammary carcinomas.
Carcinoma
Adenylate cyclase, cyclic adenosin 3':5'-monophosphate phosphodiesterase, and regression of Walker 256 mammary carcinoma.
Carcinoma
Association of DNA repair gene polymorphisms with response to cisplatin-based concurrent chemoradiotherapy in patients with cervical carcinoma.
Carcinoma
Atacamycins A-C, 22-membered antitumor macrolactones produced by Streptomyces sp. C38.
Carcinoma
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Carcinoma
Characterisation of cyclic adenosine 3':5'-monophosphate phospodiesterase from Walker carcinoma sensitive and resistant to bifunctional alkylating agents.
Carcinoma
Cyclic AMP phosphodiesterase activity in human gingival carcinoma.
Carcinoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Carcinoma
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Carcinoma
Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells.
Carcinoma
Inhibition of cyclic adenosine 3',5'-monophosphate phosphodiesterase from Walker carcinoma by ascorbic and dehydroascorbic acids.
Carcinoma
Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine.
Carcinoma
Isolation from ascites carcinoma Krebs II cells of an unlinking enzyme hydrolyzing a covalent bond between picornavirus RNA and VPg.
Carcinoma
Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.
Carcinoma
Modulation of glucocorticoid-regulated transcription by purines: novel characteristics and implications for tissue specificity of steroid responses.
Carcinoma
Phosphodiesterase in human colon carcinoma cell line CaCo-2 in culture.
Carcinoma
Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors.
Carcinoma
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Carcinoma
Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP.
Carcinoma
[Effect of polysaccharides on the cyclic nucleotide content and phosphodiesterase activity in the organs of mice with Lewis lung carcinoma]
Carcinoma, Ehrlich Tumor
Guanine nucleotides activate cytosolic phospholipase C of ascites tumour cells stimulated by 1-oleoyl-2-acetyl-sn-glycerol.
Carcinoma, Ehrlich Tumor
Quercetin inhibition of the induction and function of cytotoxic T lymphocytes.
Carcinoma, Hepatocellular
A simple procedure for the purification of calmodulin bound to membranes; calmodulin bound to the particulate fraction of AH-66 hepatoma ascites cells.
Carcinoma, Hepatocellular
An effect of dexamethasone on adenosine 3',5'-monophosphate content and adenosine 3',5'-monophosphate phosphodiesterase activity of cultured hepatoma cells.
Carcinoma, Hepatocellular
Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Calcium-activatable phosphodiesterase and calcium-dependent modulator protein in transplantable hepatoma tissues.
Carcinoma, Hepatocellular
Cyclic 3',5'-nucleotide monophosphate phosphodiesterase activity in hepatomas of different growth rates.
Carcinoma, Hepatocellular
Cyclic AMP phosphodiesterase activity in three Morris hepatomas.
Carcinoma, Hepatocellular
Decreased activities of cyclic cytidine 3',5'-monophosphate phosphodiesterase in Morris hepatomas having varying growth rates.
Carcinoma, Hepatocellular
Dynamics of calmodulin and cyclic AMP phosphodiesterase in plasma membranes of rat livers and ascites hepatomas.
Carcinoma, Hepatocellular
EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).
Carcinoma, Hepatocellular
Inhibition of hepatoma cell growth by analogs of adenosine and cyclic AMP and the influence of enzymes in mammalian sera.
Carcinoma, Hepatocellular
No Association of the Exonuclease 1 T439M Polymorphism and Risk of Hepatocellular Carcinoma Development in the Turkish Population: a Case-control Study.
Carcinoma, Hepatocellular
Partial purification from hepatoma cells of an intracellular substance which mediates the effects of insulin on pyruvate dehydrogenase and low Km cyclic AMP phosphodiesterase.
Carcinoma, Hepatocellular
Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition.
Carcinoma, Hepatocellular
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Phosphodiesterase and ribonuclease activities of plasma membrane of rat liver and hepatoma.
Carcinoma, Hepatocellular
Phospholipase C (EC 3.1.4.11): a malignancy linked signal transduction enzyme.
Carcinoma, Hepatocellular
Positive correlation between calmodulin content and hepatoma growth rates.
Carcinoma, Hepatocellular
Studies on responsiveness of hepatoma cells to catecholamines. I. Lack of beta-adrenergic responsiveness in rat ascites hepatoma AH13 cells.
Carcinoma, Hepatocellular
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Carcinoma, Hepatocellular
The action of mitomycin C on the induction of cyclic AMP phosphodiesterase and the development of desensitization of adenylate cyclase by isoproterenol in rat ascites hepatoma AH130 cells.
Carcinoma, Hepatocellular
The antitumour agent 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) inhibits rat liver cAMP phosphodiesterase and amplifies hormone effects in hepatocytes and hepatoma cells.
Carcinoma, Hepatocellular
The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a case-control study.
Carcinoma, Hepatocellular
[Adenosine cyclic-3',5'-monophosphate phosphodiesterase in hepatomas with different growth rates]
Carcinoma, Hepatocellular
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Carcinoma, Lewis Lung
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Carcinoma, Lewis Lung
Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine.
Carcinoma, Lewis Lung
[Effect of polysaccharides on the cyclic nucleotide content and phosphodiesterase activity in the organs of mice with Lewis lung carcinoma]
Carcinoma, Renal Cell
Stimulation by cAMP of erythropoietin secretion by an established human renal carcinoma cell line.
Carcinoma, Squamous Cell
Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells.
Carcinoma, Squamous Cell
Protein kinase A regulates Rac and is required for the growth factor-stimulated migration of carcinoma cells.
Carcinoma, Squamous Cell
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Cardiac Output, Low
Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review.
Cardiac Output, Low
Catecholamine and volume therapy for cardiac surgery in Germany--results from a postal survey.
Cardiac Output, Low
Clinical and haemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery.
Cardiac Output, Low
Comparison of the haemodynamic effects of enoximone and piroximone in patients after cardiac surgery.
Cardiac Output, Low
Current practice of hemodynamic monitoring and vasopressor and inotropic therapy in post-operative cardiac surgery patients in Germany: results from a postal survey.
Cardiac Output, Low
Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock.
Cardiac Output, Low
Inotropic support of the critically ill patient. A review of the agents.
Cardiac Output, Low
[Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery]
Cardiac Output, Low
[Hemodynamic effects of new phosphodiesterase inhibitors in patients with coronary heart disease. A comparison between enoximone and R80122]
Cardiac Output, Low
[The effects of milrinone on hemodynamics in patients undergoing cardiac surgery]
Cardiac Output, Low
[Treatment of low cardiac output by phosphodiesterase inhibitors]
Cardio-Renal Syndrome
Evolving treatment strategies for management of cardiorenal syndrome.
Cardio-Renal Syndrome
Pharmacologic Management of the Cardio-renal Syndrome.
Cardiomegaly
Cyclic AMP synthesis and hydrolysis in the normal and failing heart.
Cardiomegaly
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Cardiomegaly
Decreased activity of the Na+/H+ exchanger by phosphodiesterase 5A inhibition is attributed to an increase in protein phosphatase activity.
Cardiomegaly
Function of myocardial alpha-adrenoceptors.
Cardiomegaly
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.
Cardiomegaly
Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
Cardiomegaly
Myocardial energetics: experimental and clinical studies to address its determinants and aerobic limit.
Cardiomegaly
Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes.
Cardiomegaly
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Cardiomyopathies
An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety.
Cardiomyopathies
Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.
Cardiomyopathies
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Cardiomyopathies
Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy.
Cardiomyopathies
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Cardiomyopathies
The activity of adenylate cyclase and phosphodiesterase in the isoproterenol-damaged cardiac muscle of spontaneously hypertensive rats.
Cardiomyopathies
[Enoximone as an alternative to mechanical circulatory support prior to heart transplantation]
Cardiomyopathies
[Enoximone as pharmacologic "bridging" to heart transplantation]
Cardiomyopathy, Dilated
Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure.
Cardiomyopathy, Dilated
Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.
Cardiomyopathy, Dilated
Effect of dobutamine and OPC-18790 on diastolic chamber stiffness in patients with idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
Effects of intravenous milrinone on left ventricular function in ischemic and idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
Immunomodulatory effect of pentoxifylline in suppressing experimental autoimmune myocarditis.
Cardiomyopathy, Dilated
Influence of enoximone and UDCG-115 on coronary hemodynamics in idiopathic dilated cardiomyopathy.
Cardiomyopathy, Dilated
Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart failure due to dilated cardiomyopathy.
Cardiomyopathy, Dilated
Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy: response to dobutamine and amrinone.
Cardiomyopathy, Dilated
Phosphodiesterase inhibition and positive inotropic effects.
Cardiomyopathy, Dilated
Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
Cardiomyopathy, Dilated
[Anesthetic management of a patient with dilated cardiomyopathy using olprinone]
Cardiomyopathy, Dilated
[Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone]
Cardiomyopathy, Hypertrophic
Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
Cardiotoxicity
A synopsis of research in cardiac apoptosis and its application to congestive heart failure.
Cardiotoxicity
Anagrelide-induced cardiomyopathy.
Cardiotoxicity
Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon.
Cardiotoxicity
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Cardiotoxicity
Epinephrine induced myocardial necrosis: effects of aminophylline and adrenergic blockade.
Cardiovascular Diseases
A comprehensive review on the potential therapeutic benefits of phosphodiesterase inhibitors on cardiovascular diseases.
Cardiovascular Diseases
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
Cardiovascular Diseases
Beneficial effects of tetramethylpyrazine, an active constituent of Chinese herbs, on rats with endotoxemia.
Cardiovascular Diseases
Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.
Cardiovascular Diseases
Chronic treatment with Sildenafil has no effect on folliculogenesis or fertility in C57BL/6 and C57BL/6 knockout for iNOS mice.
Cardiovascular Diseases
Clinical studies of phosphodiesterase inhibitors for cardiovascular disease.
Cardiovascular Diseases
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Cardiovascular Diseases
Drug interactions: the new phosphodiesterase inhibitor enoximone and the calcium channel blocker nifedipine in coronary surgery patients--influence on hemodynamics and plasma concentrations.
Cardiovascular Diseases
Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study.
Cardiovascular Diseases
Effect of Andrographolide on Gene Expression Profile and Intracellular Calcium in Primary Rat Myocardium Microvascular Endothelial Cells.
Cardiovascular Diseases
Effects of heterologous expression of human cyclic nucleotide Phosphodiesterase 3A (hPDE3A) on redox regulation in yeast.
Cardiovascular Diseases
Efficacy of B-Type Natriuretic Peptide Is Coupled to Phosphodiesterase 2A in Cardiac Sympathetic Neurons.
Cardiovascular Diseases
Erectile dysfunction.
Cardiovascular Diseases
Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver.
Cardiovascular Diseases
Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings.
Cardiovascular Diseases
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Cardiovascular Diseases
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease.
Cardiovascular Diseases
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
Cardiovascular Diseases
Sexual dysfunction and cardiac Risk (the Second Princeton Consensus Conference).
Cardiovascular Diseases
Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting ?-Helix Backbone Oxygen by Halogen Bonding.
Cardiovascular Diseases
Upregulation of Myocardial and Vascular Phosphodiesterase 9A in A Model of Atherosclerotic Cardiovascular Disease.
Carney Complex
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Carotid Artery Diseases
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Carotid Artery Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Catalepsy
Effect of cyclo(Leu-Gly) on cyclic GMP-phosphodiesterase activity changes associated with development of tolerance to morphine-induced antinociception, catalepsy, respiratory depression and mydriasis.
Catalepsy
[Effect of phosphodiesterase inhibitors on neuroleptic-induced catalepsy and apomorphine-induced stereotypic movements in rats]
Central Nervous System Diseases
A Novel Inhibition Modality for Phosphodiesterase 2A.
Central Nervous System Diseases
Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases.
Central Nervous System Diseases
Phosphodiesterases as a New Therapeutic Targets for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases.
Central Serous Chorioretinopathy
Central serous chorioretinopathy treatment with a systemic PDE5 and PDE6 inhibitor (sildenafil).
Cerebral Hemorrhage
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Cerebral Infarction
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Cerebral Infarction
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Cerebral Infarction
Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.
Cerebral Infarction
Tenascin-C in brain injuries and edema after subarachnoid hemorrhage: Findings from basic and clinical studies.
Cerebral Small Vessel Diseases
Antiplatelet Therapy in Cerebral Small Vessel Disease.
Cerebrovascular Disorders
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Cerebrovascular Disorders
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Cerebrovascular Disorders
Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
Cerebrovascular Disorders
Mixed Cerebrovascular Disease and the Future of Stroke Prevention.
Cerebrovascular Disorders
Progress in the Mechanism and Clinical Application of Cilostazol.
Cerebrovascular Disorders
The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation.
Chagas Disease
Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and implications for the design of parasite selective inhibitors.
Chagas Disease
Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.
Cholecystitis
Hemorrhagic cholecystitis in an elderly patient taking aspirin and cilostazol.
Cholera
5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms.
Cholera
Acetylcholine inhibits positive inotropic effect of cholera toxin in ventricular muscle.
Cholera
Action of cAMP on expression and release of adhesion molecules in human endothelial cells.
Cholera
Actions of peptide YY and neuropeptide Y on chief cells from guinea pig stomach.
Cholera
Activators of adenylate cyclase and cyclic AMP prolong calcium-dependent action potentials of mouse sensory neurons in culture by reducing a voltage-dependent potassium conductance.
Cholera
Adenosine 3:5' cyclic monophosphate synthesis by human tracheal epithelial cells.
Cholera
Alpha 2-adrenergic regulation of arylalkylamine N-acetyltransferase in organ-cultured chick pineal gland: characterization with agonists and modulation of experimentally stimulated enzyme activity.
Cholera
Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells.
Cholera
Calcitonin stimulates plasminogen activator in porcine renal tubular cells: LLC-PK1.
Cholera
Calcium and cyclic nucleotide interaction in secretion of amylase from rat pancreas in vitro.
Cholera
Calcium ion and cyclic adenosine 3',5'-monophosphate regulate proopiomelanocortin messenger ribonucleic acid levels in rat intermediate and anterior pituitary lobes.
Cholera
cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T cells while decreasing IL-2 release and NF-AT induction.
Cholera
Cholinergic inhibition of catecholamine-stimulable cyclic AMP accumulation in murine atria.
Cholera
Control of monocyte C2 production by cyclic AMP.
Cholera
Cyclic adenosine-3',5'-monophosphate stimulates the acute release of placental lactogen from human trophoblast cells.
Cholera
Cyclic AMP is a likely mediator of ovulation in the tsetse fly.
Cholera
Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils.
Cholera
Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes.
Cholera
Cyclic nucleotides, possible intracellular mediators of macrophage activation and secretory processes.
Cholera
Decrease in cAMP levels promoted by CD48-CD2 interaction correlates with inhibition of apoptosis in B cells.
Cholera
Decreased phosphodiesterase activity in cholera toxin-induced hypersecretion in suckling rats.
Cholera
Desensitization of the cAMP system in mouse Leydig cells by hCG, cholera toxin, dibutyryl cAMP and cAMP: localization of the 'lesion' to the guanine nucleotide regulatory protein-adenylate cyclase complex.
Cholera
Differences in the beta-adrenergic responsiveness between high and low passage rat glioma C6 cells.
Cholera
Discrepancy between effects of cholera toxin on net fluid movement and cAMP levels in rat jejunum, ileum, and colon.
Cholera
Effect of adenylyl cyclase activation on intracellular and extracellular cAMP and cGMP in preimplantation cattle blastocysts.
Cholera
Effects of cholera toxin and isobutylmethylxanthine on growth of human fibroblasts.
Cholera
Effects of cholera toxin and phosphodiesterase inhibitors on fluid transport and cyclic adenosine 3',5'-monophosphate concentrations in rabbit gallbladder.
Cholera
Effects of cholera toxin on cyclic AMP accumulation and bone resorption in cultured mouse calvaria.
Cholera
Effects of cholinergic and adrenergic agonists on phosphorylation of a 165,000-dalton myofibrillar protein in intact cardiac muscle.
Cholera
Effects of cyclic adenosine 3':5'-monophosphate upon glycoprotein and carcinoembryonic antigen synthesis and release by human colon cancer cells.
Cholera
Effects of GnRH and drugs that affect cAMP levels on LH synthesis and release.
Cholera
Effects of prostaglandins and cAMP levels on monocyte IL-1 production.
Cholera
Effects of sera, basic fibroblast growth factor, heparin and cyclic AMP-stimulation on proliferation of human vascular endothelial cells.
Cholera
Epidermal growth factor stimulates formation of inositol phosphates in BALB/c/3T3 cells pretreated with cholera toxin and isobutylmethylxanthine.
Cholera
Estradiol receptor and cyclic nucleotide phosphodiesterase: functional relationship, possible role of guanine nucleotide binding proteins.
Cholera
Forskolin does not activate sperm adenylate cyclase.
Cholera
Hormonal control of phosphodiesterase activity in cultured rat Sertoli cells.
Cholera
Hormonal regulation of inhibin production by cultured Sertoli cells.
Cholera
In ovo growth hormone alters growth and adipose tissue development of chickens.
Cholera
Induction of refractoriness to isoproterenol by prior treatment of C6-2B rat astrocytoma cells with cholera toxin.
Cholera
Inhibition of follicle-stimulating hormone- and adenosine-3',5'-cyclic monophosphate-induced progesterone production by calcium and protein kinase C in the rat ovary.
Cholera
Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds.
Cholera
Inhibition of ornithine decarboxylase and S-adenosylmethionine decarboxylase activities of S49 lymphoma cells by agents increasing cyclic AMP.
Cholera
Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-O-tetradecanoyl-phorbol-13-acetate.
Cholera
Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation.
Cholera
Involvement of calcium in the release of immunoreactive beta-endorphin-like peptide from dispersed cells of the neurointermediate lobe of the rat pituitary gland.
Cholera
Isolation of a mutant LLC-PK1 cell line defective in hormonal responsiveness. A pleiotropic lesion in receptor function.
Cholera
Isolation of nontoxinogenic mutants of Vibrio cholerae in a colorimetric assay for cholera toxin using the S49 mouse lymphosarcoma cell line.
Cholera
Mechanism of erythropoietin action on the erythroid progenitor cells induced from murine erythroleukemia cells (TSA8).
Cholera
Modulation of in vitro erythropoiesis: enhancement of erythroid colony growth by cyclic nucleotides.
Cholera
Multiple signal transduction mechanisms leading to the secretion of 5-hydroxytryptamine by MTC cells, a neurectodermally derived cell line.
Cholera
Oxidized-low density lipoprotein inhibits cyclic AMP production by porcine luteal cells.
Cholera
Partial reversal of doxorubicin resistance by forskolin and 1,9-dideoxyforskolin in murine sarcoma S180 variants.
Cholera
Pharmacological elevation of cyclic AMP and transmitter release at the mouse neuromuscular junction.
Cholera
Photoreactive (caged) cyclic AMP analogs induce DNA synthesis in mammary epithelial cells.
Cholera
Potentiation between intracellular cyclic-AMP-elevating agents and inducers of leukemic cell differentiation.
Cholera
Regulation by butyrate of the cAMP response to cholera toxin and forskolin in pituitary GH1 cells.
Cholera
Regulation of dome formation in differentiated epithelial cell cultures.
Cholera
Regulation of interleukin 2 synthesis by cAMP in human T cells.
Cholera
Regulation of oocyte maturation in the rainbow trout,Salmo gairdneri: role of cyclic AMP in the mechanism of action of the maturation inducing steroid (MIS), 17?-hydroxy, 20?-dihydroprogesterone.
Cholera
Relation between cyclic adenosine monophosphate and prostaglandin output by dispersed cells from human amnion and decidua.
Cholera
Role of cyclic nucleotides in the inhibition of growth-hormone secretion by somatostatin.
Cholera
Role of cytokines in the modulation of nitric oxide production by cyclic AMP.
Cholera
Role of protein kinase C in transforming growth factor-beta 1 induction of carcinoembryonic antigen in human colon carcinoma cells.
Cholera
Somatic genetic analysis of cyclic AMP action: characterization of unresponsive mutants.
Cholera
Stimulatory and inhibitory effects of cyclic AMP on pancreatic glucagon release from monolayer cultures and the controlling role of calcium.
Cholera
Studies on the mechanisms of somatostatin action on insulin release. IV. effect of somatostatin on cyclic AMP levels and phosphodiesterase activity in isolated rat pancreatic islets.
Cholera
Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.
Cholera
Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Cholera
Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP.
Cholera
The phorbol ester TPA prevents the expression of both glucagon desensitisation and the glucagon-mediated block of insulin stimulation of the peripheral plasma membrane cyclic AMP phosphodiesterase in rat hepatocytes.
Cholera
The phorbol ester, TPA inhibits glucagon-stimulated adenylate cyclase activity.
Cholera
The relationship between intracellular cyclic AMP concentrations and the in vitro growth of macrophages.
Cholera
Thyrotropin-releasing hormone activates a Ca2+-dependent polyphosphoinositide phosphodiesterase in permeable GH3 cells. GTP gamma S potentiation by a cholera and pertussis toxin-insensitive mechanism.
Cholera
Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line.
Cholera
[Mechanism of beta-endorphin release regulation--evaluation using dispersed cells of the pituitary intermediate lobe]
Cholera
[Role of phosphodiesterase in the changes of cyclic adenosine-3',5'-monophosphate in the rabbit jejunal mucosa after treatment with cholera enterotoxin]
Cholera
[The effects of cholera toxin in the release of beta-endorphin from the dispersed cells of the rat neurointermediate lobe]
Chondrosarcoma
Regulation of chondrosarcoma metabolism by cyclic adenosine 3'5'-monophosphate.
Choroideremia
Regional expression of disease-related genes in human and monkey retina.
Cleft Palate
Developmental pattern of cAMP, adenyl cyclase, and cAMP phosphodiesterase in the palate, lung, and liver of the fetal mouse: alterations resulting from exposure to methylmercury at levels inhibiting palate closure.
Colic
Pathophysiology and symptoms of renal colic in children - a case report.
Colic
Pharmacological explanation for the medicinal use of Juniperus excelsa in hyperactive gastrointestinal and respiratory disorders.
Colic
Studies on the chemical composition and possible mechanisms underlying the antispasmodic and bronchodilatory activities of the essential oil of Artemisia maritima L.
Colic
Treatment of loin pain suspected to be renal colic with papaverine hydrochloride: a prospective double-blind randomised study.
Colitis
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways.
Colitis
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
Colitis
The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice.
Colitis
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.
Colitis, Ulcerative
Clinical utility of plecanatide in the treatment of chronic idiopathic constipation.
Colitis, Ulcerative
In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
Colitis, Ulcerative
Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
Colonic Neoplasms
Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate phosphodiesterase activities in 1,2-dimethylhydrazine induced colon adenocarcinoma.
Colonic Neoplasms
Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase.
Colonic Neoplasms
Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.
Colonic Neoplasms
Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility.
Colonic Neoplasms
Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.
Colonic Neoplasms
Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors.
Color Vision Defects
A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked to mutations in the PDE6C gene.
Color Vision Defects
Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia.
Color Vision Defects
Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia.
Colorectal Neoplasms
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
Colorectal Neoplasms
Clinical utility of plecanatide in the treatment of chronic idiopathic constipation.
Colorectal Neoplasms
ETHE1 overexpression promotes SIRT1 and PGC1? mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer.
Colorectal Neoplasms
Functional alterations of human exonuclease 1 mutants identified in atypical hereditary nonpolyposis colorectal cancer syndrome.
Colorectal Neoplasms
Germline deletions of EXO1 do not cause colorectal tumors and lesions which are null for EXO1 do not have microsatellite instability.
Colorectal Neoplasms
Hereditary non-polyposis colorectal cancer and the role of hPMS2 and hEXO1 mutations.
Colorectal Neoplasms
Impact of EXO1 polymorphism in susceptibility to colorectal cancer.
Colorectal Neoplasms
Nuclear localization of human DNA mismatch repair protein exonuclease 1 (hEXO1).
Colorectal Neoplasms
Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker in human colorectal cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
Advances in the study of Lynch syndrome in China.
Colorectal Neoplasms, Hereditary Nonpolyposis
Functional alterations of human exonuclease 1 mutants identified in atypical hereditary nonpolyposis colorectal cancer syndrome.
Colorectal Neoplasms, Hereditary Nonpolyposis
Nuclear localization of human DNA mismatch repair protein exonuclease 1 (hEXO1).
Colorectal Neoplasms, Hereditary Nonpolyposis
Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.
Coma
Controlling anoxic tolerance in adult Drosophila via the cGMP-PKG pathway.
Cone-Rod Dystrophies
A new PDE6A missense variant p.Arg544Gln in rod-cone dystrophy.
Confusion
[Cyclic nucleotide phosphodiesterase in vertebrates]
Connective Tissue Diseases
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension.
Contracture
Effects of dibutyryl cyclic AMP, ouabain, and xanthine derivatives on crossbridge kinetics in rat cardiac muscle.
Contracture
Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting.
Contracture
[Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone]
Coronary Artery Disease
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Coronary Artery Disease
Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease.
Coronary Artery Disease
Molecular genetics of coronary artery disease.
Coronary Artery Disease
Some aspects of the cardiovascular pharmacology of UK 14,275 in patients with coronary artery disease.
Coronary Artery Disease
[Continuous beta-block with esmolol in combination with enoximone : Influence on cardiac function in high risk patients undergoing vascular surgery.]
Coronary Artery Disease
[Cyclic adenosine monophosphate and atherogenic factors]
Coronary Artery Disease
[Pharmacodynamic effects of the phosphodiesterase inhibitor enoximone during exposure to the volatile anesthetics halothane and isoflurane in coronary surgery patients]
Coronary Disease
Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease.
Coronary Disease
Cardiovascular effects of forskolin and phosphodiesterase-III inhibitors.
Coronary Disease
Features of coronary heart disease development in emergency workers of the Chornobyl accident depending on the action of radiation and non radiation risk factors and genotypes of single nucleotide polymorphism rs966221 of phosphodiesterase 4D gene.
Coronary Disease
[Enoximone as pharmacologic "bridging" to heart transplantation]
Coronary Disease
[Hemodynamic effects of new phosphodiesterase inhibitors in patients with coronary heart disease. A comparison between enoximone and R80122]
Coronary Disease
[Hemodynamic, anti-ischemic, metabolic and neurohumoral effects of enoximone (MDL 17,043) in patients with coronary disease]
Coronary Stenosis
Treatment of ischaemic left ventricular dysfunction with milrinone or dobutamine administered during coronary artery stenosis in the presence of beta blockade in pigs.
Coronary Thrombosis
Potentiation of phosphodiesterase inhibitor antithrombotic activity with alpha-2 adrenergic blockade.
Cough
Efficacy and safety profile of roflumilast in a real-world experience.
Cough
Studies on Bronchodilator Activity of Salvia officinalis (Sage): Possible Involvement of K(+) Channel Activation and Phosphodiesterase Inhibition.
COVID-19
Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19).
COVID-19
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
COVID-19
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
COVID-19
Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.
COVID-19
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Crohn Disease
Cytokine-based therapies in inflammatory bowel disease.
Crohn Disease
In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
Cushing Syndrome
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Cushing Syndrome
Carney complex.
Cushing Syndrome
Familial micronodular adrenocortical disease, Cushing syndrome, and mutations of the gene encoding phosphodiesterase 11A4 (PDE11A).
Cushing Syndrome
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Cystic Fibrosis
Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.
Cystic Fibrosis
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.
Cystic Fibrosis
Adrenergic secretory responses of submandibular tissues from control subjects and cystic fibrosis patients.
Cystic Fibrosis
Altered calmodulin activity in buccal epithelial cells from cystic fibrosis patients.
Cystic Fibrosis
Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
Cystic Fibrosis
Isobutylmethylxanthine fails to stimulate chloride secretion in cystic fibrosis airway epithelia.
Cystic Fibrosis
Mechanisms of anion secretion in Calu-3 human airway epithelial cells by 7,8-benzoquinoline.
Cystic Fibrosis
Potassium release in labial glands from controls and patients with cystic fibrosis.
Cystic Fibrosis
Prenatal diagnosis of cystic fibrosis by assay of amniotic fluid microvillar enzymes.
Cystic Fibrosis
The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects.
Cystitis
Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
Cystitis
Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation.
Cystitis
Uroprotective effect of pentoxifylline in cyclophosphamide-induced hemorrhagic cystitis in rats.
Death, Sudden, Cardiac
Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
Decompression Sickness
Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.
Dementia
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Dementia
Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: implication of cilostazol for diabetes mellitus-induced dementia.
Dementia
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Dementia
Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale.
Dementia
Propentofylline for dementia.
Dementia
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Dementia, Vascular
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Demyelinating Diseases
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
Demyelinating Diseases
Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors.
Demyelinating Diseases
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Dermatitis
Adenosine 3':5'-cyclic monophosphate phosphodiesterase in skin. II. Levels in atopic dermatitis.
Dermatitis
Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Dermatitis, Atopic
2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Dermatitis, Atopic
A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults.
Dermatitis, Atopic
A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves.
Dermatitis, Atopic
Adenosine 3':5'-cyclic monophosphate phosphodiesterase in skin. II. Levels in atopic dermatitis.
Dermatitis, Atopic
Altered leukocyte protein kinase activity in atopic dermatitis.
Dermatitis, Atopic
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Dermatitis, Atopic
Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis
Dermatitis, Atopic
Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Dermatitis, Atopic
Cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from patients with atopic dermatitis: correlation with respiratory atopy.
Dermatitis, Atopic
Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Dermatitis, Atopic
Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.
Dermatitis, Atopic
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models.
Dermatitis, Atopic
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Dermatitis, Atopic
Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study.
Dermatitis, Atopic
Elevated cyclic adenosine monophosphate phosphodiesterase activity in peripheral blood mononuclear leucocytes from children with atopic dermatitis.
Dermatitis, Atopic
Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.
Dermatitis, Atopic
gamma-interferon production in atopic dermatitis shows differential modification by phosphodiesterase and prostaglandin inhibition.
Dermatitis, Atopic
Immunopharmacology of the atopic diseases.
Dermatitis, Atopic
Impaired lymphocyte cyclic adenosine monophosphate responses in atopic eczema.
Dermatitis, Atopic
In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Dermatitis, Atopic
Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy.
Dermatitis, Atopic
Inositol metabolism in mononuclear leucocytes from patients with atopic dermatitis.
Dermatitis, Atopic
Modulation of leukocyte cyclic AMP phosphodiesterase activity by recombinant interferon-gamma: evidence for a differential effect on atopic monocytes.
Dermatitis, Atopic
Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.
Dermatitis, Atopic
Peripheral blood mononuclear leukocyte cyclic adenosine monophosphate specific phosphodiesterase activity in childhood atopic dermatitis.
Dermatitis, Atopic
Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis.
Dermatitis, Atopic
Phosphodiesterase and immune dysfunction in atopic dermatitis.
Dermatitis, Atopic
Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro.
Dermatitis, Atopic
Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis.
Dermatitis, Atopic
Response of mononuclear leukocyte cyclic adenosine monophosphate-phosphodiesterase activity to treatment with topical fluorinated steroid ointment in atopic dermatitis.
Dermatitis, Atopic
Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.
Dermatitis, Atopic
The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy.
Dermatitis, Atopic
The effect of in vitro exposure to histamine on mononuclear leucocyte phosphodiesterase activity in atopic dermatitis.
Dermatitis, Atopic
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Dermatitis, Atopic
Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dermatitis, Atopic
Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis.
Dermatitis, Atopic
[Changed phosphodiesterase activity of leukocytes in atopic eczema]
Dermatitis, Atopic
[Papaverin--effective in therapy of pruritus of atopic dermatitis?]
Dermatitis, Atopic
[Topical therapy for atopic eczema].
Diabetes Insipidus
Renal medullary adenylate cyclase in rats with hypothalamic diabetes insipidus.
Diabetes Insipidus, Nephrogenic
Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.
Diabetes Mellitus
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Diabetes Mellitus
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Diabetes Mellitus
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?
Diabetes Mellitus
Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis.
Diabetes Mellitus
Effect of cilostazol on the neuropathies of streptozotocin-induced diabetic rats.
Diabetes Mellitus
Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.
Diabetes Mellitus
Increased PC-1 phosphodiesterase activity and inhibition of glucose uptake in adipocytes of type 2 diabetic rats.
Diabetes Mellitus
Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus.
Diabetes Mellitus
Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus.
Diabetes Mellitus
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Diabetes Mellitus
Temporal changes in vascular reactivity in early diabetes mellitus in rats: role of changes in endothelial factors and in phosphodiesterase activity.
Diabetes Mellitus
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Diabetes Mellitus
Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.
Diabetes Mellitus
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension.
Diabetes Mellitus
[Treatment of erectile dysfunction of neurogenic genesis with inhibitors of phosphodiesterase of type 5 in patients with diabetes mellitus]
Diabetes Mellitus, Experimental
The response of cyclic 3',5'-AMP and cyclic 3',5'-GMP phosphodiesterases to experimental diabetes.
Diabetes Mellitus, Lipoatrophic
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus, Type 2
Analysis of the insulin-sensitive phosphodiesterase 3B gene in type 2 diabetes.
Diabetes Mellitus, Type 2
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Diabetes Mellitus, Type 2
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Common variants in the ENPP1 gene are not reproducibly associated with diabetes or obesity.
Diabetes Mellitus, Type 2
Could chronic Vardenafil administration influence the cardiovascular risk in men with type 2 diabetes mellitus?
Diabetes Mellitus, Type 2
Decreased glucagon-stimulated cyclic AMP production by isolated liver cells of rats with type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients.
Diabetes Mellitus, Type 2
ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes in North Indians.
Diabetes Mellitus, Type 2
Increased PC-1 phosphodiesterase activity and inhibition of glucose uptake in adipocytes of type 2 diabetic rats.
Diabetes Mellitus, Type 2
Pancreatic ?-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes.
Diabetes Mellitus, Type 2
Phosphodiesterase activity in human subcutaneous adipose tissue in insulin- and noninsulin-dependent diabetes mellitus.
Diabetes Mellitus, Type 2
Systematic search for single nucleotide polymorphisms in the 5' flanking region of the human phosphodiesterase 3B gene: absence of evidence for major effects of identified polymorphisms on susceptibility to Japanese type 2 diabetes.
Diabetes Mellitus, Type 2
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Diabetes Mellitus, Type 2
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Diabetes Mellitus, Type 2
Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.
Diabetic Angiopathies
Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F.
Diabetic Nephropathies
Effect of phosphodiesterase inhibitor on diabetic nephropathy.
Diabetic Nephropathies
Evaluation of Drug Interaction of Glimepiride with Phosphodiesterase Inhibitors Type V in Diabetic Nephropathy.
Diabetic Neuropathies
Effect of cilostazol on experimental diabetic neuropathy in the rat.
Diabetic Neuropathies
Sexual dysfunction in men and women with endocrine disorders.
Drug-Related Side Effects and Adverse Reactions
Phosphodiesterase inhibitors in inflammatory bowel disease.
Dry Eye Syndromes
Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease.
Dry Eye Syndromes
PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease.
Dyskinesias
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Dyskinesias
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
Dyskinesias
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Dyslipidemias
Xanthine-based KMUP-1 improves HDL via PPAR?/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss.
Dysostoses
Mutations causing acrodysostosis-2 facilitate activation of phosphodiesterase 4D3.
Dyspnea
Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
Dyspnea
Isolated unilateral absence of pulmonary artery in adulthood: a clinical analysis of 65 cases from a case series and systematic review.
Dyspnea
Migraine with aura following atrial septostomy for pulmonary arterial hypertension.
Embolism
Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats.
Encephalitis
Virus-induced alterations in cyclic adenosine monophosphate generation in hamster islets of Langerhans.
Encephalomyelitis
Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2',3' cyclic nucleotide 3' phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE.
Encephalomyelitis
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Encephalomyelitis
Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats.
Encephalomyelitis
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Encephalomyelitis
Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells.
Encephalomyelitis
The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents.
Encephalomyelitis
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Encephalomyelitis, Autoimmune, Experimental
Heat shock proteins and experimental autoimmune encephalomyelitis (EAE): I. Immunization with a peptide of the myelin protein 2',3' cyclic nucleotide 3' phosphodiesterase that is cross-reactive with a heat shock protein alters the course of EAE.
Encephalomyelitis, Autoimmune, Experimental
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Encephalomyelitis, Autoimmune, Experimental
Phosphodiesterase activity of nervous tissue in experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats.
Encephalomyelitis, Autoimmune, Experimental
Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?
Encephalomyelitis, Autoimmune, Experimental
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Encephalomyelitis, Autoimmune, Experimental
Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells.
Encephalomyelitis, Autoimmune, Experimental
The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents.
Encephalomyelitis, Autoimmune, Experimental
Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors.
Encephalomyelitis, Autoimmune, Experimental
Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase.
End Stage Liver Disease
NMDA receptors in hyperammonemia and hepatic encephalopathy.
End Stage Liver Disease
The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation.
Endocrine System Diseases
Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis.
Endotoxemia
Amrinone combined with dobutamine improves hemodynamics and oxygen delivery without down-regulation of cardiac beta-adrenergic receptor density in porcine endotoxemia.
Endotoxemia
Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia.
Endotoxemia
Enoximone maintains intestinal villus blood flow during endotoxemia.
Endotoxemia
Influence of amrinone on intestinal villus blood flow during endotoxemia.
Endotoxemia
Milrinone improves intestinal villus blood flow during endotoxemia.
Endotoxemia
Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Endotoxemia
Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia.
Endotoxemia
Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independent.
Endotoxemia
The effects of olprinone (a phosphodiesterase III inhibitor) on hepatic vascular bed in a porcine model of endotoxemia.
Enteritis
Necrotic enteritis locus 1 diguanylate cyclase and phosphodiesterase (cyclic-di-GMP) gene mutation attenuates virulence in an avian necrotic enteritis isolate of Clostridium perfringens.
Eosinophilia
Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.
Eosinophilia
The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways.
Eosinophilia
The potential roles of cytokines, IL-5 and IL-8, and plasma cortisol in the anti-inflammatory actions of phosphodiesterase inhibitors in sensitized guinea-pig airways.
Eosinophilia
Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Epistaxis
Epistaxis after PDE-5 inhibitors misuse.
Erectile Dysfunction
A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction.
Erectile Dysfunction
A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Erectile Dysfunction
A validated LC-MS/MS assay for the quantification of phosphodiesterase-5 inhibitors in human plasma.
Erectile Dysfunction
Administration of daily 5?mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
Erectile Dysfunction
Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.
Erectile Dysfunction
Association Between Infertility and Sexual Dysfunction in Men and Women.
Erectile Dysfunction
Atrial fibrillation after vardenafil therapy.
Erectile Dysfunction
Avanafil for the treatment of erectile dysfunction.
Erectile Dysfunction
Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.
Erectile Dysfunction
Cialis (tadalafil): a new treatment for erectile dysfunction.
Erectile Dysfunction
Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors.
Erectile Dysfunction
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Erectile Dysfunction
Clinical responses to sildenafil in Waldenstrom's macroglobulinemia.
Erectile Dysfunction
Co-crystal structures of PKG I? (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding.
Erectile Dysfunction
Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
Erectile Dysfunction
Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease.
Erectile Dysfunction
Correlations With Satisfaction Measures in Men Treated With Phosphodiesterase Inhibitors for Erectile Dysfunction.
Erectile Dysfunction
Current and future trends in the oral pharmacotherapy of male erectile dysfunction.
Erectile Dysfunction
Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease.
Erectile Dysfunction
Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract.
Erectile Dysfunction
Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
Erectile Dysfunction
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Erectile Dysfunction
Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function.
Erectile Dysfunction
Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
Erectile Dysfunction
Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease.
Erectile Dysfunction
Effect of sildenafil on renin secretion in human subjects.
Erectile Dysfunction
Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males.
Erectile Dysfunction
Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects.
Erectile Dysfunction
Effects of the specific phosphodiesterase inhibitors on alloxan-induced diabetic rabbit cavernous tissue in vitro.
Erectile Dysfunction
Erectile dysfunction drugs altered the activities of antioxidant enzymes, oxidative stress and the protein expressions of some cytochrome P450 isozymes involved in the steroidogenesis of steroid hormones.
Erectile Dysfunction
Erectile dysfunction drugs and oxidative stress in the liver of male rats.
Erectile Dysfunction
Erectile dysfunction.
Erectile Dysfunction
Erectile dysfunction: management update.
Erectile Dysfunction
Erectile dysfunction: on the efficacy of a phosphodiesterase inhibitor in patients with multiple risk factors.
Erectile Dysfunction
Erectile dysfunction: on the efficacy of a phosphodiesterase inhibitor with concurrent sex therapy.
Erectile Dysfunction
Evaluation and treatment of autonomic disorders of the urogenital system.
Erectile Dysfunction
Evaluation and treatment of erectile dysfunction in men with diabetes mellitus.
Erectile Dysfunction
Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men.
Erectile Dysfunction
FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A).
Erectile Dysfunction
Future strategies for treating erectile dysfunction.
Erectile Dysfunction
Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat.
Erectile Dysfunction
Local Treatment of Penile Prosthesis Infection as Alternative to Immediate Salvage Surgery.
Erectile Dysfunction
Management of male sexual dysfunction after cancer treatment.
Erectile Dysfunction
Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Erectile Dysfunction
Metabolism of aildenafil in vivo in rats and in vitro in mouse, rat, dog, and human liver microsomes.
Erectile Dysfunction
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.
Erectile Dysfunction
Might erectile dysfunction be due to the thermolabile variant of methylenetetrahydrofolate reductase?
Erectile Dysfunction
MONOTHERAPY FOR COMORBID ERECTILE DYSFUNCTION AND LOWER URINARY TRACT SYMPTOMS: PHOSPHODIESTERASE INHIBITOR OR ?-ADRENOCEPTOR ANTAGONIST?
Erectile Dysfunction
Myocardial Impact of NHE1 Regulation by Sildenafil.
Erectile Dysfunction
Neuropeptides and central control of sexual behaviour from the past to the present: A review.
Erectile Dysfunction
New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome: effects of tadalafil administration.
Erectile Dysfunction
New phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Erectile Dysfunction
Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction.
Erectile Dysfunction
Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case.
Erectile Dysfunction
Novel therapies for cyclic GMP control of vascular smooth muscle growth.
Erectile Dysfunction
Novel treatment options for overlapping yet distinct erectile dysfunction and andropause syndromes.
Erectile Dysfunction
Obesity, An Enemy of Male Fertility: A Mini Review.
Erectile Dysfunction
Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Erectile Dysfunction
PDE-5 and NOS II mRNA expression in menopausal women: a molecular biology study.
Erectile Dysfunction
PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy.
Erectile Dysfunction
PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study.
Erectile Dysfunction
Penile prosthetic surgery and its role in the treatment of end-stage erectile dysfunction - an update.
Erectile Dysfunction
Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature.
Erectile Dysfunction
Pharmacologic treatment of erectile dysfunction.
Erectile Dysfunction
Pharmacology of phosphodiesterase-5 inhibitors.
Erectile Dysfunction
Pharmacotherapy for erectile dysfunction.
Erectile Dysfunction
Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models.
Erectile Dysfunction
Pharmacotherapy of sexual dysfunctions : current status.
Erectile Dysfunction
Phosphodiesterase (PDE5) inhibition assay for rapid detection of erectile dysfunction drugs and analogs in sexual enhancement products.
Erectile Dysfunction
Phosphodiesterase inhibition: erectile dysfunction is only part of the story.
Erectile Dysfunction
Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Erectile Dysfunction
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Erectile Dysfunction
Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase inhibitors in female sexual dysfunction.
Erectile Dysfunction
Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men.
Erectile Dysfunction
Phosphodiesterase inhibitors in the treatment of erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions.
Erectile Dysfunction
Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.
Erectile Dysfunction
Phosphodiesterase Type 5 Inhibitors in Postprostatectomy Erectile Dysfunction: A Critical Analysis of the Basic Science Rationale and Clinical Application.
Erectile Dysfunction
Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs.
Erectile Dysfunction
Re: JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
Erectile Dysfunction
Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction.
Erectile Dysfunction
Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
Erectile Dysfunction
Safety of Phosphodiesterase-5 Inhibitors in Valvular Heart Disease.
Erectile Dysfunction
Sexual disorders in men with multiple sclerosis: evaluation and management.
Erectile Dysfunction
Should phosphodiesterase 5 selective inhibitors be used for uterine relaxation?
Erectile Dysfunction
Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease.
Erectile Dysfunction
Sildenafil citrate for female sexual arousal disorder: a future possibility?
Erectile Dysfunction
Sildenafil for erectile dysfunction.
Erectile Dysfunction
Sildenafil for selective serotonin reuptake inhibitor-induced erectile dysfunction in elderly male depressed patients.
Erectile Dysfunction
Sildenafil increases the force of right atrial contractions in vitro via the NO-guanylyl cyclase pathway involving beta-adrenoceptor linked mechanisms.
Erectile Dysfunction
Sildenafil obviates ischemia-reperfusion injury-induced acute kidney injury through peroxisome proliferator-activated receptor ? agonism in rats.
Erectile Dysfunction
Sildenafil reduces alcohol-induced gastric damage: just say 'NO'.
Erectile Dysfunction
Sildenafil Use and Increased Risk of Incident Melanoma in US Men: A Prospective Cohort Study.
Erectile Dysfunction
Sildenafil, a novel effective oral therapy for male erectile dysfunction.
Erectile Dysfunction
Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
Erectile Dysfunction
Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction.
Erectile Dysfunction
Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting ?-Helix Backbone Oxygen by Halogen Bonding.
Erectile Dysfunction
Technical advances in penile prostheses.
Erectile Dysfunction
The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction.
Erectile Dysfunction
The effect of sildenafil citrate (Viagra) on visual sensitivity.
Erectile Dysfunction
The effect of sildenafil on ocular blood flow.
Erectile Dysfunction
The effects of tadalafil on axial-pattern skin flap survival in rats.
Erectile Dysfunction
The evaluation of the effects of renal failure on erectile dysfunction in a rabbit model of chronic renal failure.
Erectile Dysfunction
The future of the oral pharmacotherapy of male erectile dysfunction: things to come.
Erectile Dysfunction
The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
Erectile Dysfunction
The Phosphodiesterase 5-Inhibitors (PDE-5i) for ERECTILE DYSFUNCTION (ED): A Therapeutic Challenge For Psychiatrists.
Erectile Dysfunction
The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups.
Erectile Dysfunction
The regulation of transient receptor potential canonical 4 (TRPC4) channel by phosphodiesterase 5 inhibitor via the cyclic guanosine 3'5'-monophosphate.
Erectile Dysfunction
The Role of Initial Success Rates and Other Factors in Determining Reliability of Outcomes of Phosphodiesterase Inhibitor Therapy for Erectile Dysfunction: A Pooled Analysis of 17 Placebo-Controlled Trials of Tadalafil for Use as Needed.
Erectile Dysfunction
The role of phosphodiesterase inhibitors in impotence.
Erectile Dysfunction
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Erectile Dysfunction
The use of antimuscarinics, phosphodiesterase type V inhibitors and phytotherapy for lower urinary tract symptoms in men.
Erectile Dysfunction
Therapy of ED: PDE-5 Inhibitors.
Erectile Dysfunction
Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
Erectile Dysfunction
Treatments for erectile dysfunction in spinal cord lesioned patients. Are there alternatives to phosphodiesterase type 5 inhibitors?
Erectile Dysfunction
Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels.
Erectile Dysfunction
Udenafil: efficacy and tolerability in the management of erectile dysfunction.
Erectile Dysfunction
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
Erectile Dysfunction
Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity.
Erectile Dysfunction
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
Erectile Dysfunction
Vardenafil Bayer Yakuhin.
Erectile Dysfunction
Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs?
Erectile Dysfunction
Words of wisdom. Re: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. Paick J-S, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, Choi HK, Suh J-K, Kim SC.
Erectile Dysfunction
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Erectile Dysfunction
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Erectile Dysfunction
[Choice of treatment in erectile dysfunction associated with hypogonadism].
Erectile Dysfunction
[Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis].
Erectile Dysfunction
[Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Erectile Dysfunction
[Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study]
Erectile Dysfunction
[Nebido in the treatment of hypogonadism syndrome and its complications in men].
Erectile Dysfunction
[New features of pharmacologic treatment of erectile dysfunction]
Erectile Dysfunction
[PDE-5 inhibitors: patients preferences].
Erectile Dysfunction
[Phosphodiesterase inhibitor for erectile dysfunction. No less effective in the diabetic patient]
Erectile Dysfunction
[Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]
Erectile Dysfunction
[Phosphodiesterase inhibitors in clinical practice. The present and the future. Part I]
Erectile Dysfunction
[Prediction of clinical efficacy of levitra (vardenafil) in patients with arteriogenic erectile dysfunction]
Erectile Dysfunction
[Psychogenic erectile dysfunction and phosphodiesterase inhibitors type 5].
Erectile Dysfunction
[Recurrence-free survival after radical prostatectomy and PDE-5 inhibitor intake].
Erectile Dysfunction
[Sexual activity and cardiovascular risks].
Erectile Dysfunction
[Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
Erectile Dysfunction
[Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
Erectile Dysfunction
[Treatment of erectile dysfunction in patients with plastic induration of the penis]
Erectile Dysfunction
[Treatment of erectile dysfunction of neurogenic genesis with inhibitors of phosphodiesterase of type 5 in patients with diabetes mellitus]
Erectile Dysfunction
[Type V phosphodiesterase inhibitor erection-provoking test with audio-visual sexual stimulation for the diagnosis of erectile dysfunction]
Escherichia coli Infections
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Esophageal Motility Disorders
Phosphodiesterase inhibitors are viable options for treating esophageal motility disorders: A case report and literature review.
exodeoxyribonuclease i deficiency
Fibroblast phosphodiesterase deficiency in Niemann-Pick disease.
exodeoxyribonuclease i deficiency
Indirect suppression of recB and recC mutations by exonuclease I deficiency.
exodeoxyribonuclease i deficiency
Trimethoprim-induced DNA polymerase I deficiency in Escherichia coli K-12.
exodeoxyribonuclease vii deficiency
Pyrimidine dimer excision in Escherichia coli strains deficient in exonucleases V and VII and in the 5' leads to 3' exonuclease of DNA polymerase I.
Familial Primary Pulmonary Hypertension
Evidence-based pharmacologic management of pulmonary arterial hypertension.
Familial Primary Pulmonary Hypertension
Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
Familial Primary Pulmonary Hypertension
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Familial Primary Pulmonary Hypertension
Phosphodiesterase inhibitors in the management of primary pulmonary hypertension.
Familial Primary Pulmonary Hypertension
[Aerosolized iloprost combined with a phosphodiesterase inhibitor in the treatment of primary pulmonary hypertension]
Fatigue Syndrome, Chronic
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
Fatty Liver
Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
Fatty Liver
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Fatty Liver
Theophylline-Based KMUP-1 Improves Steatohepatitis via MMP-9/IL-10 and Lipolysis via HSL/p-HSL in Obese Mice.
Fetal Alcohol Spectrum Disorders
Acute administration of vinpocetine, a phosphodiesterase type 1 inhibitor, ameliorates hyperactivity in a mice model of fetal alcohol spectrum disorder.
Fetal Alcohol Spectrum Disorders
Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders.
Fibromyalgia
The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system.
Fibrosarcoma
Pentoxifylline potentiates nitric oxide production and growth suppression in interferon-gamma-treated L929 fibroblasts.
Fibrosarcoma
Toxicity to tumour cells of diethylaminoreserpine.
Fissure in Ano
Manometric study of topical sildenafil (Viagra) in patients with chronic anal fissure: sildenafil reduces anal resting tone.
Fissure in Ano
Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro.
Friedreich Ataxia
Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model.
Frontotemporal Dementia
Bioinformatic Analysis Reveals Phosphodiesterase 4D-Interacting Protein as a Key Frontal Cortex Dementia Switch Gene.
Ganglioneuroma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Gastrointestinal Diseases
Relationship between phosphodiesterase inhibition induced by several Kampo medicines and smooth muscle relaxation of gastrointestinal tract tissues of rats.
Gastrointestinal Stromal Tumors
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Genetic Diseases, Inborn
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Genetic Diseases, Inborn
The role of SOS and flap processing in microsatellite instability in Escherichia coli.
Glaucoma
Use of phosphodiesterase inhibitors and prevalence of self-reported glaucoma in the United States.
Glioblastoma
Molecular cloning and expression of a human phosphodiesterase 4C.
Glioblastoma
Phosphodiesterase inhibitors control A172 human glioblastoma cell death through cAMP-mediated activation of protein kinase A and Epac1/Rap1 pathways.
Glioblastoma
Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells.
Glioma
beta Adrenergic receptor-mediated regulation of cyclic nucleotide phosphodiesterase in C6 glioma cells: vinblastine blockade of isoproterenol induction.
Glioma
Beta-adrenergic receptor regulation of a cyclic AMP phosphodiesterase in C6 glioma cells.
Glioma
C-6 glioma growth in rats: suppression with a beta-adrenergic agonist and a phosphodiesterase inhibitor.
Glioma
Cyclic AMP-mediated induction of the cyclic AMP phosphodiesterase of C-6 glioma cells.
Glioma
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Glioma
Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma.
Glioma
Regulation by a beta-adrenergic receptor of a Ca2+-independent adenosine 3',5'-(cyclic)monophosphate phosphodiesterase in C6 glioma cells.
Glioma
Regulation of cAMP levels by protein kinase C in C6 rat glioma cells.
Glioma
Response of C-6 glioma to isoproterenol and papaverine in vivo depends on beta-adrenergic receptor density.
Glioma
RNA polymerase II in C6 glioma cells. Alpha-amanitin blockade of cAMP phosphodiesterase induction by beta-adrenergic stimulation.
Glioma
Sensitivity of the Natriuretic Peptide/cGMP System to Hyperammonaemia in Rat C6 Glioma Cells and GPNT Brain Endothelial Cells.
Glioma
The beta-adrenergic receptor system in human glioma-derived cell lines: the mode of phosphodiesterase induction and the macromolecules phosphorylated by cyclic AMP-dependent protein kinase.
Glioma
The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells.
Glioma
Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas.
Glioma
Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression.
Glioma
[3H]Rolipram binding and phosphodiesterase activity in neuroblastoma N18TG-2 and glioma C6Bu-1.
Glioma
[Treatment of rat glioma with a beta-adrenergic agonist and a phosphodiesterase inhibitor in vivo]
Glomerulonephritis
Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
Glomerulonephritis
Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis.
Glomerulonephritis, Membranous
Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann Nephritis.
Glucose Intolerance
Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology.
Glucose Intolerance
Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B.
Hearing Loss
An Update on Phosphodiesterase Mutations Underlying Genetic Etiology of Hearing Loss and Retinitis Pigmentosa.
Heart Arrest
The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.
Heart Defects, Congenital
Cardiac Adenylyl Cyclase and Phosphodiesterase Expression Profiles Vary by Age, Disease, and Chronic Phosphodiesterase Inhibitor Treatment.
Heart Defects, Congenital
[Enoximone in the treatment of postoperative low cardiac output syndrome in pediatric heart surgery. Open study in tetralogy of Fallot]
Heart Diseases
Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart.
Heart Diseases
Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Heart Diseases
Identification of Murine Phosphodiesterase 5A Isoforms and their Functional Characterization in HL-1 Cardiac Cell Line.
Heart Diseases
Myocardial Response to Milrinone in Single Right Ventricle Heart Disease.
Heart Diseases
Pharmacological activity of cardiovascular agents from herbal medicine.
Heart Diseases
Phosphodiesterase 5A as a target in cardiac disease.
Heart Diseases
Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Heart Diseases
Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease.
Heart Diseases
[Comparison of the hemodynamic effects of dobutamine and enoximone in the treatment of low cardiac output after valvular surgery]
Heart Diseases
[Enoximone as pharmacologic "bridging" to heart transplantation]
Heart Failure
A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus.
Heart Failure
A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period.
Heart Failure
A review of the role of statins in heart failure treatment.
Heart Failure
Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure.
Heart Failure
Acute effects of intravenous phosphodiesterase inhibition in chronic heart failure: simultaneous pre- and afterload reduction with a single agent.
Heart Failure
Acute hemodynamic and hormonal effects of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure.
Heart Failure
Acute hemodynamic effects and preload-dependent cardiovascular profile of the partial phosphodiesterase inhibitor nanterinone in patients with mild to moderate heart failure.
Heart Failure
Acute hemodynamic effects of adibendan, a new phosphodiesterase inhibitor, for severe congestive heart failure.
Heart Failure
Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Heart Failure
Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.
Heart Failure
Acute neurohormonal and hemodynamic response to a new peak III phosphodiesterase inhibitor (ICI 153,110) in patients with chronic heart failure.
Heart Failure
Acute positive inotropic intervention: the phosphodiesterase inhibitors.
Heart Failure
Addition of enoximone to adrenergic agents in the management of severe heart failure.
Heart Failure
Addition of phosphodiesterase inhibitors to adrenergic agents in acutely ill patients.
Heart Failure
Additive haemodynamic effects of piroximone and prostacyclin in severe chronic heart failure.
Heart Failure
Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.
Heart Failure
Amrinone suppresses the synthesis of tumor necrosis factor-alpha in human mononuclear cells.
Heart Failure
Amrinone, a phosphodiesterase III inhibitor, and arachidonic acid metabolism in humans.
Heart Failure
Amrinone, a selective phosphodiesterase III inhibitor, improves microcirculation and flap survival: a comparative study with prostaglandin E1.
Heart Failure
Amrinone: is it the inotrope of choice?
Heart Failure
Analysis of responses to a selective phosphodiesterase III inhibitor, SK&F 94120, on isolated myocardium, including human ventricular myocardium from "end-stage" failure patients.
Heart Failure
Analysis on outcome of 5284 patients with coronary artery disease: The role of integrative medicine.
Heart Failure
Arterial baroreflex sensitivity is a good predictor of inotropic responses to a phosphodiesterase inhibitor in human heart failure.
Heart Failure
Augmentation of cardiac function in end-stage heart failure by combined use of dobutamine and amrinone.
Heart Failure
Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure.
Heart Failure
Baroreflex sensitivity might predict responders to milrinone in patients with heart failure.
Heart Failure
Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
Heart Failure
Calmodulin kinase II inhibition limits the pro-arrhythmic Ca2+ waves induced by cAMP-phosphodiesterase inhibitors.
Heart Failure
Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
Heart Failure
Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure.
Heart Failure
Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties.
Heart Failure
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
Heart Failure
Cardiovascular effects of milrinone.
Heart Failure
Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
Heart Failure
Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study.
Heart Failure
Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters.
Heart Failure
Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Heart Failure
CI-930, a new cardiotonic and vasodilating agent: hemodynamic comparison to dobutamine and long-term clinical effects.
Heart Failure
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Heart Failure
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
Heart Failure
Clinical pharmacokinetics of vasodilators. Part II.
Heart Failure
Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
Heart Failure
Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression.
Heart Failure
Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
Heart Failure
Comparative acute hemodynamic effects of intravenous sodium nitroprusside and MDL-17,043, a new inotropic drug with vasodilator effects, in refractory congestive heart failure.
Heart Failure
Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure.
Heart Failure
Comparative hemodynamic effects of intravenous digoxin and enoximone in severe chronic heart failure.
Heart Failure
Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients.
Heart Failure
Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method.
Heart Failure
Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study.
Heart Failure
Comparison of the initial hospitalization costs between the patients treated with dobutamine and the patients treated with amrinone for acute decompensated heart failure in a Japanese institute.
Heart Failure
Compartmentalization of beta-adrenergic signals in cardiomyocytes.
Heart Failure
Contractile responses to selective phosphodiesterase inhibitors following chronic beta-adrenoreceptor activation.
Heart Failure
Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizer.
Heart Failure
Control of arteriolar resistance in heart failure. Partial attenuation of specific phosphodiesterase inhibitor-mediated vasodilation by digitalis glycosides.
Heart Failure
Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
Heart Failure
Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
Heart Failure
Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.
Heart Failure
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Heart Failure
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.
Heart Failure
Design and Development of Novel 4-(4-(1H-Tetrazol-5-yl)-1H-pyrazol-1-yl)-6-morpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine as Cardiotonic Agent via Inhibition of PDE3.
Heart Failure
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.
Heart Failure
Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside.
Heart Failure
Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure.
Heart Failure
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Heart Failure
Difficult cases in heart failure: Bridge to beta blockade in severe heart failure: the use of phosphodiesterase inhibitors.
Heart Failure
Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure.
Heart Failure
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
Heart Failure
Does ventricular fibrillation cause myocardial stunning during defibrillator implantation?
Heart Failure
Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure.
Heart Failure
Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling.
Heart Failure
Drug treatment of patients with decompensated heart failure.
Heart Failure
Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension.
Heart Failure
Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle.
Heart Failure
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Heart Failure
Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Heart Failure
Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.
Heart Failure
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
Heart Failure
Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow.
Heart Failure
Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
Heart Failure
Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Heart Failure
Effect of the phosphodiesterase inhibitor UK 61260 on human myocardial inotropy and diastolic relaxation.
Heart Failure
Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group.
Heart Failure
Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
Heart Failure
Effects of piroximone on the right ventricular function in severe heart failure patients.
Heart Failure
Effects of serotonin in failing cardiac ventricle: Signalling mechanisms and potential therapeutic implications.
Heart Failure
Effects of the new cardiotonic phosphodiesterase inhibitor 1,2-dihydro-5- imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3-pyridine-carbonitrile hydrochloride monohydrate on aortic input impedance.
Heart Failure
Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
Heart Failure
Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure.
Heart Failure
Enhanced relaxation and reduced positive inotropic effects of amrinone in ventricular muscle from cats with subacute heart failure. Implications for drug therapy.
Heart Failure
Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac beta-adrenoceptors in the failing human heart.
Heart Failure
Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
Heart Failure
Enoximone as a bridge to heart transplantation: the Utah experience.
Heart Failure
Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction.
Heart Failure
Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis.
Heart Failure
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Heart Failure
Heart failure: therapeutic challenges and strategies and the role of phosphodiesterase inhibitors. 31 August 1988, Vienna, Austria.
Heart Failure
Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.
Heart Failure
Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure.
Heart Failure
Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure.
Heart Failure
Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
Heart Failure
Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
Heart Failure
Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy.
Heart Failure
Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure.
Heart Failure
Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium.
Heart Failure
Innovations in the pharmacologic management of heart failure.
Heart Failure
Inodilator therapy for heart failure. Early, late, or not at all?
Heart Failure
Inotropes and beta-blockers: is there a need for new guidelines?
Heart Failure
Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolin-2(1H)-one derivatives in isolated rat atria.
Heart Failure
Inotropic and energetic effects of altering the force-calcium relationship: mechanisms, experimental results, and potential molecular targets.
Heart Failure
Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis.
Heart Failure
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Heart Failure
Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.
Heart Failure
Intravenous milrinone in treatment of advanced congestive heart failure.
Heart Failure
Ion channel modulators as potential positive inotropic compound for treatment of heart failure.
Heart Failure
IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure.
Heart Failure
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
Heart Failure
Levosimendan in perioperative and critical care patients.
Heart Failure
Levosimendan, a New Inotropic and Vasodilator Agent.
Heart Failure
Long-term effects of an inotropic phosphodiesterase inhibitor (ICI 153,110) on the rat salivary gland, harderian gland, and intestinal mucosa.
Heart Failure
Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
Heart Failure
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
Heart Failure
Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors.
Heart Failure
Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.
Heart Failure
Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
Heart Failure
Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents.
Heart Failure
Marked and prompt hemodynamic improvement by carperitide in refractory congestive heart failure due to dilated cardiomyopathy.
Heart Failure
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type v phosphodiesterase inhibition and exogenous natriuretic Peptide: a novel strategy to improve renal function in experimental overt heart failure.
Heart Failure
Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure.
Heart Failure
Milrinone: basic and clinical pharmacology and acute and chronic management.
Heart Failure
miRNA expression in pediatric failing human heart.
Heart Failure
Models of dilated cardiomyopathy in small animals and novel positive inotropic therapies.
Heart Failure
Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group.
Heart Failure
Myocardial energetics: experimental and clinical studies to address its determinants and aerobic limit.
Heart Failure
Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.
Heart Failure
Neuroendocrine changes in heart failure and their clinical relevance.
Heart Failure
New pharmacologic interventions to increase cardiac contractility: challenges and opportunities.
Heart Failure
New therapies for the management of acute heart failure.
Heart Failure
Newer oral inotropic agents: phosphodiesterase inhibitors.
Heart Failure
Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction.
Heart Failure
Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure.
Heart Failure
Olprinone, a phosphodiesterase III inhibitor, does not affect hypoxia-induced pial arteriolar dilatation in rabbits.
Heart Failure
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Heart Failure
Patient Attributes Associated With Better Long-Term Outcomes on Palliative Milrinone.
Heart Failure
PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials.
Heart Failure
Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Heart Failure
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
Heart Failure
Pharmacokinetics of single oral dose of pimobendan in Hispaniolan Amazon parrots (Amazona ventralis).
Heart Failure
Pharmacological comparison of CK-2289, an inodilator agent, with milrinone and enoximone.
Heart Failure
Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors.
Heart Failure
Pharmacology of bipyridine phosphodiesterase III inhibitors.
Heart Failure
Pharmacology of positive inotropic phosphodiesterase III inhibitors.
Heart Failure
Pharmacology of SCH00013: a novel Ca2+ sensitizer.
Heart Failure
Pharmacotherapy of dilated cardiomyopathy.
Heart Failure
Phosphodiesterase 4 in the human heart - major player or little helper?
Heart Failure
Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines.
Heart Failure
Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Heart Failure
Phosphodiesterase III inhibitors for heart failure.
Heart Failure
Phosphodiesterase III inhibitors: long-term risks and short-term benefits.
Heart Failure
Phosphodiesterase inhibition and positive inotropic effects.
Heart Failure
Phosphodiesterase inhibition by enoximone in preparations from nonfailing and failing human hearts.
Heart Failure
Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
Heart Failure
Phosphodiesterase inhibition in heart failure.
Heart Failure
Phosphodiesterase inhibitors in refractory heart failure: bridge to beta-blockade?
Heart Failure
Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation in vivo and in vitro.
Heart Failure
Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation.
Heart Failure
Phosphodiesterase inhibitors. Do the risks outweight the benefits?
Heart Failure
Phosphodiesterase inhibitors. Its role in heart failure therapy.
Heart Failure
Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure.
Heart Failure
Physiologic response to the inotropic and vasodilator properties of enoximone.
Heart Failure
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
Heart Failure
Positive inotropic/vasodilator agents.
Heart Failure
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.
Heart Failure
Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.
Heart Failure
Potential mechanisms of improved left ventricular function with enoximone in severe congestive heart failure.
Heart Failure
Preventing LVAD implantation by early short-term mechanical support and prolonged inodilator therapy : A case series with acute refractory cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation and optimised medical strategy.
Heart Failure
Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure.
Heart Failure
Rationale for the short term use of intravenous milrinone under hemodynamic guidance in patients with severe systolic heart failure.
Heart Failure
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease.
Heart Failure
Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels.
Heart Failure
Renal and hormonal effects of phosphodiesterase III inhibition in congestive heart failure.
Heart Failure
Risks and benefits of the treatment of heart failure. Current status.
Heart Failure
Separation between vasodilation and positive inotropism by assessment of myocardial energetics in patients with dilated cardiomyopathy.
Heart Failure
Severe transient cardiac failure caused by placental chorangiosis.
Heart Failure
Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.
Heart Failure
Some new positive inotropic agents.
Heart Failure
Specific phosphodiesterase inhibition and maximal and submaximal exercise performance in patients with congestive heart failure.
Heart Failure
Stability of Milrinone Lactate in 5% Dextrose Injection and 0.9% Sodium Chloride Injection at Concentrations of 400, 600, and 800 micrograms/mL.
Heart Failure
T-wave alternans in a case with systemic lupus erythematosus-related myocarditis.
Heart Failure
The acute effect of an oral "inotropic" placebo on the exercise capacity of patients with chronic cardiac failure.
Heart Failure
The effect of positive inotropes on the failing human myocardium.
Heart Failure
The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation.
Heart Failure
The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.
Heart Failure
The role of phosphodiesterase inhibitors in heart failure.
Heart Failure
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Heart Failure
The vasorelaxatory effect of the milrinone on the preconstricted rat aorta.
Heart Failure
The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History.
Heart Failure
Therapeutic achievements of phosphodiesterase inhibitors and the future.
Heart Failure
Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors.
Heart Failure
Topical application of amrinone (a selective phosphodiesterase III inhibitor) for relief of vasospasm.
Heart Failure
Treatment of heart failure with enoximone, a new phosphodiesterase inhibitor. Düsseldorf, Federal Republic of Germany. September 25-27, 1987. Proceedings.
Heart Failure
Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
Heart Failure
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS.
Heart Failure
Use of levosimendan in patients with ischemic heart disease following mechanical reperfusion.
Heart Failure
Various subtypes of phosphodiesterase inhibitors differentially regulate pulmonary vein and sinoatrial node electrical activities.
Heart Failure
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
Heart Failure
What do the newer inotropic drugs have to offer?
Heart Failure
[Current treatment of chronic heart failure]
Heart Failure
[Effects of amrinone on renal blood flow and cardiac function, in comparison with those of milrinone and olprinone, in anesthetized dog]
Heart Failure
[Effects of R80122. The influence of a new phosphodiesterase inhibitor on global and intestinal hemodynamics in coronary surgery patients]
Heart Failure
[Efficacy of intravenous milrinone in the treatment of acute congestive cardiac failure. Results of a French multicenter study]
Heart Failure
[Enoximone/dobutamine comparison in chronic congestive cardiac insufficiency with low cardiac output]
Heart Failure
[Infusion therapy at outpatient clinic in chronic end-stage heart failure]
Heart Failure
[Inotropic therapy in heart failure: general aspects and clinical results]
Heart Failure
[Long-term therapy of chronic cardiac insufficiency using enoximone]
Heart Failure
[Monitoring and treatment of patients with shock in the intensive care unit]
Heart Failure
[New positive inotropic drugs in acute and chronic heart failure]
Heart Failure
[Pathophysiologic aspects and modern treatment of congestive heart failure]
Heart Failure
[Phosphodiesterase inhibitors--a new therapeutic principle in heart failure]
Heart Failure
[Phosphodiesterase inhibitors]
Heart Failure
[Positive inotropic substances in therapy of heart failure: digitalis, catecholamines, phosphodiesterase inhibitors]
Heart Failure
[Potentialitis of phosphodiesterase inhibitors in management of patients with chronic heart failure complicating cardiac ischemia]
Heart Failure
[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]
Heart Failure
[Therapy of verapamil poisoning with noradrenaline and the phosphodiesterase inhibitor enoximone]
Heart Failure
[Treatment of chronic heart failure in the child]
Heart Failure
[Treatment of chronic heart failure: current views]
Heart Failure
[Use of new inotropic agents in the treatment of acute cardiac failure]
Heart Failure
[Usefulness of exercise tests in the evaluation of the effects of treatment in chronic cardiac insufficiency]
Heart Failure
[Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone]
Heart Failure, Systolic
Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful?
Heart Failure, Systolic
Role of nonglycosidic inotropic agents: indications, ethics, and limitations.
Hepatic Veno-Occlusive Disease
A phosphodiesterase III inhibitor protects rat liver from sinusoidal obstruction syndrome through heme oxygenase-1 induction.
Hepatic Veno-Occlusive Disease
A Phosphodiesterase III Inhibitor Protects Rat Liver From Sinusoidal Obstruction Syndrome Through Heme Oxygenase-1 Induction.
Hepatic Veno-Occlusive Disease
Phosphodiesterase III inhibitor attenuates rat sinusoidal obstruction syndrome through inhibition of platelet aggregation in Disse's space.
Hepatitis
Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein.
Hepatitis
Crystal structure of the mouse hepatitis virus ns2 phosphodiesterase domain that antagonizes RNase L activation.
Hepatitis
Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice.
Hepatitis
[Clinical significance of serum phosphodiesterase activities in viral hepatitis]
Hepatitis B
Exonuclease I and III improve the detection efficacy of hepatitis B virus covalently closed circular DNA.
Hepatitis E
Detection of negative sense RNA in packaged hepatitis E virions using improved strand specific RT-PCR method.
Hepatitis, Autoimmune
PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.
Hepatitis, Chronic
Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein.
Hepatorenal Syndrome
[Is there a role for pentoxifylline in the treatment of alcoholic hepatitis?]
Hernias, Diaphragmatic, Congenital
Nitric oxide activity through guanylate cyclase and phosphodiesterase modulation is impaired in fetal lambs with congenital diaphragmatic hernia.
Herpes Simplex
Herpes Simplex Virus 1 DNA Polymerase RNase H Activity Acts in a 3'-to-5' Direction and Is Dependent on the 3'-to-5' Exonuclease Active Site.
Herpes Simplex
Involvement of eucaryotic deoxyribonucleic acid polymerases alpha and gamma in the replication of cellular and viral deoxyribonucleic acid.
Herpes Zoster
Calmodulin-like activity and calcium-dependent phosphodiesterase in purified cells of the rat zona glomerulosa and zona fasciculata.
Herpes Zoster
Effects of atrial natriuretic factor on the renin-aldosterone system: in vivo and in vitro studies.
HIV Infections
Inhibition of cytotoxicity and cytokine release of CD8+ HIV-specific cytotoxic T lymphocytes by pentoxifylline.
HIV Infections
Mass spectrometric phosphoproteome analysis of HIV-infected brain reveals novel phosphorylation sites and differential phosphorylation patterns.
Hodgkin Disease
t(4;8)(q27;q24) in Hodgkin lymphoma cells targets phosphodiesterase PDE5A and homeobox gene ZHX2.
Huntington Disease
Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.
Huntington Disease
Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition.
Huntington Disease
Exclusion of DNA changes in the beta-subunit of the c-GMP phosphodiesterase gene as the cause for Huntington's disease.
Huntington Disease
Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Huntington Disease
Pharmacological investigation of biochemical and behavioral effects resembling Huntington's disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor.
Huntington Disease
Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington's Disease.
Huntington Disease
Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Huntington Disease
Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
Hydrocephalus
Preventive effects of cilostazol against the development of shunt-dependent hydrocephalus after subarachnoid hemorrhage.
Hydronephrosis
Analyses of renal medullary lipid droplets from normal, hydronephrotic, and indomethacin treated rabbits.
Hyperalgesia
A Novel Compound Analgesic Cream (Ketamine, Pentoxifylline, Clonidine, DMSO) for Complex Regional Pain Syndrome Patients.
Hyperalgesia
Alpha 1-adrenoceptor-mediated sympathetically dependent mechanical hyperalgesia in the rat.
Hyperalgesia
Direct cutaneous hyperalgesia induced by adenosine.
Hyperalgesia
Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia.
Hyperalgesia
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats.
Hyperalgesia
Mediation of serotonin hyperalgesia by the cAMP second messenger system.
Hyperalgesia
Multiple second messenger systems act sequentially to mediate rolipram-induced prolongation of prostaglandin E2-induced mechanical hyperalgesia in the rat.
Hyperalgesia
Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats.
Hyperalgesia
Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
Hyperalgesia
The effects of local pentoxifylline and propentofylline treatment on formalin-induced pain and tumor necrosis factor-alpha messenger RNA levels in the inflamed tissue of the rat paw.
Hyperalgesia
Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain.
Hyperalgesia
Topical combinations to treat microvascular dysfunction of chronic postischemia pain.
Hypercalcemia
Thiazide diuretics do not potentiate cAMP response to parathyroid hormone.
Hyperglycemia
Selective reversal of hyperglycemia-evoked gastric myoelectric dysrhythmias by nitrergic stimulation in healthy humans.
Hyperglycemia
The mechanism of chlorothiazide-induced carbohydrate intolerance.
Hyperlipidemias
A review of the role of statins in heart failure treatment.
Hyperlipidemias
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Hyperlipidemias
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Hyperprolactinemia
Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.
Hypersensitivity
1,25-Dihydroxyvitamin D3 potentiates the decreased response of lymphocytes from atopic subjects to agents that increase intracellular cyclic adenosine monophosphate.
Hypersensitivity
Complementary roles for exonuclease 1 and Flap endonuclease 1 in maintenance of triplet repeats.
Hypersensitivity
Interaction of the antiallergic agent AA-344 with biogenic amines and prostaglandins in production of cyclic AMP in rat mast cells.
Hypersensitivity
Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways.
Hypersensitivity
The action of phosphodiesterase inhibitors on the hypersensitivity of frog photoreceptor.
Hypersensitivity
The role of phosphodiesterase enzymes in allergy and asthma.
Hypersensitivity
Zaprinast diminished pain and enhanced opioid analgesia in a rat neuropathic pain model.
Hypertension
A phosphodiesterase inhibitor promotes the premature development of adverse cardiac remodelling mediated by beta-adrenergic activation in hypertension.
Hypertension
Advances in the medical treatment of pulmonary hypertension.
Hypertension
Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats.
Hypertension
Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.
Hypertension
Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12.
Hypertension
Cardiovascular effects of Juniperus excelsa are mediated through multiple pathways.
Hypertension
Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.
Hypertension
Clinical and Molecular Perspectives of Monogenic Hypertension.
Hypertension
Clinical Effects of Phosphodiesterase 3A Mutations in Inherited Hypertension With Brachydactyly.
Hypertension
Comparative Effectiveness of Pharmacological Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
Hypertension
Contrasting effects of hypoglycemia on plasma renin activity and cyclic adenosine 3',5'-monophosphate (cyclic AMP) in low renin and normal renin essential hypertension.
Hypertension
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
Hypertension
Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries.
Hypertension
Discovery of pyridoindole derivatives as potential inhibitors for phosphodiesterase 5A: in silico and in vivo studies.
Hypertension
Discovery of two novel hetero-tricyclic lead scaffolds as PDE5A inhibitor: virtual screening, molecular docking and pharmacophore modeling approach.
Hypertension
Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis.
Hypertension
Endothelin receptor antagonists for pulmonary arterial hypertension.
Hypertension
Evidence-based pharmacologic management of pulmonary arterial hypertension.
Hypertension
Evolution of aortic and cardiac cyclic AMP phosphodiesterase during the onset of mineralpcorticoid hypertension in the rat [proceedings].
Hypertension
Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors.
Hypertension
Excessive nitric oxide function and blood pressure regulation in patients with autonomic failure.
Hypertension
Further evidence for the involvement of cAMP in central blood pressure regulation.
Hypertension
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Hypertension
Increased inositol trisphosphate in erythrocytes of spontaneously hypertensive rats.
Hypertension
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
Hypertension
Intravenous pentoxifylline does not affect the exercise-induced pulmonary arterial, capillary or venous hypertension in Thoroughbred horses.
Hypertension
Levosimendan is not effective in reducing pulmonary pressures in patients with idiopathic pulmonary arterial hypertension: report of two cases.
Hypertension
Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy.
Hypertension
Long-term inhaled iloprost use in children with pulmonary arterial hypertension.
Hypertension
Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary y hypertension.
Hypertension
New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.
Hypertension
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Hypertension
Outcomes of Liver Transplantation for Porto-Pulmonary Hypertension in Model for End-Stage Liver Disease Era.
Hypertension
PDE3A mutations cause autosomal dominant hypertension with brachydactyly.
Hypertension
Phosphodiesterase 3A and Arterial Hypertension.
Hypertension
Phosphodiesterase type V: a novel therapeutic target for hypertension.
Hypertension
Platelet cyclic AMP in essential hypertension.
Hypertension
Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment.
Hypertension
Pulmonary hypertension and right ventricular function in advanced heart failure.
Hypertension
Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
Hypertension
Relaxant effect and possible mechanism of 17-nor-subincanadine E in rabbit corpora cavernosa.
Hypertension
Renal phosphodiesterase 4B is activated in the Dahl salt-sensitive rat.
Hypertension
Retraction: Urdaneta F, Willert JL, Beaver T, Naik B, Kirby DS, Lobato EB. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. Ann Thorac Surg 2004;78:14337.
Hypertension
RNA Sequencing Reveals Novel Transcripts from Sympathetic Stellate Ganglia During Cardiac Sympathetic Hyperactivity.
Hypertension
Scleroderma - new aspects in pathogenesis and treatment.
Hypertension
Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats.
Hypertension
Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry.
Hypertension
Sildenafil reduces alcohol-induced gastric damage: just say 'NO'.
Hypertension
Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
Hypertension
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Hypertension
The activity of adenylate cyclase and phosphodiesterase in the isoproterenol-damaged cardiac muscle of spontaneously hypertensive rats.
Hypertension
[Phosphodiesterase characteristics of the fat cells in spontaneous hypertension in rats]
Hypertension
[Pulmonary arterial hypertension-specific drugs - current status]
Hypertension
[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension]
Hypertension
[Pulmonary hypertension in COPD and interstitial lung diseases]
Hypertension
[Pulmonary hypertension. Pathophysiology and current concepts of medication therapy]
Hypertension
[Transport of calcium and distribution of calmodulin in the erythrocytes in primary arterial hypertension]
Hypertension
[Update in the diagnosis and therapy for pulmonary arterial hypertension]
Hypertension, Portal
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Hypertension, Pregnancy-Induced
Control of vascular reactivity in pregnancy.
Hypertension, Pulmonary
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Hypertension, Pulmonary
A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass.
Hypertension, Pulmonary
A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease.
Hypertension, Pulmonary
A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
Hypertension, Pulmonary
Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children.
Hypertension, Pulmonary
Advances in the medical treatment of pulmonary hypertension.
Hypertension, Pulmonary
Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension.
Hypertension, Pulmonary
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Hypertension, Pulmonary
Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Hypertension, Pulmonary
Cellular pathophysiology and therapy of pulmonary hypertension.
Hypertension, Pulmonary
Chronic treatment with Sildenafil has no effect on folliculogenesis or fertility in C57BL/6 and C57BL/6 knockout for iNOS mice.
Hypertension, Pulmonary
Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity.
Hypertension, Pulmonary
Contrasting effects of isoproterenol and phosphodiesterase III inhibitor on intracellular calcium transients in cardiac myocytes from failing hearts.
Hypertension, Pulmonary
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
Hypertension, Pulmonary
E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats.
Hypertension, Pulmonary
Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension.
Hypertension, Pulmonary
Effects of low-dose milrinone on weaning from cardiopulmonary bypass and after in patients with mitral stenosis and pulmonary hypertension.
Hypertension, Pulmonary
Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms.
Hypertension, Pulmonary
Heart Failure Treated with Low-dose Milrinone in a Full-term Newborn.
Hypertension, Pulmonary
Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults.
Hypertension, Pulmonary
High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements?
Hypertension, Pulmonary
Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Hypertension, Pulmonary
Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension.
Hypertension, Pulmonary
Isolated unilateral absence of pulmonary artery in adulthood: a clinical analysis of 65 cases from a case series and systematic review.
Hypertension, Pulmonary
Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension.
Hypertension, Pulmonary
Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors.
Hypertension, Pulmonary
Milrinone attenuates serotonin-induced pulmonary hypertension and bronchoconstriction in dogs.
Hypertension, Pulmonary
Nitric oxide and pulmonary hypertension.
Hypertension, Pulmonary
Nitric oxide in conjunction with milrinone better stabilized pulmonary hemodynamics after Fontan procedure.
Hypertension, Pulmonary
Novel peptide for attenuation of hypoxia-induced pulmonary hypertension via modulation of nitric oxide release and phosphodiesterase -5 activity.
Hypertension, Pulmonary
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition.
Hypertension, Pulmonary
Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review.
Hypertension, Pulmonary
Phosphodiesterase inhibitors for pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.
Hypertension, Pulmonary
Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension.
Hypertension, Pulmonary
Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension.
Hypertension, Pulmonary
Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension.
Hypertension, Pulmonary
Recent Advances in Chronic Thromboembolic Pulmonary Hypertension.
Hypertension, Pulmonary
Retraction: Urdaneta F, Willert JL, Beaver T, Naik B, Kirby DS, Lobato EB. Effects of a new phosphodiesterase enzyme type V inhibitor (UK 343-664) versus milrinone in a porcine model of acute pulmonary hypertension. Ann Thorac Surg 2004;78:14337.
Hypertension, Pulmonary
Right ventricular function and failure: a review.
Hypertension, Pulmonary
Selective pulmonary vasodilatory effect of ZSY-27 in dogs with pulmonary hypertension due to pulmonary embolism.
Hypertension, Pulmonary
Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Hypertension, Pulmonary
Sildenafil for pulmonary hypertension.
Hypertension, Pulmonary
Sildenafil inhibits chronically hypoxic upregulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle.
Hypertension, Pulmonary
Sildenafil suppresses the proliferation and enhances the apoptosis of hemangioma endothelial cells.
Hypertension, Pulmonary
Site-specific effect of guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition in isolated lamb lungs.
Hypertension, Pulmonary
Study on the clinical efficacy of specific phosphodiesterase inhibitor in patients with pulmonary hypertension due to left heart disease.
Hypertension, Pulmonary
The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report.
Hypertension, Pulmonary
The vasorelaxatory effect of the milrinone on the preconstricted rat aorta.
Hypertension, Pulmonary
Therapeutic methods used in patients with Eisenmenger syndrome.
Hypertension, Pulmonary
Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry.
Hypertension, Pulmonary
Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension.
Hypertension, Pulmonary
Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
Hypertension, Pulmonary
Zaprinast attenuates hypoxic pulmonary artery injury and causes less aortic relaxation than milrinone.
Hypertension, Pulmonary
[Anesthesia for heart transplantation in newborn and suckling infants. Special aspects of the hypoplastic left heart syndrome]
Hypertension, Pulmonary
[Endothelin receptor antagonist, phosphodiesterase inhibitor, thromboxane inhibitor]
Hypertension, Pulmonary
[Postoperative management for severe pulmonary hypertension in a patient with congenital mitral stenosis and patent ductus arteriosus]
Hypertension, Pulmonary
[Pregnant woman with pulmonary hypertension].
Hypertension, Pulmonary
[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension]
Hyperthyroidism
Adrenergic regulation of lipolysis in fat cells from hyperthyroid and hypothyroid patients.
Hyperthyroidism
Phosphodiesterase activity in human subcutaneous adipose tissue in hyper- and hypothyroidism.
Hyperthyroidism
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Hyperthyroidism
The atrial natriuretic peptide- and catecholamine-induced lipolysis and expression of related genes in adipose tissue in hypothyroid and hyperthyroid patients.
Hyperthyroidism
Thyroid hormone modulation of epinephrine-induced lipolysis in rat adipocytes: a possible role of calcium.
Hypertrophy, Right Ventricular
The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.
Hypogonadism
Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study.
Hypogonadism
Hypogonadism in the man with erectile dysfunction: what to look for and when to treat.
Hypogonadism
Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.
Hypogonadism
Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.
Hypogonadism
[Choice of treatment in erectile dysfunction associated with hypogonadism].
Hypogonadism
[The role of testosterone drugs in combined therapy of erectile dysfunction in patients with metabolic syndrome]
Hypokinesia
Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors.
Hypokinesia
[Catecholamine concentration and adenyl cyclase and phosphodiesterase activities of the sarcolemma of myocardial cells during hypokinesia and in experimental information neuroses]
Hypotension
Cardiomegaly of the larger twin in monochorionic twin pregnancies warrants neonatal intensive care even without twin-to-twin transfusion syndrome.
Hypotension
Combination therapy with albumin and pentoxifylline protects against acute kidney injury during endotoxemic shock in mice.
Hypotension
Combined use of adenosine and amrinone inhibits reperfusion injury of rat liver.
Hypotension
Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation.
Hypotension
Levosimendan does not improve survival time in a rat model of verapamil toxicity.
Hypotension
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Hypotension
Pharmacokinetics and pharmacodynamics of olprinone after cardiac surgery.
Hypotension
Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.
Hypotension
Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.
Hypotension
Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.
Hypotension
[Therapy of verapamil poisoning with noradrenaline and the phosphodiesterase inhibitor enoximone]
Hypotension, Orthostatic
Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2.
Hypothyroidism
Adrenergic regulation of lipolysis in fat cells from hyperthyroid and hypothyroid patients.
Hypothyroidism
Frequency and effect on serum TSH of phosphodiesterase 8B (PDE8B) gene polymorphisms in patients with sporadic nonautoimmune subclinical hypothyroidism.
Hypothyroidism
Genetic association study of phosphodiesterase 8B gene with subclinical hypothyroidism in pregnant women.
Hypothyroidism
Local and systemic alterations in cyclic 3',5' AMP phosphodiesterase activity in relation to tail regeneration under hypothyroidism and T4 replacement in the lizard, Mabuya carinata.
Hypothyroidism
Mutations in the c-erbA beta 1 gene: do they underlie euthyroid fibromyalgia?
Hypothyroidism
Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy.
Hypothyroidism
Phosphodiesterase activity in human subcutaneous adipose tissue in hyper- and hypothyroidism.
Idiopathic Pulmonary Fibrosis
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
Idiopathic Pulmonary Fibrosis
Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.
Immune System Diseases
PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.
Impotence, Vasculogenic
Purification of a dimethyladenosine compound from silkworm pupae as a vasorelaxation substance.
Infarction, Middle Cerebral Artery
Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia.
Infarction, Middle Cerebral Artery
Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia.
Infarction, Middle Cerebral Artery
PDE5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
Infarction, Middle Cerebral Artery
Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.
Infections
A rapid procedure for isolation of large quantities of Escherichia coli DNA polymerase I utilizing a lambdapolA transducing phage.
Infections
Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
Infections
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Infections
Associations between single-nucleotide polymorphisms of human exonuclease 1 and the risk of hepatocellular carcinoma.
Infections
Characterization of lambdapolA transducing phages; effective expression of the E. coli polA gene.
Infections
Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in Mycobacterium tuberculosis leads to reduced virulence in a mouse model of infection.
Infections
Derivation of Pre-oligodendrocytes from Human Endometrial Stromal Cells by Using Overexpression of MicroRNA 338.
Infections
Efficient cloning of hepatitis B virus DNA from single-stranded replicative intermediates and its application to S1 mapping of viral RNA in human liver tissue.
Infections
Genetic variation in Trex1 affects HIV-1 disease progression.
Infections
HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection.
Infections
Involvement of the beta-adrenergic system in the cardiac chronic form of experimental Trypanosoma cruzi infection.
Infections
Isolation and characterization of a lambdapolA transducing phage.
Infections
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Infections
Rotavirus Controls Activation of the 2'-5'-Oligoadenylate Synthetase/RNase L Pathway Using at Least Two Distinct Mechanisms.
Infections
The Bacterial Second Messenger Cyclic di-GMP Regulates Brucella Pathogenesis and Leads to Altered Host Immune Response.
Infections
The EAL domain containing protein STM2215 (rtn) is needed during Salmonella infection and has cyclic di-GMP phosphodiesterase activity.
Infections
The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa.
Infections
TREX1 531C>T Polymorphism is Associated with High Proviral Load Levels in HTLV-1-Infected Persons.
Infections
[Activity of the cyclic adenosine monophosphate phosphodiesterase of the blood lymphocytes in patients with a Lamblia infection susceptible and resistant to lambliacides]
Infertility
Novel in situ gelling vaginal sponges of sildenafil citrate-based cubosomes for uterine targeting.
Infertility
Phosphodiesterase 8B Polymorphism rs4704397 Is Associated with Infertility in Subclinical Hypothyroid Females: A Case-Control Study.
Infertility, Female
Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility.
Infertility, Female
Phosphodiesterase 8B Polymorphism rs4704397 Is Associated with Infertility in Subclinical Hypothyroid Females: A Case-Control Study.
Infertility, Female
Regulation of meiotic maturation.
Inflammatory Bowel Diseases
Phosphodiesterase inhibitors in inflammatory bowel disease.
Influenza, Human
Interaction of plasma membranes with influenza virus. VII. Effect on 3',5'-cyclic adenosine monophosphate phosphodiesterase activity.
Influenza, Human
Role of calcium dependent regulator protein (CDR) in inhibition of 3',5'-c AMP-phosphodiesterase by influenza virus. I. Isolation and purification of CDR and CDR-dependent 3',5'-c' AMP-phosphodiesterase from chick embryos.
Influenza, Human
Role of calcium-dependent regulator protein (CDR) in inhibition of 3',5'-c AMP-phosphodiesterase by influenza virus. II. Kinetic studies on inhibition of CDR-dependent phosphodiesterase by influenza virus.
Insulin Resistance
A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Insulin Resistance
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Insulin Resistance
Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.
Insulin Resistance
Discriminative insulin antagonism of stimulatory effects of various cAMP analogs on adipocyte lipolysis and hepatocyte glycogenolysis.
Insulin Resistance
Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP.
Insulin Resistance
Early and rapid development of insulin resistance, islet dysfunction and glucose intolerance after high-fat feeding in mice overexpressing phosphodiesterase 3B.
Insulin Resistance
Effect of phosphodiesterase inhibition on insulin resistance in obese individuals.
Insulin Resistance
Effects of Chinese Medicinal Formula BNG-1 on Phosphodiesterase 3B Expression, Hepatic Steatosis, and Insulin Resistance in High Fat Diet-induced NAFLD Mice.
Insulin Resistance
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Insulin Resistance
Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice.
Insulin Resistance
In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity.
Insulin Resistance
Insulin resistance of fat cells from spontaneously diabetic KK mice. Analysis of insulin-sensitive phosphodiesterase.
Insulin Resistance
Insulin-sensitive adenosine 3',5'-cyclic monophosphate phosphodiesterase of hepatocyte plasma membrane.
Insulin Resistance
Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B.
Insulin Resistance
Metabolic consequences of ENPP1 over-expression in adipose tissue.
Insulin Resistance
Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
Insulin Resistance
Pharmaceutical reversal of insulin resistance.
Insulin Resistance
Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.
Insulin Resistance
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Insulin Resistance
Urinary PC-1 activity in patients with type 1 diabetes mellitus.
Intellectual Disability
Phosphodiesterase activity is regulated by CC2D1A that is implicated in non-syndromic intellectual disability.
Intellectual Disability
Restoration of neuronal plasticity by a phosphodiesterase type 1 inhibitor in a model of fetal alcohol exposure.
Intermittent Claudication
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Intermittent Claudication
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
Intermittent Claudication
Analysis of the cilostazol safety database.
Intermittent Claudication
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
Intermittent Claudication
Cilostazol for treatment of cerebral infarction.
Intermittent Claudication
Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.
Intermittent Claudication
Cilostazol Inhibits Cytokine-Induced Tetrahydrobiopterin Biosynthesis in Human Umbilical Vein Endothelial Cells.
Intermittent Claudication
Cilostazol may improve outcome in critical limb ischemia.
Intermittent Claudication
Cilostazol promotes production of melanin by activating the microphthalmia-associated transcription factor (MITF).
Intermittent Claudication
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells.
Intermittent Claudication
Cilostazol.
Intermittent Claudication
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Intermittent Claudication
Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
Intermittent Claudication
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
Intermittent Claudication
Drug treatment of peripheral arterial disease in the elderly.
Intermittent Claudication
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Intermittent Claudication
Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
Intermittent Claudication
Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-? and cAMP Pathways in Vascular Cells.
Intermittent Claudication
Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Intermittent Claudication
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Intermittent Claudication
Medical therapy for intermittent claudication.
Intermittent Claudication
Metabolic inertia in contracting skeletal muscle: a novel approach for pharmacological intervention in peripheral vascular disease.
Intermittent Claudication
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Intermittent Claudication
Optimization, ex vivo permeation, and stability study of lipid nanocarrier loaded gelatin capsules for treatment of intermittent claudication.
Intermittent Claudication
Oral administration of cilostazol improves survival rate after rat liver ischemia/reperfusion injury.
Intermittent Claudication
Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormone.
Intermittent Claudication
Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers.
Intermittent Claudication
Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease.
Intermittent Claudication
Regulation of intestinal hPepT1 (SLC15A1) activity by phosphodiesterase inhibitors is via inhibition of NHE3 (SLC9A3).
Intermittent Claudication
Reversal of Osteopenia in Ovariectomized Rats by Pentoxifylline: Evidence of Osteogenic and Osteo-Angiogenic Roles of the Drug.
Intermittent Claudication
Treating peripheral arterial disease in patients with diabetes.
Intermittent Claudication
[Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol]
Ischemic Attack, Transient
Neuroprotective effect of cilostazol against retinal ischemic damage via inhibition of leukocyte-endothelial cell interactions.
Ischemic Stroke
A haplotype of the phosphodiesterase 4D (PDE4D) gene is associated with myocardial infarction and with cardiometabolic parameters: the GEA study.
Ischemic Stroke
Advances in the genetic basis of coronary artery disease.
Ischemic Stroke
Association between PDE4D polymorphism and ischemic stroke in young population.
Ischemic Stroke
Cilostazol Reduces PAC-1 Expression on Platelets in Ischemic Stroke.
Ischemic Stroke
Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.
Ischemic Stroke
Influence of Genetic Variation in PDE3A on Endothelial Function and Stroke.
Ischemic Stroke
Molecular genetics of coronary artery disease.
Ischemic Stroke
Phosphodiesterase 4 D gene polymorphism in relation to intracranial and extracranial atherosclerosis in ischemic stroke.
Ischemic Stroke
[Plasma levels of cyclic nucleotides, phosphodiesterase, thyroid hormones and insulin in patients with ischemic stroke]
Kidney Diseases, Cystic
Caffeine Accelerates Cystic Kidney Disease in a Pkd1-Deficient Mouse Model.
Kidney Diseases, Cystic
Polycystin-2 and phosphodiesterase 4C are components of a ciliary A-kinase anchoring protein complex that is disrupted in cystic kidney diseases.
Kidney Failure, Chronic
Advances in the medical treatment of pulmonary hypertension.
Kidney Failure, Chronic
The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.
Leber Congenital Amaurosis
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Leiomyoma
Changes in beta(2)-adrenoceptor expression and in adenylyl cyclase and phosphodiesterase activity in human uterine leiomyomas.
Leiomyoma
Characterization of soluble cyclic AMP phosphodiesterases and partial purification of a major form in human leiomyoma of the uterus.
Leukemia
Beta 2 receptor-mediated stimulation of Friend erythroleukemia cell growth by thyroid hormones.
Leukemia
Comparison of two methods of staining apoptotic cells of leukemia cell lines. Terminal deoxynucleotidyl transferase and DNA polymerase I reactions.
Leukemia
Cyclic AMP phosphodiesterase in human lymphocytes and lymphoblasts.
Leukemia
Demonstration, in leukemia L-1210 cells, of a phosphodiesterase acting on 3':5'-cyclic CMP but not on 3':5'-cyclic AMP or 3':5'-cyclic GMP.
Leukemia
Differential inhibition of various deoxyribonucleic acid polymerases by Evans blue and aurintricarboxylic acid.
Leukemia
Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.
Leukemia
Effects of VP-16 on cell growth and metabolism of nucleic acids in mouse leukemia L-1210 cells and on the activity of DNA polymerase I of E. coli.
Leukemia
Fidelity of HIV-1 reverse transcriptase copying RNA in vitro.
Leukemia
Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.
Leukemia
Influence of DNA sequence on the nature of mispairing during DNA synthesis.
Leukemia
Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate.
Leukemia
Systematic validation of hypothesis-driven candidate genes for cervical cancer in a genome-wide association study.
Leukemia
Terminal deoxynucleotidyltransferase. Serological studies and radioimmunoassay.
Leukemia
[Construction of a cDNA library from liver tissue of rhesus monkey, Macaca mulatta]
Leukemia, Erythroblastic, Acute
Beta 2 receptor-mediated stimulation of Friend erythroleukemia cell growth by thyroid hormones.
Leukemia, Erythroblastic, Acute
Regulation of cyclic 3',5'-adenosine monophosphate phosphodiesterase in Friend erythroleukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis.
Leukemia, Lymphocytic, Chronic, B-Cell
Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in normal and chronic lymphocytic leukemia lymphocytes.
Leukemia, Lymphocytic, Chronic, B-Cell
Excision of beta-D- and beta-L-nucleotide analogs from DNA by the human cytosolic 3'-to-5' exonuclease.
Leukemia, Lymphocytic, Chronic, B-Cell
Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.
Leukemia, Lymphocytic, Chronic, B-Cell
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The cAMP signaling pathway as a therapeutic target in lymphoid malignancies.
Leukemia, Lymphocytic, Chronic, B-Cell
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
Leukemia, Lymphocytic, Chronic, B-Cell
Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Carboxyamidotriazole: a novel inhibitor of both cAMP-phosphodiesterases and cGMP-phosphodiesterases.
Leukemia, Lymphoid
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells.
Leukemia, Lymphoid
Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Activity of cyclic nucleotide phosphodiesterases in granulocytes of chronic myelogenous leukemia (CML). A preliminary report.
Leukemia, Myeloid
Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.
Leukemia, Myeloid, Acute
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Leukodystrophy, Globoid Cell
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
Leukoencephalopathies
TREX1 is expressed by microglia in normal human brain and increases in regions affected by ischemia.
Lipidoses
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Liver Cirrhosis
Genome-wide analysis of copy number variation identifies candidate gene loci associated with the progression of non-alcoholic fatty liver disease.
Liver Cirrhosis
Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model.
Liver Cirrhosis
Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Liver Diseases
Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
Liver Diseases
Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high-fat diet-induced nonalcoholic fatty liver in rats.
Liver Diseases
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Liver Diseases
Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
Liver Diseases
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Diseases
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention.
Liver Diseases
Phosphodiesterases (PDEs) hydrolyze the 3' phosphoester bond of the purine 3',5'-cyclic monophosphates, cAMP and cGMP.
Liver Diseases
The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation.
Liver Diseases
[Symposium: Evaluation of methods of enzymatic diagnosis in various fields. A. Internal medicine. 3. Liver diseases. Diagnosis of liver diseases by means of serum phosphodiesterase.]
Liver Diseases, Alcoholic
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Liver Failure
Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors.
Liver Failure
Tumor necrosis factor production in the perfused mouse liver and its pharmacological modulation by methylxanthines.
Liver Neoplasms
Serum 5'--nucleotide phosphodiesterase isozyme--V test for human liver cancer.
Liver Neoplasms, Experimental
A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts.
Liver Neoplasms, Experimental
Decreased activity of cytidine 3':5'-monophosphate (cyclic CMP) phosphodiesterase in the fast-growing Morris hepatoma 3924A, but not in the slow-growing Morris hepatoma 9618A.
Liver Neoplasms, Experimental
Increased activity of low-Km cyclic adenosine 3':5'-monophosphate phosphodiesterase in plasma membranes of Morris hepatoma 5123tc (h).
Liver Neoplasms, Experimental
The isolation and characterization of cyclic nucleotide phosphodiesterases from Morris hepatoma 5123tc(h) and rat liver.
Lordosis
Effect of guanine derivatives on lordosis behavior in estrogen primed rats.
Lordosis
Facilitation of progesterone induced lordosis behavior by phosphodiesterase inhibitors in estrogen primed rats.
Lung Diseases
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.
Lung Diseases
Aminophylline promotes mitochondrial biogenesis in human pulmonary bronchial epithelial cells.
Lung Diseases
Cyclic adenosine monophosphate in acute ischemic stroke: some to update, more to explore.
Lung Diseases
Future developments in the pharmacotherapy of lung disease.
Lung Diseases
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Lung Diseases
Immunoreactivity of S100 beta in heart, skeletal muscle, and kidney in chronic lung disease: possible induction by cAMP.
Lung Diseases
Lung injury after simulated cardiopulmonary bypass in an isolated perfused rat lung preparation: Role of mitogen-activated protein kinase/Akt signaling and the effects of theophylline.
Lung Diseases
New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.
Lung Diseases
Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats.
Lung Diseases
Treatment initiation in paediatric pulmonary hypertension: insights from a multinational registry.
Lung Diseases, Interstitial
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Lung Diseases, Interstitial
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Lung Diseases, Obstructive
Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases.
Lung Diseases, Obstructive
Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases.
Lung Diseases, Obstructive
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Lung Injury
A novel fluid resuscitation strategy modulates pulmonary transcription factor activation in a murine model of hemorrhagic shock.
Lung Injury
A possible involvement of oxidative lung injury in endotoxin-induced bronchial hyperresponsiveness to substance P in guinea pigs.
Lung Injury
Attenuation of pulmonary fibrosis in mice by aminophylline.
Lung Injury
DSM-RX78, a new phosphodiesterase inhibitor, suppresses superoxide anion production in activated human neutrophils and attenuates hemorrhagic shock-induced lung injury in rats.
Lung Injury
Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine.
Lung Injury
Inhibition of chlorine-induced lung injury by the type 4 phosphodiesterase inhibitor rolipram.
Lung Injury
Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury.
Lung Injury
Pharmacokinetics, biodistribution and toxicology following intravenous and oral administration of DSM-RX78 and EFB-1, two new 2-(2-fluorobenzamido)benzoate-based PDE4 inhibitors, to rats.
Lung Injury
Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.
Lung Injury
Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect.
Lung Injury
Resolution acute respiratory distress syndrome through reversing the imbalance of Treg/Th17 by targeting the cAMP signaling pathway.
Lung Injury
Science review: Redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for nuclear factor-kappaB.
Lung Injury
Selective phosphodiesterase 3 inhibitor olprinone attenuates meconium-induced oxidative lung injury.
Lung Injury
Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury.
Lung Injury
Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Lung Injury
[Effect of inhaling specific phosphodiesterase inhibitor on lung injury induced by cardiopulmonary bypass].
Lung Neoplasms
A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer.
Lung Neoplasms
A Novel Flavonoid Kushenol Z from Sophora flavescens Mediates mTOR Pathway by Inhibiting Phosphodiesterase and Akt Activity to Induce Apoptosis in Non-Small-Cell Lung Cancer Cells.
Lung Neoplasms
A study on the levels of calmodulin and DNA in human lung cancer cells.
Lung Neoplasms
DAXAS and COPD Correlation with Cancer.
Lung Neoplasms
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Lung Neoplasms
Genetic risk of lung cancer associated with a single nucleotide polymorphism from EXO1: a meta analysis.
Lung Neoplasms
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.
Lupus Erythematosus, Cutaneous
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Lupus Erythematosus, Systemic
Loss of Trex1 in Dendritic Cells Is Sufficient To Trigger Systemic Autoimmunity.
Lupus Erythematosus, Systemic
T Cells Produce IFN-? in the TREX1 D18N Model of Lupus-like Autoimmunity.
Lupus Erythematosus, Systemic
TREX1 variants in Sjogren's syndrome related lymphomagenesis.
Lyme Disease
The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains.
Lymphoma
A role for DNA polymerase in the specificity of nucleotide incorporation opposite N-acetyl-2-aminofluorene adducts.
Lymphoma
cAMP metabolism in an S49 mouse lymphoma variant with diminished phosphodiesterase activity.
Lymphoma
Cyclic AMP-dependent protein kinase: pivotal role in regulation of enzyme induction and growth.
Lymphoma
Identification by direct photoaffinity labeling of an altered phosphodiesterase in a mutant S49 lymphoma cell.
Lymphoma
Poly (ADP-ribose) metabolism in alkylated mouse L5178Y cells.
Lymphoma
[Effects of aminophylline on proliferation and apoptosis in Raji lympho-blastoid cell line]
Lymphoma, B-Cell
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Lymphoma, B-Cell
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.
Lymphoma, B-Cell
No donor KMUP-1 improves hepatic ischemia-reperfusion and hypoxic cell injury by inhibiting oxidative stress and pro-inflammatory signaling.
Lymphoma, B-Cell
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Lymphoma, Follicular
Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.
Lymphoma, Large B-Cell, Diffuse
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Malaria
cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission.
Malaria
Phosphodiesterase beta is the master regulator of cAMP signalling during malaria parasite invasion.
Malaria
Plasmodium falciparum STEVOR phosphorylation regulates host erythrocyte deformability enabling malaria parasite transmission.
Malaria, Cerebral
Selective damage of hippocampal neurons in murine cerebral malaria prevented by pentoxifylline.
Malnutrition
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Mandibular Fractures
The effect of two phosphodiesterase inhibitors on bone healing in mandibular fractures (animal study in rats).
Mastocytoma
Differential effect of sodium butyrate on cyclic AMP phosphodiesterase activities in butyrate sensitive and resistant mastocytoma cells.
Mastocytoma
Inhibition of salvage synthesis of nucleic acid by adenosine 3',5'-cyclic decylphosphoramidate in mastocytoma P-815 cells.
Measles
[The influence of L-dopa and of thymus fraction on the survival rate of whole-body-irradiated mice]
Meconium Aspiration Syndrome
Effects of intravenous phosphodiesterase inhibitors and corticosteroids on severe meconium aspiration syndrome.
Melanoma
Antitumor efficacy of reticulol from Streptoverticillium against the lung metastasis model B16F10 melanoma. Lung metastasis inhibition by growth inhibition of melanoma.
Melanoma
Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid.
Melanoma
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Melanoma
Characterization of a human melanoma cell line (KHm-1) containing phosphodiesterase activity only for cyclic adenosine 3':5'-monophosphate.
Melanoma
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Melanoma
Effect of theophylline on the transport of tyrosine in cultured B-16 mouse melanoma cells.
Melanoma
Exonuclease 1 (EXO1) gene variation and melanoma risk.
Melanoma
Growth and pigmentation in genetically related Cloudman S91 melanoma cell lines treated with 3-isobutyl-1-methyl-xanthine and beta-melanocyte-stimulating hormone.
Melanoma
Hard times for oncogenic BRAF-expressing melanoma cells.
Melanoma
Induction of differentiated phenotypes in melanoma cells by a combination of an adenosine 3',5'-cyclic monophosphate stimulating agent and D-alpha tocopheryl succinate.
Melanoma
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.
Melanoma
Pentoxifylline impedes migration in B16F10 melanoma by modulating Rho GTPase activity and actin organisation.
Melanoma
Pentoxifylline inhibits integrin-mediated adherence of 12(S)-HETE and TNFalpha-activated B16F10 cells to fibronectin and endothelial cells.
Melanoma
Pentoxifylline Modulates Cell Surface Integrin Expression and Integrin Mediated Adhesion of B16F10 Cells to Extracellular Matrix Components.
Melanoma
Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells.
Melanoma
Phosphodiesterase inhibitors such as Viagra do not increase melanoma risk, review finds.
Melanoma
PRESM: Personalized Reference Editor for Somatic Mutation discovery in cancer genomics.
Melanoma
Stimulation of cyclic GMP efflux in human melanocytes by hypergravity generated by centrifugal acceleration.
Melanoma
Stimulation of melanotic expression in a melanoma cell line by theophylline.
Melanoma
Theophylline incorporation into the nucleic acids of theophylline-stimulated melanoma cells.
Melanoma
Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma.
Melanoma
Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Melanoma
Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Melanoma
[Regulatory role of DOPA and components of the cyclic adenosine-3',5'-monophosphate system]
Melanoma, Experimental
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Melanoma, Experimental
Growth and pigmentation in genetically related Cloudman S91 melanoma cell lines treated with 3-isobutyl-1-methyl-xanthine and beta-melanocyte-stimulating hormone.
Memory Disorders
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Memory Disorders
Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.
Memory Disorders
Febrile seizures impair memory and cAMP response-element binding protein activation.
Memory Disorders
Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.
Memory Disorders
Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801.
Memory Disorders
Pentoxifylline reverses age-related deficits in spatial memory.
Memory Disorders
Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
Meningitis
Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram.
Mesenteric Ischemia
Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine.
Metabolic Syndrome
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Mitochondrial Diseases
Mice lacking the mitochondrial exonuclease MGME1 accumulate mtDNA deletions without developing progeria.
Mitral Valve Insufficiency
Hemodynamic efficacy of E-1020 in comparison with dopamine on acute mitral regurgitation in anesthetized dogs.
Mouth Neoplasms
Serum phosphodiesterase levels in oral cancer.
Movement Disorders
Clinical findings of autosomal-dominant striatal degeneration and PDE8B mutation screening in parkinsonism and related disorders.
Mucolipidoses
Radiometric assays of N-acetylglucosaminylphosphotransferase and alpha-N-acetylglucosaminyl phosphodiesterase with substrates labeled in the glucosamine moiety.
Multiple Myeloma
Chronicles in drug discovery.
Multiple Myeloma
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Multiple Sclerosis
Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis.
Multiple Sclerosis
Epstein-Barr virus, 9.4 T MRI and phosphodiesterase inhibitors in multiple sclerosis.
Multiple Sclerosis
Glycerylphosphocholine phosphocholine phosphodiesterase activity is reduced in multiple sclerosis plaques.
Multiple Sclerosis
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Multiple Sclerosis
Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis.
Multiple Sclerosis
Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.
Multiple Sclerosis
Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis.
Multiple Sclerosis
Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats.
Multiple Sclerosis
Simultaneous measurement of 2':3' cyclic-nucleotide 3' phosphodiesterase and RNase activities in sera and spinal fluids of multiple sclerosis patients.
Multiple Sclerosis
The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Multiple Sclerosis
The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis.
Multiple Sclerosis
Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis.
Multiple Sclerosis
Vinpocetine inhibits oligodendroglial precursor cell differentiation.
Multiple Sclerosis, Relapsing-Remitting
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Muscular Atrophy
Phosphodiesterase 4 inhibition restrains muscle proteolysis in diabetic rats by activating PKA and EPAC/Akt effectors and inhibiting FoxO factors.
Muscular Atrophy
Phosphodiesterase-4 inhibition reduces proteolysis and atrogenes expression in rat skeletal muscles.
Muscular Diseases
Imidazole myopathy. Production of the myopathy and its dependence on acetylcholine.
Muscular Diseases
[Cyclic 3',5'-AMP metabolism in progressive muscular dystrophy patients]
Muscular Diseases
[Pathogenesis of several forms of progressive muscular dystrophy]
Muscular Dystrophies
NO more muscle fatigue.
Muscular Dystrophy, Duchenne
Calcium, calmodulin and 3',5'-cyclic nucleotide phosphodiesterase activity in human muscular disorders.
Muscular Dystrophy, Duchenne
Chronicles in drug discovery.
Muscular Dystrophy, Duchenne
Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse Model of Duchenne Muscular Dystrophy.
Myasthenia Gravis
Involvement of phosphodiesterases in autoimmune diseases.
Myasthenia Gravis
Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor.
Myasthenia Gravis
The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Myocardial Infarction
Adenoviral short hairpin RNA therapy targeting phosphodiesterase 5a relieves cardiac remodeling and dysfunction following myocardial infarction.
Myocardial Infarction
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Myocardial Infarction
Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection.
Myocardial Infarction
Effects of milrinone on left ventricular remodeling after acute myocardial infarction.
Myocardial Infarction
Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion.
Myocardial Infarction
Impact of chronotropic effect of cilostazol after acute myocardial infarction: insights from change in left ventricular volume and function.
Myocardial Infarction
Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
Myocardial Infarction
Modulation of inotropic therapy by venodilation in acute heart failure: a randomised comparison of four inotropic agents, alone and combined with isosorbide dinitrate.
Myocardial Infarction
Molecular genetics of coronary artery disease.
Myocardial Infarction
Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathway.
Myocardial Infarction
Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction.
Myocardial Infarction
Phosphodiesterase 5a Inhibition with Adenoviral Short Hairpin RNA Benefits Infarcted Heart Partially through Activation of Akt Signaling Pathway and Reduction of Inflammatory Cytokines.
Myocardial Infarction
Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors.
Myocardial Infarction
Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.
Myocardial Infarction
The phosphodiesterase 8B gene rs4704397 is associated with thyroid function, risk of myocardial infarction and body height. The Tromsø Study.
Myocardial Infarction
[Cyclic adenosine monophosphate and atherogenic factors]
Myocardial Infarction
[Early echocardiographic identification of viable myocardium after acute myocardial infarct using inotropic agents: comparison of dobutamine and enoximone]
Myocardial Infarction
[Systems for regulating the level of Ca2+, cyclic nucleotides, and reverse absorption of neurotransmitters in isolated nerve endings of the rat brain during development of myocardial infarct]
Myocardial Ischemia
Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
Myocardial Ischemia
Cardiac drugs: new inotropes.
Myocardial Ischemia
Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.
Myocardial Ischemia
Effect of isometric handgrip on systolic time intervals in patients with ischemic heart disease and cyclic amp phosphodiesterase inhibitor pretreatment.
Myocardial Ischemia
Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs.
Myocardial Ischemia
Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs.
Myocardial Ischemia
Effects of enoximone and R 80122, a new selective phosphodiesterase III inhibitor, on hemodynamics and myocardial energetics in patients with ischemic heart disease.
Myocardial Ischemia
Effects of the antianginal drug trapidil on atrioventricular conduction disturbances during acute myocardial ischemia.
Myocardial Ischemia
Inhibition of phosphodiesterase type III before aortic cross-clamping preserves intramyocardial cyclic adenosine monophosphate during cardiopulmonary bypass.
Myocardial Ischemia
Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: the Montreal Heart Institute experience.
Myocardial Ischemia
Newer treatments for decompensated heart failure: focus on levosimendan.
Myocardial Ischemia
[Effects of the phosphodiesterase III inhibitor in ischemic heart disease]
Myocardial Reperfusion Injury
Effect of a cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury.
Myocardial Stunning
Ca(2+) sensitization and diastolic function of normal and stunned porcine myocardium.
Myocardial Stunning
Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
Myocardial Stunning
Comparison between the effects of a novel Ca++ sensitizer and a phosphodiesterase inhibitor on stunned myocardium.
Myocardial Stunning
Does ventricular fibrillation cause myocardial stunning during defibrillator implantation?
Myocardial Stunning
Effect of milrinone and atrial pacing on stunned myocardium.
Myocardial Stunning
Treating metabolic impairment and myocardial stunning with phosphodiesterase inhibitor type III, milrinone, administered prior to coronary artery occlusion in the presence of calcium channel blockade in pigs.
Myoma
[Peptide-activator of cyclic nucleotide phosphodiesterases in the rat and human uterus]
Neonatal Sepsis
Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns.
Neoplasm Metastasis
Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
Neoplasm Metastasis
Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Neoplasm Metastasis
Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.
Neoplasm Metastasis
Inhibition of experimental metastasis of human adenocarcinoma by cilostazol, a platelet phosphodiesterase inhibitor.
Neoplasm Metastasis
Novel pyrimidopyrimidine derivatives for inhibition of cellular proliferation and motility induced by h-prune in breast cancer.
Neoplasm Metastasis
Phosphodiesterase 3A Represents a Therapeutic Target that Drives Stem Cell-like Property and Metastasis in Breast Cancer.
Neoplasm Metastasis
Prune cAMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis.
Neoplasm Metastasis
Silencing lncRNA ZFAS1 or elevated microRNA-135a represses proliferation, migration, invasion and resistance to apoptosis of osteosarcoma cells.
Neoplasm Metastasis
Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
Neoplasm Metastasis
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]
Neoplasms
5'-nucleotide phosphodiesterase activity of floxuridine-resistant mouse glioma.
Neoplasms
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Neoplasms
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and ?-catenin transcriptional activity.
Neoplasms
A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.
Neoplasms
A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Neoplasms
A study of cyclic nucleotide metabolism and the histology of rat liver during 3'-methyl-4-dimethylamino-azobenzene carcinogenesis. II. Cyclic AMP metabolism.
Neoplasms
Action of cAMP on expression and release of adhesion molecules in human endothelial cells.
Neoplasms
Activation of cyclic AMP phosphodiesterase by phorbol and protein kinase C pathway: differences in normal and diabetic tissue.
Neoplasms
Activation of the human "beta 2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists.
Neoplasms
Adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate phosphodiesterase activities in 1,2-dimethylhydrazine induced colon adenocarcinoma.
Neoplasms
Adenosine 3',5'-monophosphate phosphodiesterase activity in experimental animal tumours which are either sensitive or resistant to bifunctional alkylating agents.
Neoplasms
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies.
Neoplasms
Adenyl cyclase and phosphodiesterase in human cerebral tumors.
Neoplasms
Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP.
Neoplasms
Amrinone and theophylline differentially regulate cytokine and nitric oxide production in endotoxemic mice.
Neoplasms
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.
Neoplasms
APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival.
Neoplasms
Association between three exonuclease 1 polymorphisms and cancer risks: a meta-analysis.
Neoplasms
Association of DNA repair gene polymorphisms with response to cisplatin-based concurrent chemoradiotherapy in patients with cervical carcinoma.
Neoplasms
Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells.
Neoplasms
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Neoplasms
Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Neoplasms
Benzoquinones and Terphenyl Compounds As Phosphodiesterase-4B Inhibitors from a Fungus of the Order Chaetothyriales (MSX 47445).
Neoplasms
Biochemical properties of cyclic nucleotide phosphodiesterase in metastasizing and nonmetastasizing rat mammary carcinomas.
Neoplasms
Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.
Neoplasms
Ca2+ and partly GTP gamma S-dependent particulate phospholipase C hydrolyzing phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate is inhibited by diacyl(acyl-acetyl) glycerols.
Neoplasms
Caffeine and other phosphodiesterase inhibitors are potent inhibitors of the promotional effect of TPA on morphological transformation of hamster embryo cells.
Neoplasms
Caffeine stimulates the proliferation of human lung adenocarcinoma cells and small airway epithelial cells via activation of PKA, CREB and ERK1/2.
Neoplasms
Calmodulin activation of cyclic AMP phosphodiesterase in the B16 mouse melanoma.
Neoplasms
Characterisation of cyclic adenosine 3':5'-monophosphate phospodiesterase from Walker carcinoma sensitive and resistant to bifunctional alkylating agents.
Neoplasms
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Neoplasms
Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Neoplasms
Clinical Relevance of the Anti-inflammatory Effects of Roflumilast on Human Bronchus: Potentiation by a Long-Acting Beta-2-Agonist.
Neoplasms
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition.
Neoplasms
Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.
Neoplasms
Constitutive activation of p70S6k in cancer cells.
Neoplasms
Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
Neoplasms
Correlation between in vitro DNA synthesis, DNA strand separation and in vivo multiplication of cancer cells.
Neoplasms
Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility.
Neoplasms
Cyclic AMP specific, calcium independent phosphodiesterase from a malignant murine mast cell tumor.
Neoplasms
Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death.
Neoplasms
Cyclic nucleotide phosphodiesterase activity in muscle of patients with carcinoma.
Neoplasms
Cyclic nucleotide phosphodiesterase activity of human normal and carcinomatous lung tissue.
Neoplasms
Cyclic nucleotide phosphodiesterases in neoplastic and nonneoplastic human mammary tissues.
Neoplasms
Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.
Neoplasms
Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells.
Neoplasms
Cyclic-AMP phosphodiesterase activity in crown-gall tumor formation.
Neoplasms
Cytokine-induced adhesion molecule expression on human umbilical vein endothelial cells is not regulated by cyclic adenosine monophosphate accumulation.
Neoplasms
Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.
Neoplasms
Differential phosphodiesterase expression and cytosolic Ca2+ in human CNS tumour cells and in non-malignant and malignant cells of rat origin.
Neoplasms
Dipyridamole Inhibits Lipogenic Gene Expression by Retaining SCAP-SREBP in the Endoplasmic Reticulum.
Neoplasms
Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP.
Neoplasms
Draft Genome Sequence of Marine Actinomycete Streptomyces sp. Strain NTK 937, Producer of the Benzoxazole Antibiotic Caboxamycin.
Neoplasms
Dual regulation of tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition.
Neoplasms
Editorial Comment on: Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha.
Neoplasms
Effect of in vivo administration of 3-isobutyl 1-methyl xanthine (IBMX) on cyclic AMP levels, and DNA synthesis in Ehrlich ascites tumor cells.
Neoplasms
Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188.
Neoplasms
Effect of phosphodiesterase III inhibitor on plasma concentrations of endothelin-1 and tumour necrosis factor in patients with acute heart failure.
Neoplasms
Effect of phosphodiesterase inhibitors on platelet aggregation and tumor metastasis.
Neoplasms
Effect of TNF alpha production inhibitors BRL 61063 and pentoxifylline on the response of rats to poly I:C.
Neoplasms
Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Neoplasms
Effects of medroxyprogesterone acetate (MPA) on phosphodiesterase (PDE) activity in DMBA-induced rat mammary tumours.
Neoplasms
Effects of Phosphodiesterase Inhibitors on the Inflammatory Response of Endothelial Cells Stimulated by Myeloperoxidase-Modified Low-Density Lipoprotein or Tumor Necrosis Factor Alpha.
Neoplasms
Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells.
Neoplasms
Endogenous protein inhibitor of mitochondrial c-AMP phosphodiesterase in tumour bearing rats.
Neoplasms
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Neoplasms
Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Neoplasms
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Neoplasms
Evidence for a calmodulin inhibitory substance(s) isolated from human meningiomas.
Neoplasms
Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
Neoplasms
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Neoplasms
Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.
Neoplasms
Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival.
Neoplasms
Exonuclease 1 (EXO1) is a Potential Prognostic Biomarker and Correlates with Immune Infiltrates in Lung Adenocarcinoma.
Neoplasms
Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.
Neoplasms
Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy.
Neoplasms
Expression of the functional cone phototransduction cascade in retinoblastoma.
Neoplasms
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Neoplasms
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Neoplasms
Gene expression in thyroid autonomous adenomas provides insight into their physiopathology.
Neoplasms
Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias.
Neoplasms
Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.
Neoplasms
Germline Variants in Phosphodiesterase Genes and Genetic Predisposition to Pediatric Adrenocortical Tumors.
Neoplasms
Growth-dependent AIB and meAIB uptake in LLC-PK1 cells: effects of differentiation inducers and of TPA.
Neoplasms
Guanine nucleotides activate cytosolic phospholipase C of ascites tumour cells stimulated by 1-oleoyl-2-acetyl-sn-glycerol.
Neoplasms
Hard times for oncogenic BRAF-expressing melanoma cells.
Neoplasms
Human Exonuclease 1 (EXO1) Regulatory Functions in DNA Replication with Putative Roles in Cancer.
Neoplasms
Human neuroblastoma in nude mice.
Neoplasms
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
Neoplasms
Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor ?.
Neoplasms
Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat.
Neoplasms
Identification and treatment of T2-low asthma in the era of biologics.
Neoplasms
Identification of a functional glucocorticoid response element in the phenylethanolamine N-methyltransferase promoter using fusion genes introduced into chromaffin cells in primary culture.
Neoplasms
Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.
Neoplasms
Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumors.
Neoplasms
Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells.
Neoplasms
Inactivation of Exonuclease 1 in mice results in DNA mismatch repair defects, increased cancer susceptibility, and male and female sterility.
Neoplasms
Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas.
Neoplasms
Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterparts.
Neoplasms
Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/{beta}-Catenin-Mediated Transcription in Human Breast Tumor Cells.
Neoplasms
Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores.
Neoplasms
Inhibitors of phosphodiesterase as cancer therapeutics.
Neoplasms
Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-?B dependent mechanisms in apoE-/- mice.
Neoplasms
Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition.
Neoplasms
Is hEXO1 a cancer predisposing gene?
Neoplasms
Isolation and characterization of calmodulin from an insulin-secreting tumour.
Neoplasms
Isolation and characterization of the plasma membrane from Yoshida hepatoma cells.
Neoplasms
Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway.
Neoplasms
Lack of steroidogenic response to cyclic AMP and ACTH in adrenal cells from rats bearing the MtTF4 tumor.
Neoplasms
Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
Neoplasms
Lowering of innate resistance of the lungs to the growth of blood-borne cancer cells in states of topical and systemic stress.
Neoplasms
Management of male sexual dysfunction after cancer treatment.
Neoplasms
Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
Neoplasms
MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway.
Neoplasms
Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms.
Neoplasms
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Neoplasms
Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Neoplasms
Novel Polyfunctional Pyridines as Anticancer and Antioxidant Agents. Synthesis, Biological Evaluation and in Silico ADME-T Study.
Neoplasms
NSAIDs: Old Drugs Reveal New Anticancer Targets.
Neoplasms
Overcoming of P-glycoprotein mediated vincristine resistance of L1210/VCR mouse leukemic cells could be induced by pentoxifyline but not by theophylline and caffeine.
Neoplasms
Overexpression of autotaxin is associated with human renal cell carcinoma and bladder carcinoma and their progression.
Neoplasms
Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats.
Neoplasms
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth.
Neoplasms
Pentoxifylline attenuates hypoxic-ischemic brain injury in immature rats.
Neoplasms
Pentoxifylline downregulates nitric oxide and tumor necrosis factor-alpha induced by mycobacterial lipoarabinomannan in a macrophage cell line.
Neoplasms
Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis.
Neoplasms
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Neoplasms
Pentoxifylline in preterm neonates: a systematic review.
Neoplasms
Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway.
Neoplasms
Pentoxifylline reduces acute lung injury in chronic endotoxemia.
Neoplasms
Pentoxifylline triggers autophagy via ER stress response that interferes with Pentoxifylline induced apoptosis in human melanoma cells.
Neoplasms
Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis.
Neoplasms
Peripheral Enthesitis in Spondyloarthritis: Lessons from Targeted Treatments.
Neoplasms
Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors.
Neoplasms
Phorbol 12-myristate-13-acetate (PMA) stimulates a differential expression of cholecystokinin (CCK) and c-fos mRNA in a human neuroblastoma cell line.
Neoplasms
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Neoplasms
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors.
Neoplasms
Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors.
Neoplasms
Phosphodiesterase 3A: a new player in development of interstitial cells of Cajal and a prospective target in gastrointestinal stromal tumors (GIST).
Neoplasms
Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
Neoplasms
Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.
Neoplasms
Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression.
Neoplasms
Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.
Neoplasms
Phosphodiesterase inhibitors as anti-cancer drugs.
Neoplasms
Placental extracellular vesicles-associated microRNA-519c mediates endotoxin adaptation in pregnancy.
Neoplasms
Platyphylloside Isolated From Betula platyphylla Inhibit Adipocyte Differentiation and Induce Lipolysis Via Regulating Adipokines Including PPAR? in 3T3-L1 Cells.
Neoplasms
Poly(ADP-ribose)-binding promotes Exo1 damage recruitment and suppresses its nuclease activities.
Neoplasms
Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.
Neoplasms
Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line.
Neoplasms
Purification and properties of Rauscher leukemia virus DNA polymerase and selective inhibition of mammalian viral reverse transcriptase by inorganic phosphate.
Neoplasms
Quercetin inhibition of the induction and function of cytotoxic T lymphocytes.
Neoplasms
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Neoplasms
Regression and differentiation of neuroblastoma tumors in mice treated with differentiating agents--prostaglandin E1 and a phosphodiesterase inhibitor, RO 20-1724.
Neoplasms
Regulation of CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC in response to second messenger activators.
Neoplasms
Regulation of cyclic adenosine 3',5'-monophosphate in relation to growth of dimethylbenz[a]anthracene-induced mammary tumors in rats.
Neoplasms
Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations.
Neoplasms
Resveratrol Promotes Remyelination in Cuprizone Model of Multiple Sclerosis: Biochemical and Histological Study.
Neoplasms
Role of soluble guanylyl cyclase-cyclic GMP signaling in tumor cell proliferation.
Neoplasms
Rolipram optimizes therapeutic effect of bevacizumab by enhancing proapoptotic, antiproliferative signals in a glioblastoma heterotopic model.
Neoplasms
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Neoplasms
Serological analysis of human deoxyribonucleic acid polymerases. Preparation and properties of antiserum to deoxyribonucleic acid polymerase I from human lymphoid cells.
Neoplasms
Significant association of the
Neoplasms
Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
Neoplasms
Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin.
Neoplasms
Structural chemoproteomics and drug discovery.
Neoplasms
Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.
Neoplasms
Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Neoplasms
Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
Neoplasms
Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
Neoplasms
Synovial fluid levels of tumor necrosis factor-alpha in the inflamed rat knee: modulation by dexamethasone and inhibitors of matrix metalloproteinase and phosphodiesterase.
Neoplasms
Synthesis and properties of some novel anti-calmodulin drugs.
Neoplasms
Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.
Neoplasms
Synthesis of tumour necrosis factor-alpha in tissue culture of rat caecum: lack of suppression by phosphodiesterase inhibitors and prostanoids.
Neoplasms
Targeting cancer with phosphodiesterase inhibitors.
Neoplasms
Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells.
Neoplasms
Targeting tumor cells based on Phosphodiesterase 3A expression.
Neoplasms
Targetting cancer with Ru(III/II)-phosphodiesterase inhibitor adducts: a novel approach in the treatment of cancer.
Neoplasms
The beta-adrenergic receptor system in human glioma-derived cell lines: the mode of phosphodiesterase induction and the macromolecules phosphorylated by cyclic AMP-dependent protein kinase.
Neoplasms
The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Neoplasms
The exonuclease 1 Glu589Lys gene polymorphism and cancer susceptibility: evidence based on a meta-analysis.
Neoplasms
The Human Tyrosyl-DNA Phosphodiesterase 1 (hTdp1) Inhibitor NSC120686 as an Exploratory Tool to Investigate Plant Tdp1 Genes.
Neoplasms
The interaction between the Wnt/?-catenin signaling cascade and PKG activation in cancer.
Neoplasms
The involvement of the 3':5'-cyclic-AMP phosphodiesterase in transformation and growth of crown-gall tumors in Bryophyllum daigremontianum.
Neoplasms
The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa.
Neoplasms
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Neoplasms
The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Neoplasms
The proofreading domain of Escherichia coli DNA polymerase I and other DNA and/or RNA exonuclease domains.
Neoplasms
The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytoskeletal organization of rat mammary adenocarcinoma cells.
Neoplasms
The role of tumour necrosis factor-alpha (TNF-alpha) in fever and the acute phase reaction in rabbits.
Neoplasms
The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Neoplasms
The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.
Neoplasms
The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
Neoplasms
The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
Neoplasms
The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.
Neoplasms
Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Neoplasms
Therapeutic options for severe asthma.
Neoplasms
Therapeutic targets for treating fibrotic kidney diseases.
Neoplasms
Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis.
Neoplasms
Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
Neoplasms
TREX1 Cuts Down on Cancer Immunogenicity.
Neoplasms
Tumor necrosis factor-alpha activates nuclear factor kappa B and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells.
Neoplasms
Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase.
Neoplasms
Unraveling the molecular basis of micronodular adrenal hyperplasia.
Neoplasms
Virtual screening using ligand-based pharmacophores for inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1).
Neoplasms
Yessotoxin activates cell death pathways independent of Protein Kinase C in K-562 human leukemic cell line.
Neoplasms
[adenylate cyclase system in Ehrlich ascites tumor cells sensitive and resistant to 5-fluorouracil]
Neoplasms
[Concentration of cyclic nucleotides, activity of adenylate cyclase, 3',5'-AMP phosphodiesterase and guanylate cyclase in plasma membranes from liver and hepatomas of different degrees of malignancy]
Neoplasms
[Effect of selective phosphodiesterase 4 inhibitors on nuclear factor kappa B, tumor necrosis factor-? and interleukin-8 expression in peripheral blood mononuclear cells in rheumatoid arthritis with interstitial lung disease].
Neoplasms
[Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection]
Neoplasms
[Insertion of mouse kappa light chain immunoglobulin gene sequences into a bacterial plasmid]
Neoplasms, Germ Cell and Embryonal
Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.
Nephritis
Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats.
Nephrotic Syndrome
Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention.
Nephrotic Syndrome
Phosphodiesterases (PDEs) hydrolyze the 3' phosphoester bond of the purine 3',5'-cyclic monophosphates, cAMP and cGMP.
Nephrotic Syndrome
Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
Nervous System Diseases
Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings.
Neuralgia
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Neuralgia
Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells.
Neuralgia
Impairment of adenylyl cyclase-mediated glutamatergic synaptic plasticity in the periaqueductal grey in a rat model of neuropathic pain.
Neuralgia
Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation.
Neuralgia
Zaprinast diminished pain and enhanced opioid analgesia in a rat neuropathic pain model.
Neurilemmoma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Neuritis
Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline.
Neuritis, Autoimmune, Experimental
Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline.
Neuroblastoma
A further study on the regulation of cyclic nucleotide phosphodiesterase activity in neuroblastoma cells: effect of growth.
Neuroblastoma
Adenosine analogues stimulate cyclic AMP-accumulation in cultured neuroblastoma and glioma cells.
Neuroblastoma
Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells.
Neuroblastoma
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, stimulates nitric oxide production and sodium potassium adenosine triphosphatase activity in SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Comparison of the effect of isobutylmethylxanthine and phosphodiesterase-selective inhibitors on cAMP levels in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Cyclic 3',5'-AMP phosphodiesterase activity during cyclic AMP-induced differentiation of neuroblastoma cells in culture.
Neuroblastoma
Cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in malignant and cyclic adenosine 3':5'-monophosphate-induced "differentiated" neuroblastoma cells.
Neuroblastoma
Cyclic AMP-mediated induction of ornithine decarboxylase of glioma and neuroblastoma cells.
Neuroblastoma
Cyclic nucleotide phosphodiesterase isozymes in neuroblastoma cells.
Neuroblastoma
Cyclic nucleotides in the regulation of expression of differentiated functions in neuroblastoma cells.
Neuroblastoma
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Neuroblastoma
Determination of 2-5A synthetase and 2-5A phosphodiesterase in neuroblastoma cells by analytical capillary isotachophoresis: effects of cytokines and comparison with radioenzymatic methods.
Neuroblastoma
Differences and similarities between guanosine 3',5'-cyclic monophosphate phosphodiesterase and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in neuroblastoma cells in culture.
Neuroblastoma
Distinct isozyme patterns of cyclic nucleotide phosphodiesterase in human neuroblastoma and ganglioneuroma; a possible marker of differentiation of neural crest-derived tumors and Schwann cells.
Neuroblastoma
Effect of a phosphodiesterase inhibitor on cyclic GMP changes induced by muscarinic agonists in mouse neuroblastoma cells [proceedings]
Neuroblastoma
Expression of calmodulin-dependent phosphodiesterase, calmodulin-dependent protein phosphatase, and other calmodulin-binding proteins in human SMS-KCNR neuroblastoma cells.
Neuroblastoma
Glucocorticoids increase tyrosine hydroxylase activity in cultured murine neuroblastoma.
Neuroblastoma
Inhibitors of cyclic-nucleotide phosphodiesterase induce morphological differentiation of mouse neuroblastoma cell culture.
Neuroblastoma
Manganese inhibits adenylate cyclase activity and stimulates phosphodiesterase activity in neuroblastoma cells: its possible implication in manganese-poisoning.
Neuroblastoma
Mouse neuroblastoma adenylate cyclase. Adenosine and adenosine analogues as potent effectors of adenylate cyclase activity.
Neuroblastoma
Multiple forms of cyclic 3',5'-AMP phosphodiesterase of rat cerebrum and cloned astrocytoma and neuroblastoma cells.
Neuroblastoma
Neuroblastoma clones: prostaglandin versus dibutyryl cyclic AMP, 8-benzylthio-cyclic AMP, phosphodiesterase inhibitors and x-rays.
Neuroblastoma
Potentiation by BL191 of differentiation of neuroblastoma cells induced by dibutyryl cAMP and prostaglandin E(1).
Neuroblastoma
Regression and differentiation of neuroblastoma tumors in mice treated with differentiating agents--prostaglandin E1 and a phosphodiesterase inhibitor, RO 20-1724.
Neuroblastoma
Role of cyclic AMP in differentiation of human neuroblastoma cells in culture.
Neuroblastoma
Rottlerin is a pan phosphodiesterase inhibitor and can induce neurodifferentiation in IMR-32 human neuroblastoma cells.
Neuroblastoma
Sequence-dependent trafficking and activity of GDE2, a GPI-specific phospholipase promoting neuronal differentiation.
Neuroblastoma
Stimulation by prostaglandin E1 of adenosine 3':5'-cyclic monophosphate formation in neuroblastoma cells in the presence of phosphodiesterase inhibitors.
Neuroblastoma
Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
Neuroblastoma
[3H]Rolipram binding and phosphodiesterase activity in neuroblastoma N18TG-2 and glioma C6Bu-1.
Neurodegenerative Diseases
cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins.
Neurodegenerative Diseases
Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
Neurodegenerative Diseases
Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline.
Neurodegenerative Diseases
In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation.
Neurodegenerative Diseases
Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.
Neurodegenerative Diseases
Sildenafil-evoked photoreceptor oxidative stress in vivo is unrelated to impaired visual performance in mice.
Neurodegenerative Diseases
The perspective of caffeine and caffeine derived compounds in therapy.
Neurodegenerative Diseases
XRCC1 protects against the lethality of induced oxidative DNA damage in nondividing neural cells.
Neuroinflammatory Diseases
Multifunctional Ligands Targeting Phosphodiesterase as the Future Strategy for the Symptomatic and Disease-Modifying Treatment of Alzheimer's Disease.
Neuroinflammatory Diseases
Phosphodiesterases as a New Therapeutic Targets for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases.
Neuroinflammatory Diseases
Phosphoinositide 3-Kinase Gamma Contributes to Neuroinflammation in a Rat Model of Surgical Brain Injury.
Neuroinflammatory Diseases
Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
Neuroinflammatory Diseases
The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects via the PKA signaling pathway in neuroinflammation and Parkinson's disease mouse models.
Neuroinflammatory Diseases
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.
Neurologic Manifestations
[Beta-adrenergic receptor blocker poisoning]
Neuromyelitis Optica
[Neuro-ophthalmology: the eye as a window to the brain].
Neutropenia
C16orf57, a gene mutated in poikiloderma with neutropenia, encodes a putative phosphodiesterase responsible for the U6 snRNA 3' end modification.
Niemann-Pick Disease, Type A
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Niemann-Pick Diseases
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Niemann-Pick Diseases
Diagnosis of Niemann-Pick disease using a simple and sensitive fluorimetric assay of sphingomyelinase activity.
Niemann-Pick Diseases
Fibroblast phosphodiesterase deficiency in Niemann-Pick disease.
Niemann-Pick Diseases
Sphingomyelinase and nonspecific phosphodiesterase activities in Epstein-Barr virus-transformed lymphoid cell lines from Niemann-Pick disease A, B and C.
Niemann-Pick Diseases
Studies on pyrophosphate diesterase activity in cultured human fibroblasts: a deficiency in Niemann-Pick disease.
Niemann-Pick Diseases
Studies on sphingomyelinase and beta-glucosidase activities in Niemann-Pick disease variants. Phosphodiesterase activities measured with natural and artificial substrates.
Niemann-Pick Diseases
The structure and catalytic mechanism of human sphingomyelin phosphodiesterase like 3a--an acid sphingomyelinase homologue with a novel nucleotide hydrolase activity.
Non-alcoholic Fatty Liver Disease
Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
Non-alcoholic Fatty Liver Disease
Effects of Chinese Medicinal Formula BNG-1 on Phosphodiesterase 3B Expression, Hepatic Steatosis, and Insulin Resistance in High Fat Diet-induced NAFLD Mice.
Non-alcoholic Fatty Liver Disease
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
Non-alcoholic Fatty Liver Disease
n-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review.
Obesity
A stop-codon of the phosphodiesterase 11A gene is associated with elevated blood pressure and measures of obesity.
Obesity
Adenosine, prostaglandins and phosphodiesterase as targets for obesity pharmacotherapy.
Obesity
Anthocyanin Bioactivity in Obesity and Diabetes: The Essential Role of Glucose Transporters in the Gut and Periphery.
Obesity
Association of genetic variation in ENPP1 with obesity-related phenotypes.
Obesity
Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects.
Obesity
Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients.
Obesity
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Obesity
Inhibitory Activities of Pancreatic Lipase and Phosphodiesterase from Korean Medicinal Plant Extracts.
Obesity
Insulin resistance of fat cells from spontaneously diabetic KK mice. Analysis of insulin-sensitive phosphodiesterase.
Obesity
Structural chemoproteomics and drug discovery.
Obesity
The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes.
Obstetric Labor, Premature
Improving the relaxing effect of terbutaline with phosphodiesterase inhibitors: Studies on pregnant rat uteri in vitro.
Obstetric Labor, Premature
In vitro study of phosphodiesterase-inhibiting drugs: a complement to beta-sympathomimetic drug therapy in premature labor?
Ocular Hypotension
Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors.
Oligohydramnios
Endocrine and pharmacological factors which influence the onset of labour in rhesus monkeys.
Oligospermia
Modulation of sperm membrane conformation by pentoxifylline in oligospermia: a biophysical investigation of sperm membrane in vitro.
Optic Nerve Diseases
The phosphodiesterase inhibitors and non-arteritic anterior ischaemic optic neuropathy: increased vigilance is necessary.
Optic Nerve Diseases
[Neuro-ophthalmology: the eye as a window to the brain].
Optic Neuropathy, Ischemic
Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Optic Neuropathy, Ischemic
Optic neuropathy associated with the use of over-the-counter sexual enhancement supplements.
Optic Neuropathy, Ischemic
[Neuro-ophthalmology: the eye as a window to the brain].
Orchitis
Syphilitic orchitis mimicking a testicular tumor in a clinically occult HIV-infected young man: a case report with emphasis on a challenging pathological diagnosis.
Osteoarthritis
Cilostazol protects rat chondrocytes against nitric oxide-induced apoptosis in vitro and prevents cartilage destruction in a rat model of osteoarthritis.
Osteoarthritis
Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice.
Osteoarthritis
Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.
Osteonecrosis
Preventive Effect of Phosphodiesterase Inhibitor Pentoxifylline Against Medication-Related Osteonecrosis of the Jaw: An Animal Study.
Osteoporosis
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Osteoporosis
KMUP-1 promotes osteoblast differentiation through cAMP and cGMP pathways and signaling of BMP-2/Smad1/5/8 and Wnt/?-catenin.
Osteoporosis
Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Osteoporosis
Therapeutic potential of phosphodiesterase inhibitors in the treatment of osteoporosis: Scopes for therapeutic repurposing and discovery of new oral osteoanabolic drugs.
Osteoporosis
[Effect of phosphodiesterase IV inhibitors on bone tissue: a possibility for its use as a new agent to treat osteoporosis]
Osteosarcoma
Characterization of phosphodiesterase 3 in human malignant melanoma cell line.
Osteosarcoma
Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists.
Osteosarcoma
TREX1 suppression imparts cancer-stem-cell-like characteristics to CD133- osteosarcoma cells through the activation of E2F4 signaling.
Ovarian Neoplasms
Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer.
Ovarian Neoplasms
FTO-Dependent N6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.
Ovarian Neoplasms
Gene expression in the spermatogenically inactive "dark" and maturing "light" testicular tissues of the prepubertal colt.
Ovarian Neoplasms
Tumor markers for ovarian cancer.
Pancreatic Neoplasms
Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells.
Pancreatic Neoplasms
cAMP protection of pancreatic cancer cells against apoptosis induced by ERK inhibition.
Pancreatitis
PENTOXIFYLLINE PREVENTS LOSS OF PP2A PHOSPHATASE ACTIVITY AND RECRUITMENT OF HISTONE ACETYLTRANSFERASES TO PRO-INFLAMMATORY GENES IN ACUTE PANCREATITIS.
Pancreatitis
Rolipram and SP600125 Suppress the Early Increase in PTP1B Expression During Cerulein-Induced Pancreatitis in Rats.
Pancreatitis
Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
Pancreatitis
The Selective Inhibition of Type IV Phosphodiesterase Attenuates the Severity of the Acute Pancreatitis in Rats.
Papilloma
Increased cyclic adenosine 3':5'-monophosphate phosphodiesterase activity in the epidermis of phorbol ester-treated mouse skin and in papillomas.
Parasitic Diseases
Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases.
Parkinson Disease
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
Parkinson Disease
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Parkinson Disease
PET Radioligands for imaging of the PDE10A in human: current status.
Parkinson Disease
Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Parkinson Disease
The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.
Parkinson Disease
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
Parkinsonian Disorders
PDE8B mutation is not associated with Parkinson's disease in a Taiwanese population.
Parkinsonian Disorders
Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism.
Pediatric Obesity
Impact of phosphodiesterase 8B gene rs4704397 variation on thyroid homeostasis in childhood obesity.
Penile Induration
Biofilm and penile prosthesis infections in the era of coated implants: a review.
Penile Induration
Conservative management options for Peyronie's disease.
Penile Induration
Partial Priapism Treated with Pentoxifylline.
Penile Induration
Penile blood cyclic guanosin monophosphate level is associated with penile Doppler ultrasound findings.
Penile Induration
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.
Penile Induration
[Treatment of erectile dysfunction in patients with plastic induration of the penis]
Peripheral Arterial Disease
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
Peripheral Arterial Disease
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Peripheral Arterial Disease
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
Peripheral Arterial Disease
Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study.
Peripheral Arterial Disease
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Peripheral Arterial Disease
Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model.
Peripheral Arterial Disease
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Peripheral Arterial Disease
Macro- and microrheological parameters of blood in patients with cerebral and peripheral atherosclerosis: the molecular change mechanisms after pentoxifylline treatment.
Peripheral Arterial Disease
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
Peripheral Arterial Disease
Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction.
Peripheral Arterial Disease
Pharmacokinetic modeling analysis of cilostazol and its active metabolites (OPC-13015 and OPC-13213) after multiple oral doses of cilostazol in healthy Korean volunteers.
Peripheral Arterial Disease
Progress in the Mechanism and Clinical Application of Cilostazol.
Peripheral Arterial Disease
Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
Peripheral Arterial Disease
The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
Peripheral Arterial Disease
The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow.
Peripheral Arterial Disease
[Prospects of clinical application of cilostazol for peripheral artery disease].
Peripheral Nervous System Diseases
The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease.
Peripheral Vascular Diseases
Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-?B from the Toll-like receptor signaling pathways.
Peripheral Vascular Diseases
Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.
Peripheral Vascular Diseases
Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phospshodiesterase in rats.
Peripheral Vascular Diseases
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
Peripheral Vascular Diseases
Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.
Peripheral Vascular Diseases
Cilostazol prevents retinal ischemic damage partly via inhibition of tumor necrosis factor-?-induced nuclear factor-kappa B/activator protein-1 signaling pathway.
Peripheral Vascular Diseases
Cilostazol suppresses angiotensin II?induced apoptosis in endothelial cells.
Peripheral Vascular Diseases
Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats.
Peripheral Vascular Diseases
Endothelium-dependent effects of pentoxifylline in rat aorta.
Peripheral Vascular Diseases
Improvement in the outcome of rejection with pentoxifylline in renal transplantation: a randomized controlled trial.
Peripheral Vascular Diseases
Pentoxifylline enhances antioxidative capability and promotes mitochondrial biogenesis for improving age-related behavioral deficits.
Peripheral Vascular Diseases
Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons.
Peripheral Vascular Diseases
Pentoxifylline inhibits neointimal formation and stimulates constrictive vascular remodeling after arterial injury.
Peripheral Vascular Diseases
Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney.
Peripheral Vascular Diseases
Plasma factor and platelet sensitivity to prostacyclin in patients with peripheral vascular disease before and after treatment with a combination of a cyclooxygenase and a phosphodiesterase inhibitor.
Peripheral Vascular Diseases
Topical cilostazol inhibits neointimal hyperplasia in a rat interposition vein graft model.
Peripheral Vascular Diseases
[Pentoxifylline: a cheap substitute for anti-TNFalpha agents?]
Peripheral Vascular Diseases
[Potential therapeutic approaches for prevention and treatment of diabetic nephropathy and neuropathy: evidences of cilostazol]
Pheochromocytoma
Activation of phosphodiesterase IV during desensitization of the A2A adenosine receptor-mediated cyclic AMP response in rat pheochromocytoma (PC12) cells.
Pheochromocytoma
Catecholamine-synthesizing enzymes and chromogranin proteins in drug-induced proliferative lesions of the rat adrenal medulla.
Pheochromocytoma
Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells.
Pheochromocytoma
Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline.
Pheochromocytoma
Mitogenic and antimitogenic effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in adult rat chromaffin cell cultures.
Photophobia
Calcium dependence of the activation and inactivation kinetics of the light-activated phosphodiesterase of retinal rods.
Photophobia
Engineering of a red-light-activated human cAMP/cGMP-specific phosphodiesterase.
Photophobia
Excised patches of plasma membrane from vertebrate rod outer segments retain a functional phototransduction enzymatic cascade.
Photophobia
Light-induced infrared light scattering signal in the retina: effect of phosphodiesterase inhibitors.
Pituitary Neoplasms
The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
Pituitary Neoplasms
Thyroliberin stimulates rapid hydrolysis of phosphatidylinositol 4,5-bisphosphate by a phosphodiesterase in rat mammotropic pituitary cells. Evidence for an early Ca2+-independent action.
Pneumococcal Infections
Unique Roles for Streptococcus pneumoniae Phosphodiesterase 2 in Cyclic di-AMP Catabolism and Macrophage Responses.
Pneumonia
Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness.
Pneumonia
Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
Pneumonia
Effects of interleukin-10 and modulators of cyclic AMP formation on endotoxin-induced inflammation in rat lung.
Pneumonia
Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine.
Pneumonia
Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.
Pneumonia
Impacts of anti-inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation.
Pneumonia
Inhibition of phosphodiesterase suppresses allergic lung inflammation by regulating MCP-1 in an OVA-induced asthma murine model with co-exposure to lipopolysaccharide.
Pneumonia
MicroRNA-30d-5p ameliorates lipopolysaccharide-induced acute lung injury via activating AMPK?.
Pneumonia
Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.
Pneumonia
Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
Pneumonia
Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Polycystic Kidney Diseases
Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Mapping of the familial Mediterranean fever gene to chromosome 16.
Polycystic Kidney, Autosomal Dominant
Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease.
Polyuria
Fluoride inhibition of the hydro-osmotic response of the toad urinary bladder to antidiuretic hormone.
Polyuria
Lithium-induced polyuria: effect of lithium on adenylate cyclase and adenosine 3',5'-monophosphate phosphodiesterase in medullary ascending limb of Henle's loop and in medullary collecting tubules.
Polyuria
Sildenafil and glyceryl trinitrate reduce tactile allodynia in streptozotocin-injected rats.
Pre-Eclampsia
Characterization of changes in mechanical responses to histamine in omental resistance arteries in pre-eclampsia.
Pre-Eclampsia
Increased serum phosphodiesterase activity in women with pre-eclampsia.
Pre-Eclampsia
Phosphodiesterase Inhibition in the Treatment of Preeclampsia: What Is New?
Pre-Eclampsia
Phosphodiesterase Inhibitor Effect on Small Artery Function in Preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A heat-stable protein inhibitor of cyclic 3',5'-nucleotide phosphodiesterase.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of PDE4 phosphodiesterase activity induces growth suppression, apoptosis, glucocorticoid sensitivity, p53, and p21(WAF1/CIP1) proteins in human acute lymphoblastic leukemia cells.
Premature Birth
Is the relaxing effect of beta-adrenergic agonists on the human myometrium only transitory?
Premature Ejaculation
Pharmacotherapy of sexual dysfunctions : current status.
Premature Ejaculation
The Control of Male Sexual Responses.
Priapism
Partial Priapism Treated with Pentoxifylline.
Priapism
Pharmacologically-induced Recreational Priapism: Case Report and Review.
Priapism
Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy.
Priapism
Second Pathways in the Pathophysiology of Ischemic Priapism and Treatment Alternatives.
Priapism
Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.
Priapism
Words of wisdom. Re: feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism.
Primary Myelofibrosis
Pulmonary hypertension in patients with hematological disorders following splenectomy.
Prostatic Hyperplasia
Chronic treatment with Sildenafil has no effect on folliculogenesis or fertility in C57BL/6 and C57BL/6 knockout for iNOS mice.
Prostatic Hyperplasia
Effect of acute administration of sildenafil to rats with detrusor overactivity induced by chronic deficiency of nitric oxide.
Prostatic Hyperplasia
Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway.
Prostatic Hyperplasia
Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.
Prostatic Hyperplasia
PDE5 inhibitors for LUTS.
Prostatic Hyperplasia
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Prostatic Hyperplasia
Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
Prostatic Hyperplasia
Re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with ?-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
Prostatic Hyperplasia
Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Prostatic Hyperplasia
[Functional urology: synopsis of the 101st Congress of the French Association of Urology]
Prostatic Hyperplasia
[Should we prescribe phosphodiesterase inhibitors for the treatment of symptomatic benign prostatic hyperplasia].
Prostatic Neoplasms
Biofilm and penile prosthesis infections in the era of coated implants: a review.
Prostatic Neoplasms
Erectile dysfunction.
Prostatic Neoplasms
Exonuclease 1 expression is associated with clinical progression, metastasis, and survival prognosis of prostate cancer.
Prostatic Neoplasms
Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.
Prostatic Neoplasms
Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Prostatic Neoplasms
Influence of a single-nucleotide polymorphism of the DNA mismatch repair-related gene exonuclease-1 (rs9350) with prostate cancer risk among Chinese people.
Prostatic Neoplasms
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
Prostatic Neoplasms
Phosphodiesterase 11A (PDE11A) Genetic Variants May Increase Susceptibility to Prostatic Cancer.
Prostatic Neoplasms
Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway.
Prostatic Neoplasms
Phosphodiesterase sequence variants may predispose to prostate cancer.
Prostatic Neoplasms
Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer.
Prostatic Neoplasms
Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.
Prostatic Neoplasms
Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer.
Prostatic Neoplasms
The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells.
Prostatic Neoplasms
The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.
Prostatitis
Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review.
Protein-Energy Malnutrition
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Pruritus
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Pruritus
[Papaverin--effective in therapy of pruritus of atopic dermatitis?]
Pseudohypoparathyroidism
Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor.
Pseudohypoparathyroidism
Parathyroid hormone resistance syndromes - Inactivating PTH/PTHrP signaling disorders (iPPSDs).
Pseudomonas Infections
The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa.
Pseudorabies
Activation of the human "beta 2-interferon/hepatocyte-stimulating factor/interleukin 6" promoter by cytokines, viruses, and second messenger agonists.
Psoriasis
A Phase I Randomized Trial to Assess the Effect on skin infiltrate thickness and Tolerability of Topical Phosphodiesterase Inhibitors in the Treatment of Psoriasis Vulgaris Using a Modified Psoriasis Plaque Test.
Psoriasis
An update on the safety of apremilast for the treatment of plaque psoriasis.
Psoriasis
Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
Psoriasis
Apremilast for the management of moderate to severe plaque psoriasis.
Psoriasis
Apremilast Normalizes Gene Expression of Inflammatory Mediators in Human Keratinocytes and Reduces Antigen-Induced Atopic Dermatitis in Mice.
Psoriasis
Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
Psoriasis
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Psoriasis
Mononuclear leukocyte cyclic adenosine monophosphate responses in psoriasis are normal.
Psoriasis
Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects.
Psoriasis
Pharmacology of psoriasis.
Psoriasis
Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.
Psoriasis
Phosphodiesterase in psoriasis.
Psoriasis
Proximal Renal Tubular Acidosis (Fanconi syndrome) Induced by Apremilast: A Case Report.
Psoriasis
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.
Psoriasis
The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models.
Psoriasis
Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Psoriasis
Worsening of Lymphopenia during Apremilast Treatment.
Psoriasis
[Immediate results of treatment of psoriasis with phosphodiesterase inhibitors]
Psychomotor Agitation
Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Pulmonary Arterial Hypertension
Advances in the medical treatment of pulmonary hypertension.
Pulmonary Arterial Hypertension
Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats.
Pulmonary Arterial Hypertension
Comparative Effectiveness of Pharmacological Interventions for Pulmonary Arterial Hypertension: A Systematic Review and Network Meta-Analysis.
Pulmonary Arterial Hypertension
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
Pulmonary Arterial Hypertension
Curcumin analogues inhibit phosphodiesterase-5 and dilate rat pulmonary arteries.
Pulmonary Arterial Hypertension
Endothelin receptor antagonists for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Evidence-based pharmacologic management of pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors.
Pulmonary Arterial Hypertension
Improving Survival in Patients with Pulmonary Arterial Hypertension: Focus on Intravenous Epoprostenol.
Pulmonary Arterial Hypertension
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
Pulmonary Arterial Hypertension
Long-term inhaled iloprost use in children with pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.
Pulmonary Arterial Hypertension
Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment.
Pulmonary Arterial Hypertension
Pulmonary hypertension and right ventricular function in advanced heart failure.
Pulmonary Arterial Hypertension
Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
Scleroderma - new aspects in pathogenesis and treatment.
Pulmonary Arterial Hypertension
Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry.
Pulmonary Arterial Hypertension
Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
Pulmonary Arterial Hypertension
[Pulmonary arterial hypertension-specific drugs - current status]
Pulmonary Arterial Hypertension
[Pulmonary hypertension and right ventricular failure. Part XII. Nitrous oxide and phosphodiesterase inhibitors in the treatment of primary pulmonary arterial hypertension]
Pulmonary Arterial Hypertension
[Pulmonary hypertension in COPD and interstitial lung diseases]
Pulmonary Arterial Hypertension
[Pulmonary hypertension. Pathophysiology and current concepts of medication therapy]
Pulmonary Arterial Hypertension
[Update in the diagnosis and therapy for pulmonary arterial hypertension]
Pulmonary Disease, Chronic Obstructive
A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.
Pulmonary Disease, Chronic Obstructive
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.
Pulmonary Disease, Chronic Obstructive
A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice.
Pulmonary Disease, Chronic Obstructive
A Novel, Pan-PDE Inhibitor Exerts Anti-Fibrotic Effects in Human Lung Fibroblasts via Inhibition of TGF-? Signaling and Activation of cAMP/PKA Signaling.
Pulmonary Disease, Chronic Obstructive
A Way to Increase the Bioaccesibility and Photostability of Roflumilast, a COPD Treatment, by Cyclodextrin Monomers.
Pulmonary Disease, Chronic Obstructive
ABCD of the phosphodiesterase family: interaction and differential activity in COPD.
Pulmonary Disease, Chronic Obstructive
ACP Journal Club. Review: oral phosphodiesterase 4 inhibitors reduce exacerbations but increase adverse events in COPD.
Pulmonary Disease, Chronic Obstructive
An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Ariflo (SmithKline Beecham plc).
Pulmonary Disease, Chronic Obstructive
Cardiac effects of current treatments of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities.
Pulmonary Disease, Chronic Obstructive
Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Pulmonary Disease, Chronic Obstructive
Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD.
Pulmonary Disease, Chronic Obstructive
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Clinical Considerations for Roflumilast: A New Treatment for COPD.
Pulmonary Disease, Chronic Obstructive
Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.
Pulmonary Disease, Chronic Obstructive
Cross-talk between PKA-C? and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.
Pulmonary Disease, Chronic Obstructive
Cyclic AMP enhancing drugs modulate eicosanoid release from human alveolar macrophages.
Pulmonary Disease, Chronic Obstructive
Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.
Pulmonary Disease, Chronic Obstructive
Direct Inhibitory Effect of the Phosphodiesterase-4 Inhibitor, Roflumilast, on Neutrophil Migration in COPD.
Pulmonary Disease, Chronic Obstructive
Dose dependent effects of tadalafil and roflumilast on ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Pulmonary Disease, Chronic Obstructive
Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.
Pulmonary Disease, Chronic Obstructive
Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Pulmonary Disease, Chronic Obstructive
Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction.
Pulmonary Disease, Chronic Obstructive
Efficacy and safety profile of roflumilast in a real-world experience.
Pulmonary Disease, Chronic Obstructive
Enantiomer Discrimination Illustrated by the High Resolution Crystal Structures of Type 4 Phosphodiesterase.
Pulmonary Disease, Chronic Obstructive
Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Evaluation of PDE4 inhibition for COPD.
Pulmonary Disease, Chronic Obstructive
Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers.
Pulmonary Disease, Chronic Obstructive
Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline.
Pulmonary Disease, Chronic Obstructive
Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies.
Pulmonary Disease, Chronic Obstructive
Hesperetin, a Selective Phosphodiesterase 4 Inhibitor, Effectively Suppresses Ovalbumin-Induced Airway Hyperresponsiveness without Influencing Xylazine/Ketamine-Induced Anesthesia.
Pulmonary Disease, Chronic Obstructive
Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.
Pulmonary Disease, Chronic Obstructive
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor.
Pulmonary Disease, Chronic Obstructive
Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review.
Pulmonary Disease, Chronic Obstructive
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats: tissue inhibitor of metalloproteinase 1, a potential predictive biomarker.
Pulmonary Disease, Chronic Obstructive
Modulation of Cytokine Production by Cyclic Adenosine Monophosphate Analogs in Human Leukocytes.
Pulmonary Disease, Chronic Obstructive
Novel antiinflammatory therapies for COPD.
Pulmonary Disease, Chronic Obstructive
Novel drug targets for asthma and COPD: Lessons learned from in vitro and in vivo models.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4 inhibition of beta2-integrin adhesion caused by leukotriene B4 and TNF-alpha in human neutrophils.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase activity in neutrophils from horses with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Phosphodiesterase inhibitors in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Pulmonary Disease, Chronic Obstructive
Positioning new pharmacotherapies for COPD.
Pulmonary Disease, Chronic Obstructive
Pulmonary hypertension associated with COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast for COPD.
Pulmonary Disease, Chronic Obstructive
Roflumilast for the treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
Pulmonary Disease, Chronic Obstructive
Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Pulmonary Disease, Chronic Obstructive
Roflumilast: doubtful efficacy but clear harms in COPD.
Pulmonary Disease, Chronic Obstructive
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Pulmonary Disease, Chronic Obstructive
Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Synthesis and biological activity of Pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.
Pulmonary Disease, Chronic Obstructive
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).
Pulmonary Disease, Chronic Obstructive
The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Pulmonary Disease, Chronic Obstructive
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Pulmonary Disease, Chronic Obstructive
Therapeutic responses in asthma and COPD. Bronchodilators.
Pulmonary Disease, Chronic Obstructive
Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.
Pulmonary Disease, Chronic Obstructive
[Effect of phosphodiesterase inhibitor on expression of IL-8 mRNA in peripheral blood mononuclear cells from COPD patients.]
Pulmonary Disease, Chronic Obstructive
[Pulmonary hypertension in COPD and interstitial lung diseases]
Pulmonary Disease, Chronic Obstructive
[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD]
Pulmonary Disease, Chronic Obstructive
[Treatment of chronic obstructive pulmonary disease--traditional bronchodilatation and targeted anti-inflammatory therapy].
Pulmonary Edema
Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema.
Pulmonary Edema
Are sildenafil and theophylline effective in the prevention of high-altitude pulmonary edema?
Pulmonary Edema
Cytokine immunopathogenesis of enterovirus 71 brain stem encephalitis.
Pulmonary Edema
Inhibition of lipopolysaccharide-induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs.
Pulmonary Edema
Therapeutic efficacy of milrinone in the management of enterovirus 71-induced pulmonary edema.
Pulmonary Embolism
Selective pulmonary vasodilatory effect of ZSY-27 in dogs with pulmonary hypertension due to pulmonary embolism.
Pulmonary Eosinophilia
Increased respiratory burst and phosphodiesterase activity in alveolar eosinophils in chronic eosinophilic pneumonia.
Pulmonary Eosinophilia
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats.
Pulmonary Eosinophilia
Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines.
Pulmonary Heart Disease
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Raynaud Disease
Systemic sclerosis - focus on dermatological aspects. Part 2: diagnostics, therapy.
Renal Insufficiency
Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure.
Renal Insufficiency
From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
Renal Insufficiency
Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure.
Renal Insufficiency
Phosphodiesterase III inhibitor olprinone chlorate is not significantly removed by continuous venovenous hemodiafiltration.
Renal Insufficiency
[The etiology and management of congestive heart failure in the elderly]
Renal Insufficiency, Chronic
Effects of dopamine on kidney function and on the adenyl cyclase phosphodiesterase system in man.
Renal Insufficiency, Chronic
Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
Reperfusion Injury
Combined use of adenosine and amrinone inhibits reperfusion injury of rat liver.
Reperfusion Injury
Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice.
Reperfusion Injury
Effect of olprinone, a phosphodiesterase III inhibitor, on hepatic ischemiareperfusion injury in rats.
Reperfusion Injury
Effects of amrinone on hepatic ischemia-reperfusion injury in rats.
Reperfusion Injury
Effects of amrinone on ischaemia-reperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin E1.
Reperfusion Injury
Inotropic support of the heart that fails to successfully wean from cardiopulmonary bypass: the Montreal Heart Institute experience.
Reperfusion Injury
Long-acting oral phosphodiesterase inhibition preconditions against reperfusion injury in an experimental lung transplantation model.
Reperfusion Injury
Nebulized phosphodiesterase III inhibitor during warm ischemia attenuates pulmonary ischemia-reperfusion injury.
Reperfusion Injury
Pharmacological activity of cardiovascular agents from herbal medicine.
Reperfusion Injury
Role of cyclic nucleotides in ischemia and reperfusion injury of canine livers.
Reperfusion Injury
The effect of amrinone on liver regeneration in experimental hepatic resection model.
Reperfusion Injury
The Effect of Sildenafil and Udenafil on Testicular Damage Following Ischemia-Reperfusion Injury in Rats.
Reperfusion Injury
The protective effects of tadalafil on renal damage following ischemia reperfusion injury in rats.
Reperfusion Injury
[Anti-inflammatory effects of pentoxifylline: importance in cardiac surgery]
Respiratory Distress Syndrome
Chronicles in drug discovery.
Respiratory Distress Syndrome
Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition.
Respiratory Hypersensitivity
Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Respiratory Insufficiency
Blockade of phosphodiesterase 4 reverses morphine-induced ventilatory disturbance without loss of analgesia.
Respiratory Tract Diseases
[Theophylline and selective phosphodiesterase inhibitor in therapy of obstructive respiratory tract diseases]
Retinal Degeneration
Activation of survival pathways in the degenerating retina of rd10 mice.
Retinal Degeneration
Activation of the molecular chaperone, sigma 1 receptor, preserves cone function in a murine model of inherited retinal degeneration.
Retinal Degeneration
Adenoviral-mediated gene transfer to retinal explants during development and degeneration.
Retinal Degeneration
Basic fibroblast growth factor: increased gene expression in inherited and light-induced photoreceptor degeneration.
Retinal Degeneration
Caspase-3 inhibitor transiently delays inherited retinal degeneration in C3H mice carrying the rd gene.
Retinal Degeneration
cGMP-Phosphodiesterase Inhibition Prevents Hypoxia-Induced Cell Death Activation in Porcine Retinal Explants.
Retinal Degeneration
Changes in morphology of retinal ganglion cells with eccentricity in retinal degeneration.
Retinal Degeneration
Cyclic-nucleotide phosphodiesterase: an early defect in inherited retinal degeneration of C3H mice.
Retinal Degeneration
Delivery of genes to the eye using lentiviral vectors.
Retinal Degeneration
Differential Modification of Phosducin Protein in Degenerating rd1 Retina Is Associated with Constitutively Active Ca2+/Calmodulin Kinase II in Rod Outer Segments.
Retinal Degeneration
Do cGMP Levels Drive the Speed of Photoreceptor Degeneration?
Retinal Degeneration
Linkage of photoreceptor degeneration by apoptosis with inherited defect in phototransduction.
Retinal Degeneration
Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina.
Retinal Degeneration
Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration.
Retinal Degeneration
Retinal degeneration in Aipl1-deficient mice: a new genetic model of Leber congenital amaurosis.
Retinal Degeneration
The search for mutations in the gene for the beta subunit of the cGMP phosphodiesterase (PDEB) in patients with autosomal recessive retinitis pigmentosa.
Retinal Degeneration
Tool from ancient pharmacopoeia prevents vision loss.
Retinal Degeneration
Two pathways of rod photoreceptor cell death induced by elevated cGMP.
Retinal Diseases
Photoreceptor Phosphodiesterase (PDE6): Structure, Regulatory Mechanisms, and Implications for Treatment of Retinal Diseases.
Retinal Diseases
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
Retinal Diseases
The molecular architecture of photoreceptor phosphodiesterase 6 (PDE6) with activated G protein elucidates the mechanism of visual excitation.
Retinal Dystrophies
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Retinal Dystrophies
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina.
Retinitis Pigmentosa
A novel mutation and phenotypes in phosphodiesterase 6 deficiency.
Retinitis Pigmentosa
A novel mutation in exon 17 of the beta-subunit of rod phosphodiesterase in two RP sisters of a consanguineous family.
Retinitis Pigmentosa
Adenoviral-mediated gene transfer to retinal explants during development and degeneration.
Retinitis Pigmentosa
Advancing Gene Therapy for PDE6A Retinitis Pigmentosa.
Retinitis Pigmentosa
An Update on Phosphodiesterase Mutations Underlying Genetic Etiology of Hearing Loss and Retinitis Pigmentosa.
Retinitis Pigmentosa
Atypical retinal degeneration 3 in mice is caused by defective PDE6B pre-mRNA splicing.
Retinitis Pigmentosa
Birt-Hogg-Dubé syndrome associated with chorioretinopathy and nyctalopia: a case report and review of the literature.
Retinitis Pigmentosa
Delivery of genes to the eye using lentiviral vectors.
Retinitis Pigmentosa
Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors.
Retinitis Pigmentosa
Differential Modification of Phosducin Protein in Degenerating rd1 Retina Is Associated with Constitutively Active Ca2+/Calmodulin Kinase II in Rod Outer Segments.
Retinitis Pigmentosa
Evaluation of the gene encoding the gamma subunit of rod phosphodiesterase in retinitis pigmentosa.
Retinitis Pigmentosa
Evidence against involvement of recoverin in autosomal recessive retinitis pigmentosa in 42 Spanish families.
Retinitis Pigmentosa
Functional rescue of degenerating photoreceptors in mice homozygous for a hypomorphic cGMP phosphodiesterase 6 b allele (Pde6bH620Q).
Retinitis Pigmentosa
Gene Supplementation Rescues Rod Function and Preserves Photoreceptor and Retinal Morphology in Dogs, Leading the Way Towards Treating Human PDE6A-Retinitis Pigmentosa.
Retinitis Pigmentosa
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors.
Retinitis Pigmentosa
Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa.
Retinitis Pigmentosa
Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa.
Retinitis Pigmentosa
Gene therapy successfully delays degeneration in a mouse model of PDE6A-linked retinitis pigmentosa (RP 43).
Retinitis Pigmentosa
Homozygous tandem duplication within the gene encoding the beta-subunit of rod phosphodiesterase as a cause for autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Identification of a novel R552O mutation in exon 13 of the beta-subunit of rod phosphodiesterase gene in a Spanish family with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Increased Plasma cGMP in a Family With Autosomal Recessive Retinitis Pigmentosa Due to Homozygous Mutations in the PDE6A Gene.
Retinitis Pigmentosa
Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina.
Retinitis Pigmentosa
Modifications of retinal neurons in a mouse model of retinitis pigmentosa.
Retinitis Pigmentosa
Mutation spectrum of the gene encoding the beta subunit of rod phosphodiesterase among patients with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Mutations in phosphodiesterase 6 identified in familial cases of retinitis pigmentosa.
Retinitis Pigmentosa
Mutations in the ?-subunit of rod phosphodiesterase identified in consanguineous Pakistani families with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina.
Retinitis Pigmentosa
Prenylation defects in inherited retinal diseases.
Retinitis Pigmentosa
Proteomic Profiling Suggests Central Role Of STAT Signaling during Retinal Degeneration in the rd10 Mouse Model.
Retinitis Pigmentosa
Recessive mutations in the gene encoding the beta-subunit of rod phosphodiesterase in patients with retinitis pigmentosa.
Retinitis Pigmentosa
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
Retinitis Pigmentosa
Targeted next-generation sequencing reveals that a compound heterozygous mutation in phosphodiesterase 6a gene leads to retinitis pigmentosa in a Chinese family.
Retinitis Pigmentosa
The Molecular Organization of Human cGMP Specific Phosphodiesterase 6 (PDE6): Structural Implications of Somatic Mutations in Cancer and Retinitis Pigmentosa.
Retinitis Pigmentosa
The search for mutations in the gene for the beta subunit of the cGMP phosphodiesterase (PDEB) in patients with autosomal recessive retinitis pigmentosa.
Retinitis Pigmentosa
Therapeutic Window for Phosphodiesterase 6-Related Retinitis Pigmentosa.
Retinitis Pigmentosa
[A study of PDE6B gene mutation and phenotype in Chinese cases with retinitis pigmentosa]
Retinitis Pigmentosa
[Identification of 2 allelic mutations of the gene of the phosphodiesterase beta subunit in a Spanish family with recessive autosomic retinitis pigmentosa]
Retinitis Pigmentosa
[Molecular cloning of the genes in genetic chorioretinal diseases--positional cloning and the candidate gene approach]
Retinitis Pigmentosa
[Screening gene mutations of the beta subunit of phosphodiesterase in the Chinese retinitis pigmentosa patients]
Retinoblastoma
Cyclic nucleotide phosphodiesterase and protein activator in human cancer cell lines and Brown-Pearce carcinoma.
Rheumatic Diseases
Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases.
Rhinitis, Allergic
Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Rhinitis, Allergic, Seasonal
Quercetin inhibition of the induction and function of cytotoxic T lymphocytes.
Rosacea
An oral phosphodiesterase inhibitor (apremilast) for inflammatory rosacea in adults: a pilot study.
Sarcoma
Apparent allosterism by avian myeloblastosis virus reverse transcriptase and E. coli DNA polymerase I.
Sarcoma
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
Sarcoma
Nucleases and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in murine sarcoma virus (Moloney)-infected mice.
Sarcoma
Properties of 2',3'-dideoxy-2',3'-dehydrothymidine 5'-triphosphate in terminating DNA synthesis catalyzed by several different DNA polymerases.
Sarcoma
Seven loci on human chromosome 4 map onto sheep chromosome 6: a proposal to restore the original nomenclature of this sheep chromosome.
Sarcoma, Avian
Adenylate cyclase and cyclic AMP phosphodiesterase of normal and Rous sarcoma virus transformed chicken embryo fibroblasts.
Sarcoma, Avian
An electron microscopic method for the mapping of proteins attached to nucleic acids.
Sarcoma, Avian
Calcium-dependent regulatory protein of cyclic nucleotide metabolism in normal and transformed chicken embryo fibroblasts.
Scleroderma, Diffuse
Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil.
Scleroderma, Systemic
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis.
Scleroderma, Systemic
Differing commissioning arrangements may contribute to geographic variation in clinical management of digital ulcers in systemic sclerosis.
Scleroderma, Systemic
Innovative therapies for systemic sclerosis.
Scleroderma, Systemic
Pulmonary arterial hypertension secondary to chronic lung diseases: pathogenesis and medical treatment.
Scleroderma, Systemic
Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
Scleroderma, Systemic
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.
Scleroderma, Systemic
Treatment of complications associated with systemic sclerosis.
Seizures
Biochemical aspects of pentylenetetrazole induced seizure.
Seizures
Cerebral phosphoinositide, triacylglycerol and energy metabolism during sustained seizures induced by bicuculline.
Seizures
Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice.
Seizures
Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen.
Seizures
Protective effect of calmodulin inhibitors against acute cyanide-induced lethality and convulsions in mice.
Seizures
Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment.
Seizures
[Epileptic seizures and vardenafil]
Seizures
[Seizure discharges induced by amphetamine in neuron of african snail Achatina fulica: effects of phosphodiesterase inhibitors.]
Sepsis
A Neonatal Murine Escherichia coli Sepsis Model Demonstrates That Adjunctive Pentoxifylline Enhances the Ratio of Anti- vs. Pro-inflammatory Cytokines in Blood and Organ Tissues.
Sepsis
Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
Sepsis
Effects of pentoxifylline on inflammatory cytokine expression and acute pleuropneumonia in swine.
Sepsis
Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock.
Sepsis
Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines.
Sepsis
Influence of amrinone on tissue oxygenation of jejunal mucosa during endotoxemia.
Sepsis
IV milrinone for cardiac output increase and maintenance: comparison in nonhyperdynamic SIRS/sepsis and congestive heart failure.
Sepsis
Lazaroid and pentoxifylline suppress sepsis-induced increases in renal vascular resistance via altered arachidonic acid metabolism.
Sepsis
Leukocyte phosphodiesterase expression after lipopolysaccharide and during sepsis and its relationship with HLA-DR expression.
Sepsis
Lipopolysaccharide attenuates mRNA levels of several adenylyl cyclase isoforms in vivo.
Sepsis
Olprinone improves diaphragmatic contractility and fatigability during abdominal sepsis in a rat model.
Sepsis
Pentoxifylline alone or in combination with gentamicin or vancomycin inhibits live microbe-induced pro-inflammatory cytokine production in human cord blood and cord blood monocytes in vitro.
Sepsis
Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis.
Sepsis
The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomized laboratory investigation.
Sepsis
Type IV phosphodiesterase inhibition improves cardiac contractility in endotoxemic rats.
Shock, Cardiogenic
Administration of enoximone in cardiogenic shock.
Shock, Cardiogenic
Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass.
Shock, Cardiogenic
Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock.
Shock, Cardiogenic
Levosimendan in perioperative and critical care patients.
Shock, Cardiogenic
Levosimendan reversing low output syndrome after heart transplantation.
Shock, Cardiogenic
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Shock, Cardiogenic
Post-operative effects of olprinone after coronary artery bypass grafting.
Shock, Cardiogenic
[Continuous infusion of enoximone in the treatment of acute myocardial ischemia with low output syndrome]
Shock, Cardiogenic
[Enoximone as an alternative to mechanical circulatory support prior to heart transplantation]
Shock, Septic
Amrinone administration in endotoxin shock.
Shock, Septic
Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock.
Shock, Septic
Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial.
Shock, Septic
Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression.
Shock, Septic
Cytokine production and its manipulation by vasoactive drugs.
Shock, Septic
Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes.
Shock, Septic
Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock.
Shock, Septic
Lymphatic flow modulation as adjunct therapy for septic shock.
Shock, Septic
The effects of milrinone on hemodynamics in an experimental septic shock model.
Sinusitis
[Present status of the treatment for olfactory dysfunction].
Skin Diseases
Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
Skin Diseases
East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.
Skin Diseases
Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Skin Diseases
Rolipram inhibits polarization and migration of human T lymphocytes.
Skin Diseases
Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis.
Skin Ulcer
Raynaud's phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options.
Sleep Apnea Syndromes
Obesity and male infertility: a practical approach.
Sleep Deprivation
Phosphodiesterase inhibitors roflumilast and vardenafil prevent sleep deprivation-induced deficits in spatial pattern separation.
Small Cell Lung Carcinoma
Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors.
Spasm
Experimental cerebral vasospasm and cyclic adenosine monophosphate (c-AMP).
Spasm
The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery.
Spasm
Treatment of experiment delayed cerebral arterial spasm with a beta2-adrenergic stimulator and a phosphodiesterase inhibitor.
sphingomyelin phosphodiesterase deficiency
Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease.
Spinal Cord Diseases
Cilostazol, a selective Type III phosphodiesterase inhibitor: prevention of cervical myelopathy in a rat chronic compression model.
Spinal Cord Injuries
Cilostazol, a type III phosphodiesterase inhibitor, reduces ischemia/reperfusion-induced spinal cord injury.
Spinal Cord Injuries
Erectile dysfunction.
Spinal Cord Injuries
Inhibition of phosphodiesterase IV enzyme improves locomotor and sensory complications of spinal cord injury via altering microglial activity: Introduction of Roflumilast as an alternative therapy.
Spinal Cord Injuries
Performance and safety of treatment options for erectile dysfunction in patients with spinal cord injury: A review of the literature.
Spinal Cord Injuries
Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury.
Spinocerebellar Ataxias
DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1.
Spinocerebellar Ataxias
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes.
Spinocerebellar Ataxias
In vitro complementation of Tdp1 deficiency indicates a stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation.
Spinocerebellar Ataxias
Spinocerebellar ataxia with axonal neuropathy.
Spinocerebellar Ataxias
Tdp1 protects against oxidative DNA damage in non-dividing fission yeast.
Spinocerebellar Ataxias
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Spinocerebellar Ataxias
Unrepaired oxidative DNA damage induces an ATR/ATM apoptotic-like response in quiescent fission yeast.
Starvation
Adenylate cyclase and phosphodiesterase in the rat gastric mucosa after starvation, feeding and pentagastrin.
Starvation
Attenuation of phosphate starvation responses by phosphite in Arabidopsis.
Starvation
Changes in phosphodiesterase activity of human subcutaneous adipose tissue during starvation.
Starvation
Desynchronization of cells on the developmental path triggers the formation of spiral waves of cAMP during Dictyostelium aggregation.
Starvation
Distribution of cyclic AMP phosphodiesterase in microdissected periportal and perivenous rat liver tissue with different dietary states.
Starvation
Effect of nutritional status on swine adipose tissue lipolytic activities.
Starvation
Induction of phosphodiesterase by cyclic adenosine 3':5'-monophosphate in differentiating Dictyostelium discoideum amoebae.
Starvation
pdsA, a gene involved in the production of active phosphodiesterase during starvation of Dictyostelium discoideum amoebae.
Starvation
The effect of starvation on phosphodiesterase activity and the content of adenosine 3' :5'-cyclic monophosphate in isolated mouse pancreatic islets.
Starvation
The stringent response promotes biofilm dispersal in Pseudomonas putida.
Starvation
YdiV: a dual function protein that targets FlhDC for ClpXP-dependent degradation by promoting release of DNA-bound FlhDC complex.
Starvation
[Relation between Escherichia coli K-12 viability and mutability and the balance between DNA and protein synthesis. III. Relation between disruptions in the balance between DNA and protein synthesis and mutagenesis and viability during thymidine deprivation of thy- cells defective with respect to recB and polA genes]
Stomach Diseases
Role of nitric oxide in physiology and pathology of the gastrointestinal tract.
Stomach Neoplasms
[Relationship between cyclic nucleotide phosphodiesterases (cPDE) and some patho-biologic behaviors of stomach cancer--I. Histochemical studies of CPDE in stomach cancer tissues]
Stroke
A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats.
Stroke
A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling.
Stroke
Advances in the genetic basis of coronary artery disease.
Stroke
Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage.
Stroke
Antiplatelet cilostazol, an inhibitor of type III phosphodiesterase, improves swallowing function in patients with a history of stroke.
Stroke
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Stroke
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study.
Stroke
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
Stroke
Cilostazol for Secondary Prevention of Stroke and Cognitive Decline: Systematic Review and Meta-Analysis.
Stroke
Cilostazol protects against microvascular brain injury in a rat model of type 2 diabetes.
Stroke
Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study.
Stroke
Cilostazol's effect on the response to perivascular nerve stimulation in isolated dog cerebral and mesenteric arteries.
Stroke
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Stroke
Eburnamine derivatives and the brain.
Stroke
Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.
Stroke
Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline.
Stroke
Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.
Stroke
Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis.
Stroke
Ibudilast, a phosphodiesterase inhibitor with anti-inflammatory activity, protects against ischemic brain injury in rats.
Stroke
Mixed Cerebrovascular Disease and the Future of Stroke Prevention.
Stroke
Molecular genetics of coronary artery disease.
Stroke
Neuroprotective effect of roflumilast under cerebral ischaemia/reperfusion injury in juvenile rats through NLRP-mediated inflammatory response inhibition.
Stroke
Role of FLAP and PDE4D in Myocardial Infarction and Stroke: Target Discovery and Future Treatment Options.
Stroke
Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors.
Stroke
The phosphodiesterase puzzlebox: PDE4D and stroke.
Stroke
The uncertain role for phosphodiesterase inhibitors in stroke prevention.
Stroke
Vinpocetine Improves Scopolamine Induced Learning and Memory Dysfunction in C57 BL/6J Mice.
Stroke
[Antiplatelet therapy: update in secondary stroke prevention].
Stroke
[The hemodynamic profile of amrinone and enoximone in patients with severe heart failure]
Subarachnoid Hemorrhage
Changes of the Expression and Activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in a Rabbit Model.
Subarachnoid Hemorrhage
Dose-Dependent Inhibitory Effects of Cilostazol on Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage.
Subarachnoid Hemorrhage
Effect of vasodilation by milrinone, a phosphodiesterase III inhibitor, on vasospastic arteries after a subarachnoid hemorrhage in vitro and in vivo: effectiveness of cisternal injection of milrinone.
Subarachnoid Hemorrhage
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
Subarachnoid Hemorrhage
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
Subarachnoid Hemorrhage
The effect of phosphodiesterase inhibitor tadalafil on vasospasm following subarachnoid hemorrhage in an experimental rabbit model.
Subarachnoid Hemorrhage
Therapeutic Benefit of Cilostazol in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized and Nonrandomized Studies.
Subarachnoid Hemorrhage
To evaluate the Changes of the expression and activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in Rabbits model.
Subarachnoid Hemorrhage
Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model.
Sunburn
PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis.
Syphilis
Amplification of the DNA polymerase I gene of Treponema pallidum from whole blood of persons with syphilis.
Syphilis
Molecular subtyping of Treponema pallidum in an Arizona County with increasing syphilis morbidity: use of specimens from ulcers and blood.
Syphilis
New tests for syphilis: rational design of a PCR method for detection of Treponema pallidum in clinical specimens using unique regions of the DNA polymerase I gene.
Tachycardia
Analysis of competitive antagonism when this property occurs as part of a pharmacological resultant.
Tachycardia
Changes in systemic haemodynamics, regional myocardial function and perfusion induced by alinidine in pigs with and without narrowed coronary arteries.
Tachycardia
Coronary reactions to cardiac hyperactivity and to hypoxia in isolated perfused heart of rat.
Tachycardia
Further evidence for the involvement of cAMP in central blood pressure regulation.
Tachycardia
Phosphodiesterase-3 inhibitor (cilostazol) attenuates oxidative stress-induced mitochondrial dysfunction in the heart.
Tachycardia, Ventricular
Modulation of myocardial cyclic AMP and vulnerability to fibrillation in the rat heart.
Takotsubo Cardiomyopathy
Olprinone, phosphodiesterase III inhibitor, is useful for patients with severe acute heart failure due to takotsubo cardiomyopathy accompanied by subarachnoid hemorrhage.
Teratocarcinoma
Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.
Testicular Neoplasms
A phosphodiesterase 11 (Pde11a) knockout mouse expressed functional but reduced Pde11a: Phenotype and impact on adrenocortical function.
Testicular Neoplasms
Analysis of genetic variants of phosphodiesterase 11A in acromegalic patients.
Testicular Neoplasms
Frequent Phosphodiesterase 11A Gene (PDE11A) Defects in Patients with Carney Complex (CNC) Caused by PRKAR1A Mutations: PDE11A May Contribute to Adrenal and Testicular Tumors in CNC as a Modifier of the Phenotype.
Testicular Neoplasms
Rare inactivating PDE11A variants associated with testicular germ cell tumors.
Tetanus
Chronic hyperammonemia in vivo impairs long-term potentiation in hippocampus by altering activation of cyclic GMP-dependent-protein kinase and of phosphodiesterase 5.
Tetanus
Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase.
Tetanus
Sequential activation of soluble guanylate cyclase, protein kinase G and cGMP-degrading phosphodiesterase is necessary for proper induction of long-term potentiation in CA1 of hippocampus. Alterations in hyperammonemia.
Thrombocythemia, Essential
Atypical Takotsubo syndrome during anagrelide therapy.
Thrombocytopenia
Possible contribution of acetylamrinone and its enhancing effects on platelet aggregation under shear stress conditions in the onset of thrombocytopenia in patients treated with amrinone.
Thrombosis
Antiplatelet and antithrombotic effects of a novel selective phosphodiesterase 3 inhibitor, NSP-513, in mice and rats.
Thrombosis
Antiplatelet treatment with cilostazol after stent implantation.
Thrombosis
Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism.
Thrombosis
BF066, a Novel Dual Target Antiplatelet Agent without Significant Bleeding.
Thrombosis
Cilostazol and Primary-PCI: Mirage or Good Alternative?
Thrombosis
Cilostazol in the management of vascular disease.
Thrombosis
Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
Thrombosis
Comparison of the effects of a thromboxane synthase inhibitor or prostacyclin in combination with a phosphodiesterase inhibitor for prevention of experimental thrombosis and sudden death in rabbits.
Thrombosis
Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery.
Thrombosis
Ibudilast, a Phosphodiesterase Inhibitor, in Combination with Low-dose Aspirin Potently Inhibits Guinea Pig Carotid Artery Thrombosis without Extending Bleeding Time and Causing Gastric Mucosal Injury.
Thrombosis
Inhibition of Phosphodiesterase 3A by Cilostazol Dampens Proinflammatory Platelet Functions.
Thrombosis
Manipulation of thrombus formation in the hamster cheek pouch with drugs that interact with PGI2 in vitro.
Thrombosis
Partial segmental thrombosis of the corpus cavernosum presenting with perineal pain.
Thrombosis
Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis.
Thrombosis
The vascular effects of cilostazol.
Thrombosis
Tumor vascular disrupting agent DMXAA inhibits platelet activation and thrombosis via inhibition of TXA2 signaling and phosphodiesterase.
Thrombosis
Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.
Thyroid Cancer, Papillary
Tumor necrosis factor-alpha activates nuclear factor kappa B and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells.
Thyroid Neoplasms
Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
Thyroiditis, Subacute
Serum cyclic 3',5'-nucleotide phosphodiesterase in patients with various thyroid disorders.
Tics
Ovarian stanniocalcin is structurally unique in mammals and its production and release are regulated through the luteinizing hormone receptor.
Triple Negative Breast Neoplasms
Phosphodiesterase 7B/microRNA-200c relationship regulates triple-negative breast cancer cell growth.
Trypanosomiasis, African
Alkynamide phthalazinones as a new class of TbrPDEB1 inhibitors (Part 2).
Trypanosomiasis, African
Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.
Tuberculosis
A novel calcium binding protein in Mycobacterium tuberculosis--potential target for trifluoperazine.
Tuberculosis
Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.
Tuberculosis
c-di-AMP hydrolysis by the phosphodiesterase AtaC promotes differentiation of multicellular bacteria.
Tuberculosis
Cloning and sequence analysis of the gene encoding the DNA polymerase I from Mycobacterium tuberculosis.
Tuberculosis
Deletion of the cyclic di-AMP phosphodiesterase gene (cnpB) in Mycobacterium tuberculosis leads to reduced virulence in a mouse model of infection.
Tuberculosis
Deoxy- and dideoxynucleotide discrimination and identification of critical 5' nuclease domain residues of the DNA polymerase I from Mycobacterium tuberculosis.
Tuberculosis
DNA polymerase I of Mycobacterium tuberculosis: functional role of a conserved aspartate in the hinge joining the M and N helices.
Tuberculosis
Identification of a Mycobacterium tuberculosis Cyclic Dinucleotide Phosphodiesterase Inhibitor.
Tuberculosis
Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase.
Tuberculosis
Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis.
Tuberculosis
Phosphorylation of mycobacterial phosphodiesterase by eukaryotic-type Ser/Thr kinase controls its two distinct and mutually exclusive functionalities.
Tuberculosis
Roflumilast, a Type 4 Phosphodiesterase Inhibitor, Shows Promising Adjunctive, Host-Directed Therapeutic Activity in a Mouse Model of Tuberculosis.
Tuberculosis
Rv2577 of Mycobacterium tuberculosis Is a Virulence Factor With Dual Phosphatase and Phosphodiesterase Functions.
Tuberculosis
Structural and Biochemical Insight into the Mechanism of Rv2837c from Mycobacterium tuberculosis as a c-di-NMP Phosphodiesterase.
Tuberculosis
Structural and biochemical insight into the mechanism of Rv2837c from Mycobacterium tuberculosis as a c-di-NMP phosphodiesterase.
Tuberculosis
Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
Tuberculosis
The adenylyl cyclase Rv2212 modifies the proteome and infectivity of Mycobacterium bovis BCG.
Urinary Bladder Neck Obstruction
Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor.
Urinary Bladder Neck Obstruction
The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction.
Urinary Bladder Neoplasms
Phospholipase C-? regulates bladder cancer cells via ATM/EXO1.
Urinary Bladder, Overactive
An animal study to compare the degree of the suppressive effects on the afferent pathways of micturition between tamsulosin and sildenafil.
Urinary Bladder, Overactive
Lower Urinary Tract Symptoms: What's New in Medical Treatment?
Urinary Bladder, Overactive
Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast.
Urinary Bladder, Overactive
[Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function : An immunohistochemical and functional study.]
Urinary Calculi
Pathophysiology and symptoms of renal colic in children - a case report.
Urinary Incontinence
Expressions of vaginal endothelial nitric oxide synthase and phosphodiesterase 5 in female sexual dysfunction: a pilot study.
Urination Disorders
[Tadalafil in patients with benign prostatic hyperplasia during conservative combined therapy].
Urogenital Diseases
Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract.
Urolithiasis
Medical expulsive therapy in urolithiasis: a mixed treatment comparison network meta-analysis of randomized controlled clinical trials.
Urolithiasis
Mirabegron: A Novel and Promising Medical Expulsive Treatment for Ureteral Stones?
Urologic Diseases
Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.
Urologic Diseases
Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
Urologic Diseases
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.
Uterine Cervical Neoplasms
Three Prime Repair Exonuclease 1 (TREX1) expression correlates with cervical cancer cells growth in vitro and disease progression in vivo.
Uveitis
Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
Uveitis
The effects of 3-isobutyl-methyl-xanthine on experimentally induced ocular inflammation in the rabbit.
Vaccinia
Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases.
Vaccinia
Human DNA polymerase alpha: predicted functional domains and relationships with viral DNA polymerases.
Vaccinia
Solution structure of a DNA duplex containing the potent anti-poxvirus agent cidofovir.
Vaccinia
The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination.
Vascular Diseases
Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Vascular Diseases
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Vascular System Injuries
Biomarkers in peripheral blood associated with vascular injury in Sprague-Dawley rats treated with the phosphodiesterase IV inhibitors SCH 351591 or SCH 534385.
Vascular System Injuries
Early events in vascular injury in the rat induced by the phosphodiesterase IV inhibitor SCH 351591.
Vascular System Injuries
Histopathology of vascular injury in Sprague-Dawley rats treated with phosphodiesterase IV inhibitor SCH 351591 or SCH 534385.
Vascular System Injuries
Roflumilast-induced Local Vascular Injury Is Associated with a Coordinated Proteome and Microparticle Change in the Systemic Circulation in Pigs.
Vasculitis
Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats.
Vasculitis
Metabonomic assessment of vasculitis in rats.
Vasospasm, Intracranial
Cerebral arterial spasm. II. Etiology and treatment of experimental cerebral vasospasm.
Vasospasm, Intracranial
Changes of the Expression and Activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in a Rabbit Model.
Vasospasm, Intracranial
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model.
Vasospasm, Intracranial
Phosphodiesterase inhibitors and cerebral vasospasm.
Vasospasm, Intracranial
Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
Vasospasm, Intracranial
Therapeutic Benefit of Cilostazol in Patients with Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of Randomized and Nonrandomized Studies.
Vasospasm, Intracranial
To evaluate the Changes of the expression and activity of Phosphodiesterase V in the Basilar Artery Before and After Cerebral Vasospasm in Rabbits model.
Ventilator-Induced Lung Injury
Inhibitors of myosin light chain kinase and phosphodiesterase reduce ventilator-induced lung injury.
Ventricular Dysfunction
A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery.
Ventricular Dysfunction
Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.
Ventricular Dysfunction
Pharmacologic support of circulation in patients undergoing cardiac surgery.
Ventricular Dysfunction, Left
A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass.
Ventricular Dysfunction, Left
Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor.
Ventricular Dysfunction, Left
Ibudilast, a Phosphodiesterase Inhibitor and Toll-Like Receptor-4 Antagonist, Improves Hemorrhagic Shock and Reperfusion-Induced Left Ventricular Dysfunction by Reducing Myocardial Tumor Necrosis Factor ?.
Ventricular Dysfunction, Left
New positive inotropic agents in the treatment of left ventricular dysfunction.
Ventricular Dysfunction, Left
Newer oral inotropic agents: phosphodiesterase inhibitors.
Ventricular Dysfunction, Left
[Left ventricular dysfunction while weaning from mechanical ventilation. Contribution of enoximone]
Ventricular Dysfunction, Right
Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem.
Ventricular Dysfunction, Right
Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options.
Ventricular Fibrillation
Inhibition by simulated ischemia or hypoxia of delayed afterdepolarizations provoked by cyclic AMP: significance for ischemic and reperfusion arrhythmias.
Ventricular Fibrillation
Phosphodiesterase-5 inhibition improves macrocirculation and microcirculation during cardiopulmonary resuscitation.
Ventricular Fibrillation
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome.
Vibrio Infections
Analysis of the replication elements of the pMJ101 plasmid from the fish pathogen Vibrio ordalii.
Vision Disorders
A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6.
Vision Disorders
Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction.
WAGR Syndrome
Unique Utilization of a Phosphoprotein Phosphatase Fold by a Mammalian Phosphodiesterase Associated with WAGR Syndrome.
Waldenstrom Macroglobulinemia
Novel agents in the treatment of Waldenström's macroglobulinemia.
Werner Syndrome
Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks.
Werner Syndrome
Diverse dealings of the Werner helicase/nuclease.
Werner Syndrome
Positionally cloned human disease genes: patterns of evolutionary conservation and functional motifs.
Werner Syndrome
The exonucleolytic and endonucleolytic cleavage activities of human exonuclease 1 are stimulated by an interaction with the carboxyl-terminal region of the Werner syndrome protein.
Whooping Cough
5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms.
Whooping Cough
A novel hypothalamic peptide, pituitary adenylate cyclase activating peptide, modulates Sertoli cell function in vitro.
Whooping Cough
Alpha 1-adrenergic regulation of TSH-stimulated cyclic AMP accumulation in rat thyroid cells.
Whooping Cough
Alpha 1-adrenoceptor-mediated inhibition of cellular cAMP accumulation in neonatal rat ventricular myocytes.
Whooping Cough
Angiotensin II (A-II) steroidogenic refractoriness in Y-1 cells in the presence of A-II receptors negatively coupled to adenylate cyclase.
Whooping Cough
Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells.
Whooping Cough
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
Whooping Cough
Curosurf modulates cAMP accumulation in human monocytes through a membrane-controlled mechanism.
Whooping Cough
Different effects of phorbol ester on angiotensin II- and stable GTP analogue-induced activation of polyphosphoinositide phosphodiesterase in membranes isolated from rat renal mesangial cells.
Whooping Cough
Differential effect of pertussis toxin on adenosine and muscarinic inhibition of cyclic AMP accumulation in canine ventricular myocytes.
Whooping Cough
Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases.
Whooping Cough
Divalent cations suppress 3',5'-adenosine monophosphate accumulation by stimulating a pertussis toxin-sensitive guanine nucleotide-binding protein in cultured bovine parathyroid cells.
Whooping Cough
Effect of pertussis toxin and neomycin on G-protein-regulated polyphosphoinositide phosphodiesterase. A comparison between HL60 membranes and permeabilized HL60 cells.
Whooping Cough
Effects of GTP, forskolin, sodium fluoride, serotonin, dopamine, and carbachol on adenylate cyclase in Teleost retina.
Whooping Cough
Effects of inactivated Bordetella pertussis on phosphodiesterase in the lung of ovalbumin sensitized and challenged rats.
Whooping Cough
Evidence for the presence of cholinergic muscarinic receptors negatively linked to adenylate cyclase in the iris-ciliary body.
Whooping Cough
Evidence for the presence of serotonin receptors negatively coupled to adenylate cyclase in the rabbit iris-ciliary body.
Whooping Cough
G-proteins, the inositol lipid signalling pathway, and secretion.
Whooping Cough
GLP-1-(7-36) amide, -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function.
Whooping Cough
Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures.
Whooping Cough
Inhibition by pertussis toxin of guanyl nucleotides exchange on transducin in bovine rod cell membranes.
Whooping Cough
Inhibition of cAMP accumulation by intracellular calcium mobilization in C6-2B cells stably transfected with substance K receptor cDNA.
Whooping Cough
Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina.
Whooping Cough
Inhibition of glucagon-signaling and downstream actions by interleukin 1beta and tumor necrosis factor alpha in cultured primary rat hepatocytes.
Whooping Cough
Inhibitory effects of C4a on chemoattractant and secretagogue functions of the other anaphylatoxins via Gi protein-adenylyl cyclase inhibition pathway in mast cells.
Whooping Cough
Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation.
Whooping Cough
Lidocaine enhances Galphai protein function.
Whooping Cough
Mechanism of stress-induced attenuation of the testicular response to gonadotropin: possible involvement of testicular opioids, a pertussis toxin-sensitive G-protein, and phosphodiesterase.
Whooping Cough
Mechanism of the impairment of the glucagon-stimulated phosphoenolpyruvate carboxykinase gene expression by interleukin-6 in rat hepatocytes: inhibition of the increase in cyclic 3',5' adenosine monophosphate and the downstream cyclic 3',5' adenosine monophosphate action.
Whooping Cough
Mechanisms of leptin secretion from white adipocytes.
Whooping Cough
Modulation of islet G-proteins, alpha-glucosidehydrolase inhibition and insulin release stimulated by various secretagogues.
Whooping Cough
N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells.
Whooping Cough
Pertussis toxin enhances proenkephalin synthesis in bovine chromaffin cells.
Whooping Cough
Pertussis toxin stimulates cholecystokinin-induced cyclic AMP formation but is without effect on secretagogue-induced calcium mobilization in exocrine pancreas.
Whooping Cough
Pertussis toxin stimulates the secretion of [Met5]-enkephalin and the expression of proenkephalin A mRNA in bovine adrenal medullary chromaffin cells.
Whooping Cough
Photosensory transduction in ciliates. II. Possible role of G-protein and cGMP in Stentor coeruleus.
Whooping Cough
Photosensory transduction in ciliates. IV. Modulation of the photomovement response of Blepharisma japonicum by cGMP.
Whooping Cough
Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells.
Whooping Cough
Purification and properties of calmodulin from adrenal cortex.
Whooping Cough
Role of G-proteins and adenylate cyclase in antinociception produced by intrathecal purines.
Whooping Cough
Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide.
Whooping Cough
Role of protein kinase C in transforming growth factor-beta 1 induction of carcinoembryonic antigen in human colon carcinoma cells.
Whooping Cough
Serum uncouples elevation of cyclic adenosine monophosphate concentration from cyclic adenosine monophosphate dependent morphological changes exhibited by cultured pituicytes.
Whooping Cough
The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes.
Whooping Cough
Thyrotropin-releasing hormone activates a Ca2+-dependent polyphosphoinositide phosphodiesterase in permeable GH3 cells. GTP gamma S potentiation by a cholera and pertussis toxin-insensitive mechanism.
Whooping Cough
[Inhibitory effect of pertussis toxin on the metabolism of guanine nucleotides in transducin from bovine outer rod segments]
Wilms Tumor
Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
Xeroderma Pigmentosum
Proximity of repair patches to persistent pyrimidine dimers in DNA of normal human and xeroderma pigmentosum cells.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.